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The MHC class I chain-related molecule A (MICA) is a highly polymorphic ligand for the activating 
natural killer (NK) cell receptor NKG2D (NK group 2, member D). The single nucleotide polymorphism 
(SNP) at position 454 (A → G, rs1051792) leads to an amino acid substitution of methionine by valine 
(Met → Val) at position 129 in the α2 domain of the MICA protein. In this study, we evaluated how 
the MICA-129Met/Val polymorphism affects NK cell function and whether it is associated with the 
outcome after allogeneic hematopoietic stem cell transplantation (HSCT). Results of the functional 
analyses using transfected cell lines and recombinant proteins for both variants revealed differences 
between both MICA-129 variants. The MICA-129Met isoform was characterized by higher NKG2D 
binding avidity (P = 0.0016), faster and stronger NKG2D signaling, triggering of more NK cell 
cytotoxicity (granule exocytosis, P = 0.0174; target cell lysis, P = 0.0044) and interferon-gamma (IFN-
y) release (P < 0.0001) but also increased NKG2D down-regulation (P ≤ 0.0006). Especially at low 
MICA expression intensity, the Met variant had stronger functional effects than the Val variant. 
However, the degree of NK cell cytotoxicity and cytokine production increased steadily with 
expression intensity of the MICA-129Val variant, whereas an enhanced expression of the MICA-
129Met isoform had no or even a negative effect on NK cell function. These data demonstrate a 
strong interdependency of the MICA expression intensity and the MICA-129 genotype. To elucidate 
whether the differences between the MICA variants are indeed clinically relevant, the MICA-129 
dimorphism was determined in a cohort of patients undergoing allogeneic HSCT in the Department 
of Hematology and Medical Oncology at the University Medical Center Göttingen (320 genotyped 
patient/donor (P/D) pairs with clinical characteristics). In recipients matched on the MICA-129 
genotype, MICA-129Met variants increased the chance of survival (P = 0.0395) and reduced the risk 
to die due to acute graft-versus-host disease (aGVHD, P = 0.0117), although homozygous carriers had 
an increased risk to experience this complication (P = 0.0361) after HSCT. Thus, the presence of the 
high avidity variant of MICA may lead to a favorable outcome of HSCT due to initially stronger NKG2D 
signaling followed, however, by a more rapid NKG2D counter-regulation. Taken together, these data 
indicate that the MICA-129Met/Val polymorphism is functionally relevant and fine-tunes NK cell 
activity suggesting that it has direct effects on the outcome of HSCT but the intensity of MICA 
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The collection of organs, tissues, cells and molecules, which protects us against pathogens, is called 
the immune system. The immune system is classically divided into innate (also called natural or 
native) immunity and adaptive (also known as specific or acquired) immunity. Innate immunity is the 
first line of defense and mediates the initial protection against pathogens, while adaptive immunity 
develops more slowly and mediates the later and more specific defense. Immunity is furthermore 
subdivided into humoral and cellular immunity. Humoral immunity provides defense against 
extracellular microbes and is mediated primarily by antibodies (Abs; or immunoglobulins) produced 
by B lymphocytes. The cellular immune system combats intracellular microbes and is mediated 
mainly by T lymphocytes. Important features of adaptive immune responses are specificity and 
memory allowing the adaptive immune system to distinguish among millions of different antigens 
and to mount larger and more effective responses after repeated exposure to the same antigen. This 
remarkable specificity is achieved through the clonal expression of an enormous repertoire of B cell 
receptors (BCRs)/Abs and T cell receptors (TCRs) with distinct specificities resulting from somatic 
DNA rearrangement. The principal components of the innate immune system are barriers (formed, 
e.g., by epithelia), phagocytes (monocytes/macrophages and neutrophils), dendritic cells (DCs), 
natural killer (NK) cells, cytokines and the complement system. Thus, the innate immunity consists of 
myeloid and lymphoid cells which are able to exert rapid effector responses mediated through a 
limited repertoire of germline-encoded receptors, such as Toll-like receptors (TLRs) on DCs 
recognizing pathogen-associated molecular patterns or NK receptors on NK cells. NK cells represent a 
subset of lymphocytes, which were originally described as part of the innate immune system, 
however, a recent paradigm shift led to the understanding that they function at the interface 
between innate and adaptive immunity.  
 
1.1 Natural killer cells – function and activation 
NK cells were initially defined as large granular lymphocytes with natural cytotoxicity against tumor 
cells (Oldham and Herberman, 1973; Herberman et al., 1975; Kiessling et al., 1975). Hence, they are 
often described as first line defense against malignant cells. Later NK cells were recognized as a 
separate linage of lymphocytes with both cytotoxic and cytokine-producing effector functions 
(Trinchieri, 1989). Their capacity to distinguish between ´distressed´ cells (e.g., tumor, infected or 
irreparable injured cells affected by physical or chemical exposure) and normal cells is a crucial 




NK cells are widespread throughout lymphoid organs (including bone marrow, lymph nodes, tonsils 
and spleen) and non-lymphoid tissues (e.g., liver, lung and peripheral blood) (Westermann and Pabst, 
1992), which is in accordance with their function as innate sentinels. Based on phenotypic, functional 
and anatomical features distinct subsets of NK cells have been defined. In general, human NK cells 
can be distinguished into two subsets, which differ in their function and homing properties, on the 
basis of their surface density expression of the NK cell marker CD56; CD56dim and CD56bright NK cells 
(Cooper et al., 2001; Farag and Caligiuri, 2006). These two subsets differ in their proliferative 
potential, cytotoxic activity and capability to secret cytokines, such as interferon-gamma (IFN-γ) and 
tumor necrosis factor-alpha (TNF-α), upon stimulation. CD56dim NK cells are cytotoxic and express 
IFN-γ upon exposure to tumor cells (Anfossi et al., 2006). The percentage of CD56dimCD16+ cells in 
peripheral blood and spleen is around 90%, while most NK cells in lymph nodes and tonsils are 
CD56brightCD16- showing reduced cytotoxicity, elevated proliferative potential (Ferlazzo and Munz, 
2004) and greater levels of immunoregulatory cytokines in response to stimulation with interleukin 
(IL)-12, IL-15 and IL-18 (Cooper et al., 2001). Thus, NK cells in secondary lymphoid organs are 
phenotypically and functionally distinct from splenic and circulating NK cells.  
NK cells can kill cancer or virus-infected cells controlled by activating and inhibitory receptors. They 
possess a plethora of cell-surface receptors (Figure 1.1), which enable them to recognize their 
cellular targets while sparing healthy cells. Whether or not NK cells become activated is determined 
by engagement of these inhibitory and activating receptors and therefore by the integration of 
multiple activating and inhibitory signals. In general, negative signals from inhibitory receptors tend 
to be dominant. Inhibitory receptors recognize self major histocompatibility complex (MHC) class I 
molecules, which are constitutively expressed by most cells. Under normal conditions, NK cells are 
tolerant to healthy host cells, since activating signals are dampened by inhibitory receptors (self-
tolerance). The two major families of MHC class I-specific inhibitory receptors in humans include the 
killer cell immunoglobulin-like receptors (KIRs) and receptors consisting of CD94 and a NKG2 subunit 
such as CD94-NKG2A (Figure 1.1). These receptors contain in their intracytoplasmic domain 
immunoreceptor tyrosine-based inhibitory motifs (ITIMs), which transduce the inhibitory signals 
(Burshtyn et al., 1996; Olcese et al., 1996; Vivier et al., 2004). Activating NK cell receptors, such as the 
natural cytotoxicity receptors (NCRs) NKp46, NKp44 and NKp30, recognize cell surface molecules 
which are commonly expressed on stressed cells. Other alert molecules include infectious non-self 
ligands (e.g., viral hemagglutinins suggested to be ligands for NKp44 and NKp46) and TLR ligands 
(Vivier et al., 2008). In contrast to inhibitory receptors, activating receptors possess immunoreceptor 




cytoplasmic tails (Moretta et al., 2001) or associate with adaptor molecules carrying these motifs. If 
inhibitory receptors are not engaged – for instance when virus-infected or tumor cells down-regulate 
or lose MHC class I expression to evade killing by cytotoxic T lymphocytes (CTLs) – and activating 
ligands on target cells are additionally expressed, NK cells become activated. This situation known as 
´missing-self´ triggering of NK cell activation was first described as missing-self hypothesis by Kärre 
(Kärre, 1985; Kärre et al., 1986; Ljunggren and Kärre, 1990). Furthermore, besides the process of 
´infectious non-self recognition´ it has been shown that several activating NK cell receptors are able 
to recognize self cell-surface molecules, which expression can be up-regulated in various stress 
situations, leading to the concept of ´stress-induced self recognition´ (Raulet, 2003; Raulet and 
Guerra, 2009). Hereby, NK cells can be selectively activated, if the activating signals overcome the 
inhibitory signals. The stress-induced self was proposed first on the basis of the findings from Bauer 
et al. (1999) who showed that up-regulation of the stress-inducible MHC class I chain-related 
molecule A (MICA) switched on in stressed cells, triggers NK cell activation mediated through the 
activating NK cell receptor NKG2D (NK group 2, member D; also known as CD314). 
 
Figure 1.1.: Inhibitory receptors, activating
receptors and adhesion or co-stimulation
molecules of human NK cells.
NK cell activation programs result from the
integration of multiple activating and
inhibitory signals that vary depending on
the nature of the interacting cells. These
signals involve ITAM (immunoreceptor
tyrosine-based activation motif)-bearing
molecules and other stimulatory receptors
and adhesion molecules, as well as ITIM-
bearing inhibitory receptors. Some human
receptor-ligand interactions are depicted,
to illustrate the combinatorial nature of the
NK cell interaction repertoire. Cytokines,
chemokines and their receptors are not
shown, but are also crucial for the
regulation of NK cell functions. Inhibitory
receptors are in blue; 2B4, which can act as
an activating or an inhibitory molecule, is in
gray; other receptors are in green. KIR,
killer immunoglobulin-like receptors; LIR,
immunoglobulin-like transcript; LAIR,
leukocyte-associated immunoglobulin-like
receptor; SIGLEC, sialic acid binding
immunoglobulin-like lectins; KLRG-1, killer
cell lectin-like receptor G1; NKR-P1, NK cell
receptor protein 1; HLA, human leukocyte
antigen; LLT, lectin-like transcript; CRTAM,
class I restricted T cell-associated molecule;
Necl-2, nectin-like 2; Tactile (also known as
CD96), T cell-activated increased late
expression; CEACAM1, carcinoembryonic
antigen-related cell adhesion molecule 1;
NTB-A, NK-T-B antigen; CRACC, CD2-like
receptor-activating cytotoxic cell; VCAM-1,
vascular cell adhesion molecule-1; ICAM,
intracellular adhesion molecule. Adapted
from (Vivier et al., 2008).
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Moreover, it has been demonstrated that cross-linking of activating receptors on primary, 
unstimulated NK cells with agonist Abs does not lead to cytotoxic activity or cytokine secretion when 
only one receptor alone is cross-linked, except the CD16 receptor, whereas simultaneous cross-
linking of different pairs or combinations of activating receptors triggers effector functions (Bryceson 
et al., 2005; Bryceson et al., 2006). For instance, NKG2D (CD314) and NKp46 (CD335) need the co-
engagement of other activating NK cell receptors, such as 2B4 (CD244), to activate resting NK cells 
(Bryceson et al., 2009; Kim et al., 2010; Long et al., 2013). Because of these observations Long 
suggested the term ´co-activating´ receptors. The reason why NK cell activation by CD16 (also known 
as Fcγ receptor IIIA) does not require synergy with other receptors could be that specificity is 
determined by Ab-producing B cells (Long et al., 2013). The Fc receptor CD16 enables NK cells to 
detect Ab-coated target cells and to exert antibody-dependent cellular cytotoxicity (ADCC) (Titus et 
al., 1987). The requirement for a synergistic combination of activation receptors may therefore serve 
to prevent unrestrained activation of resting NK cells suggesting that a critical threshold of activating 
signals must be reached by these co-activating receptors to overcome inhibition signals from 
inhibitory receptors in order to mount an effective response (Lanier, 2008; Long et al., 2013). 
NK cells were initially described as lymphocytes, which exert direct cellular cytotoxicity against 
malignant or infected cells without prior activation or ´priming´. However, numerous studies in the 
last years have led to a more nuanced view of NK cells showing that the cytokine and chemokine 
environment as well as interactions with other cells, such as DCs, macrophages and T cells, play an 
important role for the regulation of NK cell cytotoxic and cytokine responses (Figure 1.2) (Long, 2007; 
Long et al., 2013). Of major importance is the cross-talk between NK cells and DCs which coordinates 
their responses by communicating through direct cell-to-cell contact and soluble factors (Degli-
Esposti and Smyth, 2005; Long et al., 2013). Potent activators of NK cell effector function include type 
I IFNs, such as IFN-α and IFN-β, and cytokines, including IL-12, IL-18 and IL-15 (Walzer et al., 2005). 
The cytokine IL-12, produced by mononuclear phagocytes and DCs, promotes secretion of the 
macrophage-activating cytokine IFN-γ by NK cells and enhances NK cell-mediated cytotoxic activity. 
Macrophages produce IL-18 which synergizes with IL-12 in stimulating the production of IFN-γ by NK 
cells. IL-2, produced by antigen-activated T cells, furthermore promotes proliferation, differentiation, 
cytotoxicity and, to some extent, also cytokine secretion of NK cells (Trinchieri, 1989). Structurally 
similar to IL-2 is IL-15, which is produced by mononuclear phagocytes among other cells and 
stimulates the proliferation of NK cells. DCs prime NK cells by trans-presenting IL-15 (Figure 1.2) 









Figure 1.2: Multiple signals control NK cell responses.  
An array of NK cell activation receptors bind to ligands on other cells. Target cell killing requires NK cell 
activation. Since NK cells do not have a single activation receptor, except CD16, but require for activation 
synergistic signals from combinations of receptors which are integrated, Long suggested the term ´co-activating 
receptor´. Inhibitory receptors (red) for MHC class I molecules exert dominant inhibition of cytotoxicity and 
secretory response, as seen in the NK cell-dendritic cell (DC) interaction. DCs also receive signals from ligands 
on NK cells (purple). In the absence of inhibition through MHC class I molecules, target cells which express 
ligands for activation receptors are killed. NK cells respond to various soluble activators, such as cytokines and 
chemokines, which deliver signals for functions as migration and survival. The pro-survival cytokine IL-15 bound 
to the IL-15 receptor (R) α chain is trans-presented by other cells such as DCs to the IL-15R βγc chains on NK 
cells. In response to soluble factors, NK cells secrete IFN-γ, TNF-α, other cytokines and chemokines. Adapted 
from (Long et al., 2013).  
 
1.1.1 NK cells in tumor immunosurveillance 
After observations in the 1970s that NK cells can kill tumor cells (Oldham and Herberman, 1973; 
Herberman et al., 1975; Kiessling et al., 1975), the antitumor effect of NK cells has been documented 




tumor cells of hematopoietic and non-hematopoietic origin (Vivier et al., 2012). In vivo, mouse NK 
cells have been shown to eliminate many transplantable and spontaneous tumors (Smyth et al., 
2002; Vesely et al., 2011). Antitumor NK cell activity requires up-regulation of ligands for NK 
activation receptors and/or loss of MHC class I molecules on tumor cells. For instance, mouse models 
with selective deletion of activating NK cell receptors, such as NKG2D, have demonstrated an 
important contribution of NK cells to tumor immunosurveillance (Gilfillan et al., 2008; Guerra et al., 
2008). Additionally, NK cell-depleted mice are more susceptible to methylcholanthrene-induced 
sarcomas. In this model, NK cells seem to use in part the NKG2D pathway to protect the host from 
tumor development (Smyth et al., 2005). In humans, selective NK cell deficiencies are extremely rare 
(Orange and Ballas, 2006). However, an epidemiological 11-year follow-up study of a general 
population has linked low peripheral blood NK cell activity with an increased incidence of cancer 
(Imai et al., 2000). Furthermore, several studies found an association between NK cell infiltration into 
tumor tissue and better disease prognosis in non-small cell lung carcinomas (Carrega et al., 2008; 
Platonova et al., 2011), renal cell carcinoma (Eckl et al., 2011) and colorectal cancer (Halama et al., 
2011). Altogether, these findings show that NK cells participate in tumor immunosurveillance in mice 
and humans. 
 
1.1.2 Effector functions of NK cells 
Cytotoxicity and cytokine production are effector functions of NK cells. NK cell activation leads to 
elimination of distressed cells directly through NK cell cytotoxicity or indirectly through the 
production of pro-inflammatory cytokines such as IFN-γ and TNF-α.  
In general, two major mechanisms of NK cell cytotoxicity exist; perforin/granzyme-mediated and 
death receptor-mediated apoptosis (Screpanti et al., 2005). Perforin/granzyme-mediated killing 
involves the delivery of the content of specialized secretory lysosomes, known as lytic granules, into 
the immunological synapse between the NK cell and its target cell (Shresta et al., 1998; Griffiths, 
2003). Two types of cytotoxic proteins, which are contained in lytic granules, are proteolytic 
granzymes, such as granzyme B (Heusel et al., 1994), and the pore-forming protein perforin 
(Catalfamo and Henkart, 2003; Voskoboinik et al., 2006). Granzymes are serine proteases, which 
cleave and thereby activate a family of death-inducing intracellular proteases, called caspases, in 
target cells. Granzymes can enter the cytoplasm of the targets via perforin-dependent mechanisms 
(Cullen and Martin, 2008). In death receptor-mediated apoptosis, death ligands on NK cells, such as 




ligand (TRAIL), can bind to death-inducing receptors expressed on the surface of target cells 
(Screpanti et al., 2001). Upon ligation of death receptors with their ligands, intracellular adapter 
molecules are recruited, which in turn can associate with initiator caspases through death effector 
domains or caspase recruitment domain interactions (Nicholson, 1999). The subsequent activation of 
the initiator caspases starts then the caspase cascade which finally results in demise of the target 
cells (Ashkenazi and Dixit, 1998). Thus, the death receptor-mediated induction of cell death does not 
require granule release. However, this death receptor-mediated pathway may play a minor role in NK 
cell cytotoxicity compared to the perforin/granzyme-mediated apoptosis which is the principal 
pathway used by NK cells to eliminate virus-infected and transformed cells (Screpanti et al., 2005).  
Besides exerting direct cytotoxicity, NK cells are furthermore major producers of immunostimulatory 
and pro-inflammatory cytokines and chemokines leading indirectly to target cell elimination 
(Trinchieri, 1989). As an example, the pro-inflammatory cytokine IFN-γ potentiates functions of 
antigen-presenting cells (APCs; monocytes, macrophages, DCs and B cells) including antimicrobial 
activity, phagocytosis, oxidative burst capability and production of nitrous oxide (Trinchieri and 
Gerosa, 1996). NK cells also produce various other cytokines, both pro-inflammatory and 
immunosuppressive, such as TNF-α and IL-10, respectively, and growth factors such as granulocyte 
macrophage-colony-stimulating factor (GM-CSF) as well as chemokines. Secretion of cytokines and 
chemokines by NK cells participates in the shaping of adaptive immune responses (Vivier et al., 
2011). 
 
1.1.3 Activating NK cell receptor NKG2D 
One of the best-characterized activating NK cell receptors is NKG2D (NK group 2, member D). This 
receptor serves as a major ´stress-induced self´ recognition receptor, which binds to up-regulated 
self-protein ligands on stressed cells, resulting in the elimination of infected cells and tumor cells 
(Raulet, 2003; Raulet et al., 2013). 
In humans, the NKG2D gene is encoded in the natural killer gene complex (NKC) on chromosome 12 
next to the other NKG2 genes (NKG2A, NKG2C, NKG2E and NKG2F) and the CD94 gene (Brown et al., 
1997). The NKG2D receptor as well as the NKG2A, NKG2C and NKG2E receptor are lectin-like, type 2 
transmembrane receptors (Houchins et al., 1991) but despite their names, the other NKG2 proteins 
are dissimilar to NKG2D in sequence, specificity and function (Raulet, 2003). NKG2D exists as 
homodimer and recognizes a diversity of self cell-surface molecules (see section 1.1.4) which are up-




sequences, are present as heterodimers with CD94 and recognize the non-classical MHC class I 
molecule human leukocyte antigen E (HLA-E) (Braud et al., 1999).  
The NKG2D receptor is present on several lymphoid and myeloid cell types. In humans, NKG2D is 
expressed by NK cells, CD8+ αβ T cells and subsets of γδ T cells, such as peripheral blood (Bauer et al., 
1999) and intestinal intraepithelial γδ T cells (Roberts et al., 2001), and NKT cells (Raulet, 2003; 
Champsaur and Lanier, 2010; Raulet et al., 2013). Furthermore, also some CD4+ αβ T cells express 
NKG2D (Jamieson et al., 2002; Groh et al., 2006), e.g., a fraction of CD4+ T cells from patients with 
rheumatoid arthritis (Groh et al., 2003). In mice, the NKG2D receptor is also expressed on NK cells, 
certain T cell subsets and in contrast to humans also on macrophages after activation with 
lipopolysaccharide and different cytokines (Diefenbach et al., 2000; Jamieson et al., 2002). In 
activated CD8+ αβ T cells (Groh et al., 2001) and subsets of γδ T cells (Girardi et al., 2001; Whang et 
al., 2009), NKG2D functions as a co-stimulatory molecule, whereas NKG2D signaling on NK cells 
triggers cytotoxicity (Billadeau et al., 2003) and cytokine secretion (Andre et al., 2004). However, it 
has been also reported that after activation of CD8+ T cells, NKG2D engagement in the absence of 
TCR activation was sufficient to elicit killing of target cells (Meresse et al., 2004). γδ T cells may also 
be directly activated by NKG2D in the absence of TCR engagement (Rincon-Orozco et al., 2005; 
Nitahara et al., 2006). Taken together, NKG2D-mediated pathways are important for detection and 
elimination of malignant cells (Guerra et al., 2008) and are critical in defense against several 
pathogens (Fang et al., 2008; Wesselkamper et al., 2008; Champsaur and Lanier, 2010; Choy and 
Phipps, 2010). Thus, the immunoreceptor NKG2D plays an important role in immunosurveillance of 
malignancies and infections. 
 
1.1.3.1 NKG2D-mediated signaling 
Many immunoreceptors are multi-subunit complexes consisting of ligand-binding recognition 
subunits, which are non-covalently associated with signal-transducing subunits, or so-called 
´adaptors´. 
The human NKG2D receptor complex is a hexamer, with one NKG2D homodimer associating with two 
homodimeric DAP10 (DNAX-activating protein of 10 kDa) adaptor molecules (Garrity et al., 2005) as 
depicted in Figure 1.3. The cytoplasmic domain of each DAP10 monomer contains one tyrosine-based 
signaling motif (YxxM; where x designates any amino acid) (Wu et al., 1999; Lanier, 2009). Receptor 
engagement induces tyrosine phosphorylation of the signaling motifs by activated Src family kinases 




NKG2D-DAP10 complex was prevented by the specific Src family kinase inhibitor PP2 (Billadeau et al., 
2003). Phosphorylated DAP10 is able to bind either the p85 subunit of phosphatidylinositol 3-kinase 
(PI3K) (Wu et al., 1999; Sutherland et al., 2002) and subsequently the adaptor molecule CrkL (v-Crk 
avian sarcoma virus CT10-homolog-like) (Segovis et al., 2009) or the adaptor Grb2 (growth factor 
receptor-bound protein 2) in association with the guanine nucleotide exchange factor VAV1 and 
SOS1 (son of sevenless 1) forming a Grb2 – VAV1 – SOS1 signaling complex (Gilfillan et al., 2002; 
Graham et al., 2006; Upshaw et al., 2006; Lanier, 2008). Mutagenesis and inhibition studies showed 
that NKG2D-mediated signaling requires both a DAP10-bound Grb2-VAV1 intermediate and the p85 








































Figure 1.3: DAP10-mediated NKG2D signaling in human NK cells. 
Cross-linking of the NKG2D receptor with its ligands induces tyrosine phosphorylation of the YINM motif in the 
cytoplasmic domain of DAP10 by auto-phosphorylated Src family kinases leading to the activation of underlying 
signaling pathways. Phosphorylated DAP10 is able to bind either the p85 subunit of PI3K and subsequently the 
adaptor CrkL or the adaptor Grb2 in association with VAV1 and SOS1 forming a Grb2 – VAV1 – SOS1 signaling 
complex. These events trigger distal signaling cascades as depicted. Akt, anti-apoptotic serine-threonine kinase; 
CrkL, v-Crk avian sarcoma virus CT10-homolog-like protein; DAG, diacylglycerol; ERK, mitogen-activated protein 
(MAP) kinase; DAP10, DNAX-activating protein of 10 kDa; Grb2, growth factor receptor-bound protein 2; IP3, 
inositol (3,4,5)-trisphosphate; Jak3, Janus kinase 3; MEK, MAP kinase; PI3K, phosphatidylinositol 3-kinase; PIP2, 
phosphatidylinositol (3,4)-bisphosphate; PIP3, phosphatidylinositol (3,4,5)-trisphosphate; PLC-y2, 
phospholipase C-2; Rac, GTPase; SLP-76, Src homology 2 (SH2) domain-containing leukocyte protein of 76 kDa; 
SOS1, son of sevenless 1; Src, Src family kinases; STAT, signal transducers and activators of transcription; VAV1, 




Binding of Grb2 to DAP10 induces phosphorylation of the downstream molecules VAV1, Src 
homology 2 (SH2) domain-containing leukocyte protein of 76 kDa (SLP-76) and phospholipase C-γ2 
(PLC-y2) (Billadeau et al., 2003; Upshaw et al., 2006) which leads to Ca2+ influx and recruitment and 
activation of several cytoplasmic enzymes such as the MAP kinases MEK and ERK. This triggers NK cell 
activation, which leads to actin cytoskeleton reorganization and cell polarization and finally results in 
granule release and cytotoxicity (Lanier, 2008). PI3K activation by binding of p85 to DAP10 induces 
production of phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which is required to form the NKG2D 
immunological synapse (Giurisato et al., 2007). PI3K additionally activates an anti-apoptotic serine-
threonine kinase called Akt, which promotes NK cell survival (Wu et al., 1999; Sutherland et al., 
2002). Moreover, it has been proposed that the intracellular signaling components of the IL-15 
receptor (IL-15R) and NKG2D-DAP10 are coupled. The Janus kinase 3 (Jak3), recruited and activated 
by the cytokine IL-15, could contribute to DAP10 phosphorylation and initiated killing of target cells 
(Horng et al., 2007). This is in accordance with observations showing the necessity for human NK cells 
to be ´primed´ by cytokine stimulation, such as IL-15 or IL-2, before certain NK cell receptors, 
including NKG2D, are competent to elicit cytotoxicity (Bryceson et al., 2005; Bryceson et al., 2006). 
The influence of NKG2D-DAP10 receptor complexes on cytokine production is less well understood. 
However, NKG2D-DAP10 complexes can induce cytokine production, such as IFN-γ and GM-CSF, if 
cross-linked with a high-avidity ligand, in vitro. Interestingly, cytokine secretion, in contrast to 
cytotoxicity, was observed only after NKG2D cross-linking by soluble recombinant NKG2D ligands, 
including MICA and ULBP1/2, (Kubin et al., 2001; Andre et al., 2004) but not by anti-NKG2D Abs 
(Billadeau et al., 2003). However, this difference has been questioned, since cytokines can be 
induced by cross-linking NKG2D with anti-NKG2D mAb, if plates are coated with a sufficiently high 
concentration of the agonist Ab (Lanier, 2008). Thus, it seems that the NKG2D/DAP10 receptor 
complex cannot only induce cytotoxicity but also production of cytokines (Lanier, 2009). 
 
1.1.4 Ligands of NKG2D 
Notably, a diversity of NKG2D ligands exists, which are not or only expressed at low levels under 
normal conditions, but can be up-regulated as a result of cellular stress, infection or malignant 
transformation (Raulet, 2003). Several NKG2D ligands have been identified in humans and mice. 
These ligands are self proteins, encoded in the host’s genome, and are related to MHC class I 




The MHC class I chain-related protein A (MICA) was the first ligand identified for human NKG2D 
followed by its close relative MICB (Bauer et al., 1999). No orthologs of MICA/B have been identified 
in the mouse and rat genome. Further NKG2D ligands in humans include up to six different UL16-
binding proteins (ULBPs; ULBP1-6), also known as retinoic acid early transcript-1 (RAET-1) proteins 
(Cosman et al., 2001; Onda et al., 2001; Steinle et al., 2001; Radosavljevic et al., 2002). In contrast to 
MICA/B, there is a family of mouse genes orthologous to the human ULBP/RAET-1 family. These 
mouse proteins include five different isoforms of retinoic acid early inducible-1 (RAE-1) proteins, one 
murine UL16-binding protein-like transcript 1 (MULT1) protein and three different isoforms of 
histocompatibility 60 (H60) proteins (Raulet, 2003; Raulet et al., 2013). The different ligands of 
NKG2D are markedly distinct in sequence, show a wide range of binding affinities to NKG2D and 
some of them are transmembrane proteins, while others are glycosylphosphatidylinositol (GPI)-
linked (Diefenbach et al., 2000; Raulet, 2003; Strong and McFarland, 2004; Champsaur and Lanier, 
2010). However, as shown by X-ray diffraction analysis the topography of binding of the different 
NKG2D ligands appears to be similar (Radaev and Sun, 2003; Strong and McFarland, 2004). 
 
1.1.4.1 Regulation of NKG2D ligand expression 
Cell surface expression of the diverse ligands of the activating NK cell receptor NKG2D must be tightly 
regulated to avoid destruction of healthy cells by NK cells. Therefore, cell and tissue-specific events 
control both transcriptional and posttranscriptional regulatory processes.  
Some NKG2D ligand transcripts, e.g., mouse RAE-1, are rarely expressed in normal cells but their 
expression is detectable in tumor and infected cells, while transcripts of other ligands, including 
human MICA/B, ULBPs and mouse MULT1, are found in healthy and diseased tissues (Cosman et al., 
2001; Radosavljevic et al., 2002; Cerwenka, 2009). MICA and MICB are inducible by heat shock in 
certain cell lines (Groh et al., 1996). The promoters of the MIC genes contain heat shock elements 
similar to those found in heat shock protein 70 (HSP70) genes, which bind to heat shock factor-1, as 
well as a binding site for the transcription factor activator protein 1 (AP-1) (Venkataraman et al., 
2007). MICA and MICB proteins have also been shown to be up-regulated in tumor cells upon 
retinoic acid (RA) treatment (Jinushi et al., 2003) – similarly as RAE-1 molecules (Nomura et al., 
1996). Furthermore, NKG2D ligand expression is induced by DNA-damaging agents, such as ionizing 
radiation, 5-fluorouracil, aphidicolin, cisplatin and UV-C (Gasser et al., 2005). Oncogenes, such as 




Moreover, expression of NKG2D ligands is regulated by posttranscriptional mechanisms, which 
include inhibition of ligand expression by microRNAs (miRNAs). Viral-encoded as well as endogenous 
cellular miRNAs can control expression of ligands, including MICA, MICB and ULBP3, by binding to 3´ 
untranslated region (3´-UTR) sites of the corresponding messenger RNA (mRNA) of the target genes 
(Stern-Ginossar et al., 2008; Raulet et al., 2013).  
Posttranslational regulation includes cleavage from the cell surface (see section 1.1.5), excretion in 
vesicles such as exosomes and secretion from the cell (Raulet et al., 2013). A further mechanism of 
posttranslational regulation of MULT1 is ubiquitin-dependent lysosomal degradation of this ligand in 
healthy cells, which is decreased in response to UV stress or heat shock in stressed cells (Nice et al., 
2009). It is conceivable that cell surface expression of other NKG2D ligands, including MICA, is also 
regulated by ubiquitination (Thomas et al., 2008; Cerwenka, 2009).  
 
1.1.5 Tumor immune evasion – NKG2D down-regulation and MICA shedding 
In general, tumors have evolved diverse immune evasion strategies to safeguard their survival, which 
often involve blinding or inhibiting immune responses. Tumor-mediated counter-regulation 
mechanisms to escape NK cell surveillance include NKG2D down-regulation after chronic exposure of 
NK cells to NKG2D ligands on tumor cells leading to impaired NK cell cytotoxic function and tumor 
cell-mediated shedding of NKG2D ligands resulting in the presence of immunosuppressive soluble 
particles of the corresponding ligands (Figure 1.4).  
Several studies have shown that persistent expression of NKG2D ligands, such as MICA, and 
sustained triggering of receptor signaling by these ligands can lead to profound down-modulation of 
the cell surface expression of NKG2D and consequent compromised NK cell-mediated cytotoxicity 
upon subsequent receptor engagement (Groh et al., 2002; Coudert et al., 2005; Oppenheim et al., 
2005; Wiemann et al., 2005). Rapid endocytosis and partial lysosomal degradation of both 
components of the NKG2D/DAP10 receptor complex may explain the loss of NKG2D membrane 
expression and the impairment in NK cell cytotoxic capacity after chronic exposure to NKG2D ligands 
(Roda-Navarro and Reyburn, 2009). Furthermore, TGF-β (Castriconi et al., 2003; Lee et al., 2004), IL-
21 (Burgess et al., 2006) and macrophage migration inhibitory factor which is also produced by tumor 
cells (Krockenberger et al., 2008) are negative regulators of NKG2D and down-modulate the receptor 






Figure 1.4: Strategies of tumor immune escape from NK cell-mediated immunosurveillance. 
(A) NK cells kill their targets by the combined release of cytotoxic granules, the expression or release of TRAIL, 
FasL and TNF and ADCC resulting in apoptosis of the target cell. Tumor cells may escape NK cell-dependent 
immunosurveillance by several pathways: (B) alterations in DNA modifying enzymes such as histone 
deacetylases (HDACs) or miRNAs, involved in epigenetic gene regulation, repress the expression of MICA/B, (C) 
persistent expression of activating ligands and sustained triggering of NKG2D leads to hypo-responsiveness and 
decreased cytotoxicity due to decreased NKG2D expression and reduced IFN-γ production, (D) tumor-released 
cytokines, such as TGF-β and IFN-γ, repress MICA/B expression, down-regulate NKG2D expression and IFN-γ 
production in NK cells and promote the conversion of CD4
+






 T (Treg) 
cells, suppressing immunosurveillance, (E) and up-regulation of MMPs and ADAMs, which promote the 
shedding of activating ligands such as MICA, which binds to NKG2D on CD4
+
 T cells and NK cells resulting in 
hypo-responsiveness in NK cells due to degradation of NKG2D and CD4
+
 T cell conversion into Treg cells. 
(Adapted from Groth et al., 2011). 
 
NKG2D is also down-regulated by circulating tumor-derived soluble NKG2D ligands. Members of the 
family of matrix metalloproteases (MMPs) and the ´a disintegrin and metalloproteinase´ (ADAM) 
family, including ADAM10 and ADAM17, cleave MICA (Salih et al., 2002; Kaiser et al., 2007; 
Waldhauer et al., 2008). The α3 domain of MICA forms a complex with the disulphide 
isomerase/chaperon endoplasmic reticulum protein 5 (ERp5) on the surface of tumor cells which 
induces a conformational change enabling the proteolytic cleavage of MICA. The soluble MICA 
(sMICA) then interacts with NKG2D, which in turn induces the internalization and degradation of the 
NKG2D/DAP10 receptor complex and stimulates the expansion of immunosuppressive NKG2D+CD4+ T 




phenomenon is called ´MICA shedding´ (Groh et al., 2002; Kaiser et al., 2007). Shedding of NKG2D 
ligands has been reported for most cancers and some hematopoietic malignancies, in which not only 
soluble ligands but also tumor-derived exosomes (Clayton et al., 2008) may contribute to NKG2D 
down-modulation. A number of clinical trials showed an association between tumor-associated or 
soluble NKG2D ligands and disease progression and poor prognosis in different malignant diseases 
(El-Gazzar et al., 2013) (see section 1.2.3).  
Taken together, these tumor-mediated counter-regulation mechanisms lead to tumor evasion from 
NK cell-mediated immunity. Thus, future studies should improve NK cell immunotherapy by 
developing strategies to overcome tumor immune evasion mechanisms (Groth et al., 2011). 
 
1.2 Highly polymorphic NKG2D ligand MICA 
MIC genes, initially also called Perth beta block transcript 11 (PERB11), were first described in 1994 
by two independent groups (Bahram et al., 1994; Leelayuwat et al., 1994). The MIC genes are highly 
conserved and are present in most mammals, except in rodents (Kumanovics et al., 2003). The 
human MIC family encompasses seven MIC genes, named MICA to MICG, which are encoded in the 
class I region of the human MHC gene complex on chromosome 6. Only the MICA gene and its 
homologue MICB are functional, whereas the other family members are pseudogenes. An important 
feature of MICA and MICB is their high degree of polymorphism. The MICA gene is located head-to-
head and approximately 46 kb or 70 kb centromeric to the HLA-B or MICB gene, respectively (Shiina 
et al., 1999; Bahram, 2000). MICA possesses six exons separated by five introns (Figure 1.5).  
 
  
Figure 1.5: Exon/intron organization of the human MICA gene. 
The MICA gene has six exons separated by five introns. Exon (EX) and intron lengths are given in base pairs (bp) 
(EMBL/GenBank/DDBJ accession number, MICA*04 (A6) X92841). Introns indicated with II are not at scale. EX1 
encodes the leader-peptide region, EX2 the G-α1-like domain, EX3 the G-α2-like domain, EX4 the C-like domain, 
EX5 a connecting, a transmembrane and a part of an intracytoplasmic region and EX6 the main part of the 
intracytoplasmic region. The length of the EX5 (132 to 150 bp) depends on a triplet repeat microsatellite 
polymorphism (GCT)n in the transmembrane region. A length of 138 bp for EX5 corresponds to an A6 allele. 
Colors are according to IMGT color menu for regions and domains (http://imgt.cines.fr). Adapted from (Frigoul 





MICA is constitutively expressed only on a few cell types such as gastrointestinal epithelium, perhaps 
as a consequence of stimulation by the neighboring bacterial flora, (Groh et al., 1996). However, 
MICA expression is induced by cellular and genotoxic stress (Groh et al., 1996; Gasser et al., 2005) 
leading to an up-regulation of the expression on malignant cells, such as on a variety of solid tumors 
of epithelial origin as well as in lymphoproliferative malignancies, or virus-infected cells (Raulet, 
2003; Champsaur and Lanier, 2010; Raulet et al., 2013). 
 
1.2.1 MICA structure and MICA-NKG2D interaction  
MICA is a type-1 transmembrane protein of 43 kDa (Bahram et al., 1994; Raulet, 2003). Its domain 
structure is similar to those of classical MHC class I molecules and comprises three extracellular 
domains, called α1 (encoded by exon 2), α2 (encoded by exon 3) and α3 (encoded by exon 4), a 
transmembrane segment, including a connecting region and a part of the cytoplasmic region, 
(encoded by exon 5) and a carboxy-terminal cytoplasmic tail (encoded by exon 6) (see above, Figure 
1.5) (Bahram, 2000). The fold of MICA forms two structural domains: the α1α2-platform domain and 
the C-type immunoglobulin-like α3 domain (Figure 1.6.) (Li et al., 2001). The MICA crystal structure 
revealed that this platform consists of four distinct α helices arranged on an eight-stranded anti-
parallel β sheet (Li et al., 1999). However, MICA does not associate with β2-microglobulin – the light 
chain of MHC class I molecules – and does not present peptides (Groh et al., 1996; Groh et al., 1999). 
Li and collaborators demonstrated that the homodimeric NKG2D receptor binds diagonally across the 
α-helical surface of the MICA platform domain in an interaction which is analogous to that seen in 
TCR-MHC class I protein complexes (Li et al., 2001). Figure 1.6 shows the crystal structure of human 
NKG2D in complex with MICA indicating that similar surfaces on each NKG2D monomer interact with 
different surfaces on either the α1 or α2 domain of a MICA protein. The MICA-NKG2D interface 
consists of a mixture of polar, hydrophobic and ionic interactions. The high overall complementarity 
at the binding site surfaces was much greater than Ab-antigen, TCR-ligand or other NCR-ligand 
interactions. Furthermore, the binding of NKG2D to MICA is of higher stability and avidity compared 
to many immunoreceptor-ligand interactions. None of the three NKG2D or eight MICA potential N-









Figure 1.6: Crystal structure of the human MICA-NKG2D complex and human MICA alone.  
(A) Side view of ribbon representation of the structure of the human NKG2D receptor in complex with its ligand 
MICA. Each NKG2D monomer interacts with either the α1 or α2 domain of a MICA protein. MICA domains are 
labeled and colored by domain (α1, yellow; α2, red; α3, green). NKG2D is a homodimer consisting of two 
monomers as illustrated by different colors (NKG2D-A monomer, blue; NKG2D-B monomer, purple). Adapted 
from (Li et al., 2001). (B) Amino acid position Met/Val 129, depicted on a ribbon diagram of the MICA crystal 
structure, is located in the β4 strand of the β-pleated sheet in the α2 domain of the protein. Adapted from 
(Steinle et al., 2001). 
 
1.2.2 MICA polymorphisms – MICA-129Met/Val dimorphism 
The MICA gene is the most polymorphic non-classical MHC class I gene in humans (Choy and Phipps, 
2010). Currently 93 MICA alleles are known encoding for 72 protein variants (IMGT/HLA database; 
http://www.ebi.ac.uk/imgt/hla/). MICA has a triplet repeat microsatellite polymorphism (GCT)n in 
the transmembrane region (encoded by exon 5; see above, Figure 1.5), which consists of alleles with 
four up to ten GCT repetitions or five repetitions with an additional nucleotide insertion, resulting in 
a premature stop codon and subsequent in a truncated MICA protein, designated as A4-10 or A5.1, 
respectively (Mizuki et al., 1997). Furthermore, the MICA gene contains several polymorphic 
positions within the exon 2, 3 and 4 which encode the three extracellular domains of the protein and 
which therefore might affect the MICA-NKG2D interaction (Table 1.1). These positions are mainly 
single amino acid substitutions (except positions 90 and 91), giving rise to dimorphic positions 
(except positions 156 and 251), and many of which are non-conservative changes (Choy and Phipps, 
2010). The α2 domain exhibits the highest number of polymorphic positions which can be found in 




site for NKG2D, harbors the most variable positions with at least one polymorphic position (position 
156) interacting directly with the NKG2D receptor (Li et al., 2001).  
 
Table 1.1: Amino acid substitutions in extracellular domains of the human MICA protein. 
















































































































Non-conservative amino acid substitutions are underlined. Adapted from (Choy and Phipps, 2010). 
 
The single nucleotide polymorphism (SNP; rs1051792; A → G) at position 454 of the MICA gene 
leading to a single amino acid substitution of methionine (Met) by valine (Val) at position 129 of the 
protein, designated as MICA-129Met/Val polymorphism, is of particular interest, since Steinle and 
colleagues revealed the Met variant as strong and the Val variant as weak binder of NKG2D. The 
amino acid 129 is located in the β4 strand of the β-pleated sheet in the α2 domain of the MICA 
protein as shown in Figure 1.6 B (Li et al., 1999; Li et al., 2001). The side chain of Met 129 is partially 
buried and forms hydrophobic interactions with glutamine (Glu) 136, alanine (Ala) 139 and Met 140. 
Therefore, its replacement by Val likely affects NKG2D binding indirectly by a conformational change 
(Steinle et al., 2001). 
 
1.2.3 Associations of MICA polymorphisms with diseases 
MICA polymorphisms have been associated with several diseases related to NK cell activity, such as 
viral infection, cancer, autoimmune disease and allograft rejection or graft-versus-host disease 
(GVHD). Underlying mechanisms include NK cell-mediated cytotoxicity and the MICA shedding 
phenomenon producing sMICA with immunosuppressive functions (see section 1.1.5) (Choy and 




However, because of the proximity of the MICA gene to HLA-B and HLA-C, which are associated with 
various disorders, it is necessary to perform large and multi-ethnic disease studies on MICA 
polymorphisms to exclude HLA class I gene associations. Initial MICA polymorphism and disease 
association studies were undertaken only in small cohorts or single-ethnic groups and/or which did 
not take into account possible HLA class I gene associations, associated autoimmune diseases, such 
as Behçet’s disease (Mizuki et al., 1997) and ankylosing spondylitis (Goto et al., 1997), with MICA 
polymorphisms. Later studies however suggested that these diseases were primarily associated with 
HLA-B alleles and that the perceived disease association with MICA alleles was due to linkage 
disequilibrium with HLA-B (Wallace et al., 1999; Salvarani et al., 2001; Mizuki et al., 2007) or only 
secondary (Martinez-Borra et al., 2000), respectively. 
 
Table 1.2: SNPs in MICA alleles associated with human diseases. 
 
Nevertheless, more refined studies also showed associations of MICA polymorphisms with infections, 
malignant and autoimmune disorders (Table 1.2). For instance, it has been reported that a SNP, 
MICA-173Lys, confers protection against rheumatoid arthritis in French and German populations 
independent of known HLA-DRB1 risk alleles (Kirsten et al., 2009). Jumnainsong et al. (2007) 
observed that two SNPs encoding the α3 domain, MICA-213Thr and MICA-251Gln, are negatively 
associated with cervical cancer. Furthermore, different microsatellite polymorphisms in the 
transmembrane region of the MICA gene were found to be associated with different cancer types. 
For example, MICA*A5 and MICA*A9 in southern Chinese Han populations are reported to be 
SNP Disease Effect Population Reference
MICA-129Met Early onset ankylosing spondylitis Susceptibility Algerian Amroun et al., 2005
MICA-129Val Chronic graft-versus-host disease Susceptibility French Boukouaci et al., 2009
MICA-129Val Nasopharyngeal carcinoma Susceptibility Tunisian Douik et al., 2009
MICA-129Met Inflammatory bowel disease Susceptibility Spanish Lopez-Hernandez et al., 2010
MICA-129Met Systemic lupus erythematosus Susceptibility Japanese Yoshida et al., 2011
MICA-129Val Ulcerative colitis Susceptibility Chinese Zhao et al., 2011
MICA-129Val Type 1 and latent autoimmune diabetes Susceptibility Algerian Raache et al., 2012
MICA-129Met Psoriatic disease Susceptibility Canadian Pollock et al., 2013
MICA-173Lys Rheumatoid arthritis Protection French, German Kirsten et al., 2009
MICA-213Thr
MICA-251Gln
Cervical cancer Protection Northeastern Thai Jumnainsong et al., 2007
MICA*A5 Leukemia Susceptibility Southern Chinese Luo et al., 2011
MICA*A5.1 Oral squamous cell carcinoma Susceptibility Japanese Tamaki et al., 2007
MICA*A5.1 Breast cancer Susceptibility Spanish Lavado-Valenzuela et al., 2009
MICA*A5.1 Hepatocellular carcinoma Susceptibility Southern Chinese Jiang et al., 2011




associated with an increased susceptibility to leukemia (Luo et al., 2011) or nasopharyngeal 
carcinoma (Tian et al., 2006), respectively. Especially the MICA*A5.1 polymorphism, giving rise to a 
truncated MICA protein, was shown to be associated with oral squamous cell carcinoma in Japanese 
patients (Tamaki et al., 2007 and 2009), breast cancer in Spanish women (Lavado-Valenzuela et al., 
2009) and hepatocellular carcinoma in a South China Han population (Jiang et al., 2011). Some of 
these studies additionally revealed a relationship between cancer patients carrying the MICA*A5.1 
polymorphism and increased serum levels of sMICA (Tamaki et al., 2009; Jiang et al., 2011). 
The MICA-129Met/Val polymorphism, which affects NKG2D binding avidity (Steinle et al., 2001), has 
been associated with malignancies and autoimmune diseases independently of HLA class I and class II 
gene associations (Table 1.2).  
The Val variant of the MICA-129 dimorphism was found to be associated with increased susceptibility 
to nasopharyngeal carcinoma in a Tunisian population (Douik et al., 2009). Since MIC molecules are 
not specifically tumor-associated antigens (Schrambach et al., 2007), the observed association of the 
MICA-129Val variant with this type of cancer can be therefore better explained by the reduced 
NKG2D avidity and possibly also by the MICA shedding phenomenon (Choy and Phipps, 2010).  
Furthermore, a number of autoimmune diseases, including ankylosing spondylitis, rheumatoid 
arthritis, inflammatory bowel disease, systemic lupus erythematosus, type 1 diabetes and latent 
autoimmune diabetes and psoriatic disease, have been associated with the MICA-129Met/Val 
polymorphism. In this context, the MICA-129Met variant was observed to be associated with an 
increased susceptibility to early onset ankylosing spondylitis in a cohort of Algerian patients 
independently of HLA-B*27 (Amroun et al., 2005). Lopez-Hernandez et al. (2010) found a higher 
frequency of the MICA-129Met/Met genotype in Spanish patients with inflammatory bowel disease 
(mainly in ulcerative colitis). Zhao et al. (2011) showed that the MICA-129Val/Val genotype was more 
frequent in Chinese patients with ulcerative colitis and that these patients had also higher serum 
levels of sMICA compared to those with the Met/Val or Met/Met genotype. A Japanese study 
described that the MICA-129Met allele was positively associated with systemic lupus erythematosus 
in contrast to the Val allele showing a negative association (Yoshida et al., 2011). Additionally, also 
the frequency of the MICA-129Val variant was increased in Algerian patients with type 1 diabetes 
and latent autoimmune diabetes in adults than in the control group (Raache et al., 2012). Pollock and 
collaborators investigated whether MICA-129 was differentially associated with skin and joint 
manifestations of psoriatic disease independently of HLA-C and HLA-B in two Canadian Caucasian 
cohorts and found that the Met allele, particular Met/Met homozygosity, was associated with 




Moreover, an association between the MICA-129Val/Val genotype and an increased risk of chronic 
GVHD (cGVHD) after hematopoietic stem cell transplantation (HSCT) in a French cohort of cancer 
patients has been reported (Boukouaci et al., 2009) (see section 1.3.3). Independently of the Val/Val 
genotype also elevated sMICA serum levels were shown to associate with the incidence of cGVHD. 
 
1.3 Therapy of cancer – NK cells and MICA polymorphisms 
The knowledge that NK cells can rapidly respond to the presence of tumor cells and participate in 
tumor immunosurveillance has prompted efforts to harness NK cell functions for the development of 
improved strategies in the treatment of cancer patients. NK cell-based therapeutic approaches are 
relatively new in cancer therapy (Terme et al., 2008). Besides monoclonal antibody-based therapies, 
which indicate that NK cell-mediated ADCC contributes to the beneficial antitumor response (Cartron 
et al., 2002; Veeramani et al., 2011), adoptive tumor immunotherapies focusing on the manipulation 
of NK cells and strategies targeting NK cell activation receptors or their ligands represent potentially 
promising approaches in cancer therapy. 
 
1.3.1 NK cells in immunotherapy of cancer 
Allogeneic hematopoietic stem cell transplantation (HSCT) is an efficient form of an immunotherapy 
and currently the only potentially curative treatment of many hematological malignancies (Dickinson, 
2008). NK cells make important contributions to graft-versus-leukemia (GVL) effects after allogeneic 
HSCT (Warren et al., 2012) without inducing graft-versus-host disease (GVHD) (Dong et al., 2009; 
Vivier et al., 2012). This feature possibly results from the differential distribution of ligands for NK 
activation receptors on hematopoietic and non-hematopoietic cells (Dong et al., 2009; Vivier et al., 
2012). ´Haplo-identical´ transplantation is one type of allogeneic HSCT, in which the related donor 
and recipient share only one HLA haplotype, and which has highlighted the potential of NK cells in 
tumor immunosurveillance. In a ´KIR ligand-mismatched´ situation, subsets of donor-derived NK cells, 
which are not inhibited by host MHC class I molecules, exert GVL effects (Figure 1.7 A) (Vivier et al., 
2012). The positive effect of KIR incompatibility in haplo-identical T cell-depleted HSCT has been 
demonstrated in various studies of patients with acute myeloid leukemia (AML) (Ruggeri et al., 2002; 
Giebel et al., 2003; Ruggeri et al., 2007) or multiple myeloma (Kröger et al., 2005). Nevertheless, HLA-




haplo-identical HSCT is used for only a minor subset of patients with poor-prognosis because of their 




Figure 1.7: Cancer therapies targeting NK cells. 
(A) Following haplo-identical or MHC-matched HSCT, NK cells of donor origin develop in the cancer patient. (B) 
Alternatively, NK cell populations can be isolated from healthy donors and activated and/or expanded in vitro 
before infusion into the patient with cancer. In both cases (allogeneic HSCT and NK cell infusion), the aim is to 
promote the antitumor function of donor NK cells in the patient. Indeed, a fraction of donor NK cells will be not 
be inhibited by the MHC class I molecules of the patient, as the KIRs expressed by the donor NK cells will not 
interact with the MHC class I molecules of the patient, and this promotes tumor cell elimination. In contrast, to 
cancer cells, most healthy cells of the patient will not activate donor NK cells, as they lack a sufficient cell-
surface density of activating ligands for the donor NK cells. Adapted from (Vivier et al., 2012). 
 
NK cells are considered as promising therapeutic tools for tumor immunotherapy also independently 
of HSCT (Terme et al., 2008). They can be isolated from healthy donors and subsequently activated 
and/or expanded in vitro before infusion into the recipient (Figure 1.7 B). In this context, allogeneic 
NK cell transfer is preferred to autologous transfer because it is known that the cytotoxic potential of 
autologous NK cells is weak compared to allogeneic NK cells (Groth et al., 2011). However, to obtain 
long-term cancer control it is necessary to increase the survival of the NK cells in the recipient. NK 
cell function could be improved by cytokine stimulation, especially IL-2 treatment, leading to an 
increased NK cell cytotoxicity and antitumor response (Fehniger et al., 2002; Huenecke et al., 2010). 
Several protocols of clinical-grade NK cell purification and in vitro population expansion are validated 




(Vivier et al., 2012). Furthermore, it has been shown that the adoptive transfer of mature HLA-
mismatched NK cells into cancer patients is also well tolerated (Miller et al., 2005). These findings 
suggest that allogeneic NK cell transfer might be a beneficial antitumor strategy. 
Altogether, the efficacy of NK cell-based tumor therapies has not been firmly established, yet. 
However, as shown by several different studies NK cells represent potential targets for tumor 
immunotherapy and the achievements regarding conditioning regimes justify the present attempts 
to further develop and improve approaches focusing on the manipulation of NK cells. For instance, 
new protocols might include monoclonal Ab cancer therapies in combination with HLA-identical or 
non-identical HSCT, with adoptive NK cell transfer or with drugs inducing the expression of ligands 
for NK activation receptors (Vivier et al., 2012). 
 
1.3.2 Targeting of NKG2D or its ligands for cancer therapy 
The activating NK cell receptor NKG2D and expression of its ligands play an important role in 
antitumor immune responses. Findings from a comprehensive study of hematopoietic malignancies 
found heterogeneous surface expression of at least one NKG2D ligand type in about 75% of leukemia 
patients (Hilpert et al., 2012). In addition, data from distinct solid tumors suggest that MICA is one of 
the most frequent NKG2D ligands (Gonzalez et al., 2006; Nausch and Cerwenka, 2008). Because NK 
cells do not effectively eliminate tumors in cancer patients, new strategies aim to increase both NK 
cell activation and tumor cell visibility to NK cells (Cerwenka, 2009). One approach is the selective up-
regulation of NKG2D ligands using antitumor agents, such as DNA damage-inducing cisplatin and 5-
fluorouracil (Gasser et al., 2005), or genotoxic drugs, including histone deacetylase (HDAC) inhibitors 
(Armeanu et al., 2005), or proteasomal inhibitors (Armeanu et al., 2005 and 2008; Nice et al., 2009). 
HDAC inhibitors have emerged as a powerful new class of small-molecule therapeutics. Over 490 
clinical trials have been initiated in the last 10 years, culminating in the approval of two distinct HDAC 
inhibitors; suberoylanilide hydroxyamic acid (SAHA; also known as vorinostat, ZolinzaTM) and FK228 
(romidepsin, IstodaxTM) (Gryder et al., 2012). A further therapeutic approach to enhance NK cell-
mediated cytotoxicity is the usage of bifunctional fusion proteins comprising of a NKG2D ligand and a 
single-chain antibody fragment (scFv) targeting a specific tumor cell surface marker (El-Gazzar et al., 
2013). An example is ULBP2/anti-syndecan-1 (CD138) scFv, also known as ULBP2/BB4, which 
activates and targets NK cells to the malignant cells in multiple myeloma. While ULBP2 binds NKG2D, 
the BB4 moiety binds to CD138 which is over-expressed on a variety of malignancies (von 




patients and can lead to down-regulation of NKG2D (see section 1.1.5), another approach aims at the 
neutralization of these soluble immunosuppressive particles using specific Abs against the 
corresponding ligands (El-Gazzar et al., 2013). These approaches in combination with other NK cell-
activating regimes and/or adoptive NK cell transfer might improve current clinical strategies in the 
treatment of cancer.  
 
1.3.3 Importance of MICA polymorphisms in HSCT 
Allogeneic HSCT offers an option for cure of several hematopoietic diseases. Currently it relies mainly 
on the HLA matching of donors and recipients which is essential to reduce the risk of graft rejection 
and GVHD and therefore to increase overall survival (Petersdorf et al., 1998; Sasazuki et al., 1998; 
Morishima et al., 2002). However, also minor histocompatibility antigens (mHags) can affect 
transplant outcome playing a role in both GVHD and GVL mechanisms (Warren et al., 2012). 
Moreover, genetic polymorphisms can influence the success of transplantations. An increasing 
number of studies in the last 15 years have demonstrated the impact of SNPs or microsatellites of 
cytokines, cytokine receptor genes or other non-HLA encoded genes including those of the innate 
immune system on the outcome of HSCT (Dickinson, 2008). Those SNPs, which alter the regulation of 
genes or the function of proteins, might not only be useful to predict risks but also to identify 
pathophysiological pathways, which could be targeted by new therapies. For instance, several SNPs 
in the TNF-α gene encoded in the HLA class III region, e.g., have been associated with an increased 
risk of GVHD and some of them lead to an increased expression of this pro-inflammatory cytokine, 
which might explain the observed association with GVHD (Dickinson, 2008). 
In the context of MICA, it has been reported that MICA and MICB genotype matching increased the 
survival after HSCT (Kitcharoen et al., 2006), whereas MICA mismatching increased the incidence of 
acute GVHD (aGVHD) (Parmar et al., 2009) although not in all studies (Anderson et al., 2009). An 
approach which does not only take into account HLA matching but also non-HLA DNA polymorphisms 
in the MHC loci as markers of blocks of ancestral haplotypes, such as beta block (the region including 
HLA-B, HLA-C, MICA and MICB) and delta block (the region including HLA-DR and HLA-DQ), is the 
DNA-based MHC block matching technique (Tay et al., 1995). MHC beta block matching was found to 
be the marker for MIC genes and correlated with MIC matching additionally to matching of HLA-B 
and HLA-C (Gaudieri et al., 2001; Kitcharoen et al., 2006). For instance, the survival of HSCT patients 
who were matched for HLA-B, HLA-C, HLA-DR and HLA-DQ was improved further with additional 




(see section 1.2.3) the MICA-129 dimorphism was found to be associated with the incidence of 
cGVHD and relapse after HSCT in a French cohort of cancer patients (Boukouaci et al., 2009). The risk 
of developing cGVHD was increased for recipients with the MICA-129Val/Val genotype and the risk of 
relapse was increased for the MICA-129Met/Met genotype. Independently of the Val/Val genotype 
also elevated sMICA serum levels were shown to be associated with the incidence of cGVHD, 
whereby the presence of anti-MICA Abs before transplantation was associated with protection 
against cGVHD (Boukouaci et al., 2009). Since MICA polymorphisms do not only feature significantly 
in disease associations but also in donor-recipient matching for transplantation, matching of MICA 
alleles of donors and recipients should be taken into consideration alongside other HLA matching 
techniques to obtain better post-transplant outcomes. 
 
1.4 Objectives 
Numerous studies have demonstrated the impact of SNPs on the outcome of HSCT. Such SNPs might 
be useful to predict risks and to identify new targets for therapy. One candidate of interest is the 
highly polymorphic MICA gene. In this study, we focused on the MICA-129Met/Val polymorphism 
which has been associated previously with the risk of cGVHD and could be causative itself due to a 
higher avidity of MICA-129Met than MICA-129Val variants to NKG2D. Since MICA is a ligand of the 
activating NK cell receptor NKG2D and NK cells have also been reported to play a crucial role in HSCT, 
it is furthermore important to understand the biological relevance of this SNP regarding NK cell 
responses. 
The aim of this project therefore was to determine the impact of the MICA-129 dimorphism on 
effector functions of NK cells. We wanted to analyze whether the two MICA-129 variants differ in 
their ability to trigger NK cell responses, including NKG2D-mediated signaling, cytotoxicity and 
cytokine release. For these experiments, recombinant MICA-129-Fc fusion proteins and MICA-129-
transfected tumor cell lines of both variants were constructed. 
Moreover, we wanted to address the question whether the MICA-129Met/Val dimorphism affects 
the outcome of allogeneic HSCT in a cohort of patients from the University Medical Center Göttingen 
to determine whether this SNP could serve as biomarker for the risk assessment of allogeneic HSCT. 
 
Materials and Methods 
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2 Materials and Methods 
2.1 Materials 
If not specified otherwise, all supplier places are located in Germany. 
 
2.1.1 General equipment 
Table 2.1:  General equipment 
Description  Label  Supplier 
Agarose gel electrophoresis 
system  
Perfect Blue™ Gel System Peglab Biotechnology 
Aqua bidest. Supply  arium® pro Sartorius AG 
Autoclave High pressure steam sterilisator FVS Integra Biosciences 
Biological Safety Cabinet  HERASave® Thermo Fisher Scientific 
 3K30 Sigma 
 Megafuge 1.0R for 96-well plates Heraeus 
 Mini Centrifuge MCF-2360  LMS Consult 
Centrifuges Multifuge 1 b 
Heraeus 
 Multifuge 3 S-R 
 RC 3B Plus Sorvall 
 Refrigerated Microcentrifuge 5417R Eppendorf 
Counting chamber Neubauer improved Krannich 
Dispenser Multipette® plus Eppendorf 
Electroporation system GenePulser® II & Cap. Extender Bio-Rad Laboratories 
Flow Cytometer FACS Calibur BD Biosciences 
 HERA freeze -80°C Heraeus 
Freezer Liebherr Comfort -20°C Liebherr GmbH 
 VIP plus -150°C SANYO Electric Co., Japan 
Homogenizer Tenbroeck schuett-biotec 
Imaging devices 
Chemilux Blot Detection Imager  
Intas Science Imaging 
UV workbench GelImager 
Incubators HERACell® 150 CO2   Heraeus 
Incubator shaker Unitron-plus Infors 
Liquid Scintillation Counters 
MicroBeta Trilux 1450                                                                
MicroBeta2 Plate Counter 
PerkinElmer, USA 
MACS separator SuperMACS™ Separator MACS Miltenyi Biotec 
Magnetic stirrer/heater RH basic 2 IKA 
Microscope Axiovert 35 Zeiss 
Microwave HF12M 900W Siemens 
pH-Meter inoLab® pH Level 1  WTW 
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Pipettes 2 µl, 20 µl, 200 µl,    
1000 µl 
Research® & Reference® Eppendorf 
Pipettor IBS PIPETBOY acu Integra Biosciences 
Power supplies 
EPS-301/-3501 XL GE Healthcare 





SDS gel chambers Hoefer SE600 Ruby GE Healthcare 
Spectrophotometer 
BioPhotometer  Eppendorf 
NanoDrop™ ND-1000 Thermo Fisher Scientific 
PowerWave 340 microplate reader BioTek 
SPR biosensor SR7500DC Reichert Technologies 
Thermal Cycler 
ABI 7500 Real-Time PCR System 
Applied Biosystems, USA 
ABI 7900HT Fast Real-Time PCR 
MasterCycler epgradient  Eppendorf 
TPersonal 48 Biometra 
Thermoblocks 
Thermomixer comfort Eppendorf 
Stuart Block Heater SBH130 Bibby Scientific 
Vortexer MS1 Minishaker IKA 
Water bath Medingen W6 Labortechnik Medingen 
Western blot device Semi-dry transfer unit TE 70 Hoefer 
 
2.1.2 Consumables 
Table 2.2:  Consumables 
Label Supplier 
2D HC 1000m sensorchip for SPR Xantec Bioanalytics 
6-well tissue culture plates, F-bottom Greiner bio-one GmbH 
24-well tissue culture plates, F-bottom Greiner bio-one GmbH 
96-well MaxiSorp™ microtiter plates Nunc 
96-well optical reaction plates for qRT-PCR Applied Biosystems, USA 
96-well suspension culture plates, F-bottom Greiner bio-one GmbH 
96-well suspension culture plates, U-bottom Greiner bio-one GmbH 
96-well tissue culture plates, V-bottom Sarstedt 
96-well Wallac OptiPlates PerkinElmer, USA 
384-well plates for TaqMan® Genotyping Assay Applied Biosystems, USA 
Adhesive sealing film for Wallac plates PerkinElmer, USA 
Amicon ultra-15 centrifugal filter units (30 kDa) Merck Millipore 
Cell culture flasks (250 ml)  Sarstedt 
Cell culture plates (3.5 cm, 6 cm, 10 cm) Greiner bio-one GmbH 
Cellstar® sterile pipettes (1 ml, 2 ml, 5 ml, 10 ml, 25 ml) Greiner bio-one GmbH 
Cell strainer (40 µm) BD Biosciences 
Cover slips Sarstedt 
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Cryo tubes Greiner bio-one GmbH 
Electroporation cuvette (4 mm gap) Peqlab Biotechnology 
FACS tubes BD Biosciences / Sarstedt 
Falcon conical tubes (15 ml, 50 ml) Greiner bio-one GmbH 
Filter units (0.2 μm, 0.45 μm) Greiner bio-one GmbH 
Gel blotting paper GB 003 Whatman, Schleicher & Schuell 
HiTrap® Protein G column (1 ml) GE Healthcare 
Leucosep® Tubes with porous barrier (50ml), conical bottom Greiner bio-one GmbH 
MACS LS columns MACS Miltenyi Biotec 
Membrane adapter Sarstedt 
Microscope slides Menzel 
Multipette® plus Combitips Eppendorf 
Needles 21 G x 1 1/2", 22 G x 1 1/4", 26 G x 1/2", 30 G x 1/2" B. Braun Melsungen AG 
Optical adhesive covers for qRT-PCR plates Applied Biosystems, USA 
Parafilm® Pechiney Plastic Packaging 
Pasteur pipettes Wilhelm Ulbrich Mainz 
Pipette tips (10 μl, 200 μl, 1000 μl) Greiner bio-one GmbH / Sarstedt 
Plastic tubes (13 ml) Sarstedt 
Reaction tubes 0.5 ml Sarstedt 
Reaction tubes (1.5 ml, 2 ml) Greiner bio-one GmbH 
Roti®-Nitrocellulose membrane Carl Roth 
Safety-Multifly®-Set Sarstedt 
SERVAPOR® dialysis tubing (12-14 MWCO) SERVA Electrophoresis GmbH 
Syringes (1 ml) Henke Sass Wolf 
Syringes (1 ml, 2 ml, 5 ml, 10 ml, 20 ml) BD Biosciences 
UVette® Eppendorf 
Weighing paper Machery-Nagel 
 
2.1.3 Chemicals and reagents 
All chemicals and reagents used in this study were of pro analysis quality and are listed in the Table 
2.3. 
Table 2.3:  Chemicals and reagents 
Chemical/Reagent Supplier 
2,2’-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) AppliChem 
2-β-Mercaptoethanol SIGMA-Aldrich® 
3,3’-diaminobenzidine (DAB) Carl Roth 
4-amino-3-(4-chlorophenyl)-1-(t-butyl)-1H-pyrazolo[3,4-d] 
pyrimidine (PP2)  
SIGMA-Aldrich® 
Agar-Agar, Kobe I Carl Roth 
Ammonium chloride (NH4Cl) Merck 
Ammonium persulfate (APS) Serva 
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Ampicillin sodium salt (C16H18N3NaO4S) Carl Roth 
Bio-Rad Protein Assay reagent Bio-Rad Laboratories 
Bovine serum albumin (BSA) PAA Laboratories 
Bromphenol Blue (Na+-salt) Merck 
Chloroform Carl Roth 
Citric acid (C6H8O7) Carl Roth 
Coomassie Brilliant Blue R-250 SIGMA-Aldrich® 
Dimethyl sulfoxide (DMSO) Merck 
dNTPs NEB®, USA 
Eosin Merck 
Ethanol (EtOH) UMG Apotheke 
Ethidium bromide HyClon 
Ethylenediaminetetraacetic acid (EDTA) Carl Roth 
FACSflow BD Biosciences 
FACS™ Lysis solution BD Biosciences 
Fetal calf serum (FCS) PAA Laboratories 
Formalin Carl Roth 
GeneRuler 1kb DNA ladder Fermentas 
Geneticin (G418 Sulfate) Biochrom 
GIBCO® Penicillin/Streptomycin Merck 
Glycerol Carl Roth 
Glycine Carl Roth 
Heparin sodium Rotexmedica 
Hexadimethrine bromide (Polybrene) Merck 
Hydrochloric acid (HCl) Carl Roth 
Isoamyl alcohol Merck 
Isopropanol Merck 
Kanamycin sulfate PAN™ BIOTECH GmbH 
Lithium chloride (LiCl) Carl Roth 
Magnesium chloride (MgCl2) Merck 
Magnesium sulfate (MgSO4) SIGMA-Aldrich® 
Mayer’s hemalum solution Merck 
Methanol Merck 
Nonidet™ P-40 SIGMA-Aldrich® 
para-coumaric acid SIGMA-Aldrich® 
Paraffin Carl Roth 
Phosphate-buffered saline (PBS) Biochrom 
Potassium chloride (KCl)  Carl Roth 
Potassium phosphate (KH2PO4) Merck 
Prestained protein marker, broad range NEB®, USA 
Propidium iodide (PI) AppliChem 
Pyruvat Biochrom 
Random primer Promega 
RNasin® Plus Ribonuclease Inhibitor Promega 
Roti®-Histokitt Carl Roth 
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Roti®-Phenol Carl Roth 
Rotiphorese® Gel 30 (37.5:1) Carl Roth 
Scintillator Optiphase HiSafe 3 PerkinElmer, USA 
Sodium azide (NaN3) Carl Roth 
Sodium carbonate (Na2CO3 / NaHCO3) Merck 
Sodium chloride (NaCl) Carl Roth 
Sodium chromate (Na2
51CrO4) Hartmann Analytic 
Sodium citrate (NaC6H5O7) Carl Roth 
Sodium hydroxide (NaOH) Carl Roth 
Sodium phosphate (Na2HPO4 / NaH2PO4) Carl Roth 
Streptavidin-horseradish peroxidase (HRP) R&D Systems® 
Sucrose Carl Roth 
TaqMan® Universal PCR Master Mix Applied Biosystems, USA 
TEMED (N,N,N’,N’-tetramethyl-ethane-1,2-diamine) AppliChem 
TiterMax® TiterMax 
Tris Carl Roth 
Tris-buffered saline (TBS) SIGMA-Aldrich® 
Triton X-100 AppliChem 
TRIzol® Reagent Invitrogen™ 
Trypan blue SIGMA-Aldrich® 
Trypsin Biochrom 
Trypton Carl Roth 
Tween-20 Carl Roth 
UltraPure™ Agarose Invitrogen™ 
Xylol Carl Roth 
Yeast extract Carl Roth 
 
2.1.4 Buffers, solutions and media 
Used buffers, solutions and media are listed in the corresponding method sections. If not specified 
otherwise, all buffers, solutions and media were stored at 4°C. Buffers, solutions as well as self-made 
media were aqueous solutions and were autoclaved at 125°C for 30 min or filtrated using a 0.2 µm 
sterile filter for sterilization.  
The following common buffers and media were used: 
PBS:  137 mM NaCl 
  2.7 mM  KCl 
  10 µM  Na2HPO4 
  2.0 mM  KH2PO4 
  dissolved in  dH2O, pH 7.2 
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TBS-T:  20 mM  Tris-HCl 
  137 mM  NaCl 
  0.1% (v/v)  Tween-20 
  dissolved in  dH2O, pH 7.6 
GIBCO® DMEM+GlutaMax™-I, Invitrogen™, UK 
X-VIVO™ 10 LAK medium without Gentamicin and Phenol Red, Lonza Cologne GmbH 
 
2.1.5 Antibodies and recombinant proteins 
Antibodies were used according to manufacturer’s instructions. Applied dilutions and concentrations 
of the antibodies and recombinant proteins are indicated in the respective method sections or figure 
legends.  
 
2.1.5.1 Primary and secondary antibodies for flow cytometry 
All antibodies listed in Table 2.4 are directed against human antigens and are conjugated to one of 
the following flourochromes: Fluorescein isothiocyanate (FITC), phycoerythrin (PE), 
phycoerythrin/cyanine 5 (PE/Cy5) or allophycocyanine (APC), respectively. Isotype controls (mouse 
IgG1 and IgG2a) conjugated to the respective dye were purchased from ImmunoTools. 
Table 2.4:  Antibodies for flow cytometry 
Antigen Isotype Clone Flourochrome Supplier 
CD3 mouse IgG2a MEM 57 FITC ImmunoTools 
CD4 mouse IgG1 RPA-T4 PE BioLegend 
CD8 mouse IgG2a 3B5 PE/Cy5 Caltag Laboratories 
CD14 mouse IgG2a Tük4 PE Caltag Laboratories 
CD16 mouse IgG1 3G8 PE/Cy5 BioLegend 
CD19 mouse IgG1 HIB19 PE BioLegend 
CD56 mouse IgG1 HCD56 PE BioLegend 
CD69 mouse IgG1 FN50 PE/Cy5 BioLegend 
CD94 mouse IgG1 HP-3D9 FITC BD Biosciences 
CD107a (LAMP-1) mouse IgG1 H4A3 FITC BioLegend 
CD226 (DNAM-1) mouse IgG1 11A8 FITC BioLegend 
CD244 (2B4) mouse IgG1 C1.7 PE BioLegend 
CD314 (NKG2D) mouse IgG1 149810 PE R&D Systems 
CD335 (NKp46) mouse IgG1 9E2 PE BioLegend 
CD336 (NKp44) mouse IgG1 P-44-8 APC BioLegend 
CD337 (NKp30) mouse IgG1 P30-15 PE BioLegend 
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MICA mouse IgG1 AMO1 - Bamomab GmbH 
TCR γ/δ mouse IgG1 B1 PE BioLegend 
 
The following antibodies were used as secondary antibodies for flow cytometry: 
Polyclonal goat anti-mouse IgG, FITC-conjugated, Jackson ImmunoResearch, Dianova GmbH 
Polyclonal goat anti-human IgG, FITC-conjugated, Jackson ImmunoResearch, Dianova GmbH 
 
2.1.5.2 Primary and secondary antibodies for western blot analysis 
For western blot analysis all primary antibodies were diluted in TBS-T supplemented with 1% BSA and 
0.01% NaN3. Secondary antibodies were diluted in TBS-T only. 
 
Primary antibodies: 
β-Actin: anti-β-Actin mouse IgG1 monoclonal antibody (mAb; AC-15), SIGMA-Aldrich™, USA 
MICA: biotinylated anti-human MICA goat IgG polyclonal antibody, R&D Systems 
OVA: anti-chicken OVA ascites mouse IgG1 mAb (OVA-14), SIGMA-Aldrich™, USA 
Phospho-Akt: anti-phospho-Akt (Ser473) (D9E) XP™ rabbit IgG mAb, Cell Signaling Technology®, UK  
Phospho-PI3K: anti-phospho-PI3K p85 (Tyr458)/p55 (Tyr199) rabbit polyclonal antibody, Cell 
Signaling Technology®, UK 
Phospho-PLCγ2: anti-phospho-PLCγ2 (Tyr759) rabbit polyclonal antibody, Cell Signaling Technology®, 
UK 
Phospho-SLP-76: anti-phospho-SLP-76 (Tyr128) rabbit IgG polyclonal antibody, SIGMA-Aldrich™, USA 
Phospho-Src: anti-phospho-Src family (Tyr419) rabbit IgG polyclonal antibody, Cell Signaling 
Technology®, UK 
Phospho-Syk: anti-phospho-Syk (Tyr352)/ZAP-70 (Tyr319) rabbit polyclonal antibody, Cell Signaling 
Technology®, UK 
Phospho-Tyr: anti-phospho-Tyr mouse mAb (4G10), Merck Millipore 




Polyclonal goat anti-mouse IgG (H+L), horseradish peroxidase (HRP)-conjugated, ImmunoPure®, USA 
Polyclonal goat anti-mouse IgG2b (H+L), HRP-conjugated, ImmunoPure®, USA 
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Polyclonal goat anti-rabbit IgG (H+L), HRP-conjugated, ImmunoPure®, USA 
Polyclonal rabbit anti-mouse IgG, HRP-conjugated, Dako GmbH 
 
2.1.5.3 Antibodies for enzyme-linked immunosorbent assay (ELISA) 
For the mouse immunoglobulin isotype G (mIgG) screening ELISA (see 2.2.5.3.3) a goat anti-mouse 
IgG antibody (Dianova GmbH) was used as capture antibody, while a goat anti-mouse antibody 
conjugated to HRP (Dianova GmbH) was used as detection antibody. The antibodies applied for the 
IFN-γ ELISA (see 2.2.5.3.1) and the sMICA ELISA (2.2.5.3.2) were components of commercial ELISA kits 
(see 2.1.12). 
 
2.1.5.4 Recombinant human proteins 
Table 2.5:  Recombinant human proteins 
Recombinant human protein Supplier 
IL-2 R&D Systems® 
IL-12 HEK ImmunoTools 
IL-15 ImmunoTools 
IL-18 MBL Co., LTD, Japan 
NKG2D-Fc chimeric fusion protein (1299-NK) R&D Systems® 
 
2.1.6 Enzymes 
Table 2.6:  Enzymes 
Label Supplier 
Calf intestine phosphatase NEB®, USA 
Collagenase, Type III, IV SIGMA-Aldrich® 
DNase I Roche Diagnostics 
Endoglycosidase Hf (Endo Hf) NEB®, USA 
M-MLV Reverse Transcriptase Promega 
Pfu Polymerase Fermentas 
Phusion High-Fidelity DNA Polymerase Finnzymes / NEB®, USA 
Proteinase K Merck 
Restriction enzymes NEB®, USA / Promega 
RNase A Roche Diagnostics 
T4 DNA Ligase  Fermentas / NEB®, USA 
Taq DNA Polymerase GeneCraft® / NEB®, USA 
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2.1.7 Bacterial strains 
The chemo-competent Escherichia coli (E. coli) strain One Shot® Top10F` from Invitrogen™ was used 
for cloning procedures and plasmid preparations. This bacterial strain has the following genotype: 
F´ lacIq Tn10 (TetR) mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 recA1 araD139 Δ(ara-
leu)7697 galU galK rpsL endA1 nupG. 
 
2.1.8 Eukaryotic cell lines 
Table 2.7:  Cell lines 
Label Description Source  
EPLC-272 
human non-small cell lung carcinoma  
cell line 
Prof. Gabriele Multhoff, Technical 
University Munich (TMU) 
 
HEK293 human embryonic kidney cells Prof. Lutz Walter, DPZ, Göttingen  
K562 human erythroleukemia cell line 
American Type Culture Collection® 
(ATCC®), USA 
 
Ltk- mouse fibroblast tumor cell line ATCC®, USA  
A375II    
Ge    
HT144    
Juso    
Malme  
Prof. Judith Johnson, Ludwig-
Maximilians-University (LMU), Munich; 
(Dressel et al., 1998) 
 
Mel Ei   
Mel Ho human melanoma cell lines  
Mel Im   
Mel La    
Mel Wei    
Parl    
Sk Mel-29    
WM266-4    
MCF-7    
MDA-MB human breast cancer cell lines Prof. Gabriele Multhoff, TMU  
T47D    
NK-92 
human non-Hodgkin's lymphoma NK cell 
line 
Dr. med. Justin Hasenkamp, UMG 
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2.1.9 Laboratory animals 
The laboratory animals used during this project were bred in the central animal facility of the 
University Medical Center Göttingen. They were kept under specific pathogen-free conditions in 
individually ventilated cages and in a 12 h light-dark cycle. Female and male mice between 12 and 20 
weeks of age were used for experiments. All animal experiments had been approved by the local 
government and were in accordance with institutional guidelines for the welfare of animals. 
Table 2.8:  Laboratory animals 




severe combined immunodeficiency 
affecting B and T cells 






severe combined immunodeficiency 





severe combined immunodeficiency 




All primers were synthesized by Metabion international AG or biomers.net GmbH, respectively, as 
salt-free, lyophilized samples. Restriction site sequences were introduced close to the 5’ end of 
cloning primers to flank the resulting amplicons with new restriction sites, if required.  
The qRT-PCR primers were designed using Integrated DNA Technologies® (IDT®)'s PrimerQuest that 
incorporates Primer3 software developed by the Whitehead Institute for Biomedical Research. The 
primer specificity was verified with the nucleotide BLAST from National Center for Biotechnology 
Information (NCBI). All qRT-PCR primers were designed to span exon-exon junctions, if feasible. In 
case of targets with two isoforms the primers were designed to target both transcripts. Primer 
sequences are shown in Table 2.9-2.12. 
Table 2.9:  Primer pairs for qRT-PCR 
Label Sequence (5' → 3') RefSeq 
GAPDH_F TGTGTCCGTCGTGGATCTGA 















Table 2.10:    Primers for cloning 




















Table 2.11:    Primers for sequencing 











Materials and Methods 
36 
 
Table 2.12:    Primers for genotyping 







Primers for SNP genotyping were purified by High-performance liquid chromatography (HPLC). 
 
2.1.11 Vectors and constructs 
Common vectors and constructs generated therefrom are listed in Table 2.13 and 2.14. 
Table 2.13:    Vectors 
Label Supplier 
pcDNA3.1TM/myc-His A(+) Invitrogen™ 
pCMV6-AC OriGene, USA 
PEGFP-1 Clontech 
pFUSE-mIgG2a-Fc1 InvivoGen, France 
 
Table 2.14:    Constructs 
Label Application 
pcDNA3.1-MICA-129Met-mIgG2a-Fc  
pcDNA3.1-MICA-129Val-mIgG2a-Fc Transfection of HEK293 cells 
pcDNA3.1-OVA-mIgG2a-Fc  
pCMV6-AC-MICA-129Met 
Transfection of Ltk- cells 
pCMV6-AC-MICA-129Val 
 
2.1.12 Commercial kits 
Table 2.15:    Commercial kits 
Label Supplier 
ABsolute™ Blue QPCR SYBR® Green Low ROX Mix Thermo Fisher Scientific 
EndoFree Plasmid Maxi Kit  QIAGEN 
CloneJET™ PCR Cloning Kit 
Fermentas 
GeneJET™ Plasmid Miniprep Kit 
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Human IFN-γ ELISA ImmunoTools 
Human MICA DuoSet ELISA R&D Systems® 
Human NK Cell Isolation Kit MACS Miltenyi Biotec 
Power SYBR® Green PCR Master Mix Applied Biosystems, USA 
PureYield™ Plasmid Midiprep System 
Promega 
Wizard® SV Gel and PCR Clean-Up System 
TaqMan® MICA-129 Genotyping Assay (Assays-by-
DesignSM Service for SNP Genotyping Assays) 
Applied Biosystems, USA 
TransIT®-293 Transfection Reagent Mirus Bio LLC, USA 
Zymoclean™ Gel DNA Recovery Kit  Zymo Research 
 
2.1.13 Software and databases 
7500 System SDS software Applied Biosystems, USA 
7900HT System SDS software Applied Biosystems, USA 
Bio Edit Ibis Biosciences 
CellQuest Pro BD Biosciences 
Cyflogic Perttu Terho & CyFlo Ltd, Finnland 
Endnote X1.0.1 Thomson Reuters 
FlowJo Tree Star, Inc., USA 
Gel GDS software Intas Science Imaging 
GelPro analyzer Media Cybernetics, USA 
GENtle Magnus Manske - University of Cologne 
ImageG National Institutes of Health (NIH), USA 
MicroBeta Workstation PerkinElmer, USA 
NCBI database National Center for Biotechnology Information (NCBI), USA 
NEB-Cutter NEB®, USA 
Oligo Analyzer Integrated DNA Technologies® (IDT®), Belgium 
Primer Quest IDT®, Belgium 
qPCR primer database RTprimerDB.org 
Scrubber 2.0 BioLogic Software, Campbell, Australia 
WinStat R. Fitch Software 
Works 2007 Microsoft 
 




2.2.1 Microbiological methods 
2.2.1.1 Transformation of chemo-competent E. coli  
Circular plasmid DNA was introduced into the chemo-competent E. coli strain Top10F` using the heat 
shock method. Therefore, bacteria were thawed on ice, 50-100 ng plasmid DNA or 10 μl of a ligation 
reaction were added and mixed gently. After 30 min incubation on ice, the mixture was heat-shocked 
at 42°C for 90 sec, briefly returned to ice and cells were then resuspended in 400 μl SOC medium. For 
cell recovering the transformation mixture was incubated in a thermoblock at 37°C and 500 rpm for 1 
h. Subsequently, the mixture was plated on LB agar plates supplemented with an appropriate 
antibiotic, according to the resistance mediated by the incorporated plasmid after successful 
transformation, and cultured at 37°C overnight. 
 
SOC medium:                   2% (w/v) Tryptone 
   0.5% (w/v) Yeast extract   
   10 mM MgCl2 
   10 mM MgSO4 
   10 mM NaCl 
   2.5 mM KCl 
   20 mM Glucose 
   dissolved in  dH2O 
     
LB medium:   0.5% (w/v) Yeast extract 
   0.5% (w/v) NaCl 
       1% (w/v) Tryptone 
   dissolved in  dH2O 
 
LB agar plates:  1.5% (w/v) agar in LB medium 
 
Antibiotic concentrations: Ampicillin: 100 μg/ml in dH2O 
Kanamycin: 50 μg/ml in dH2O 
 
2.2.1.2 Culture and storage of chemo-competent E. coli  
Chemo-competent E. coli Top10F` cells were cultured under aerobic conditions in an incubator 
shaker at 37°C and 200 rpm overnight. LB medium containing the corresponding antibiotic was used 
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for the cultures. For small volumes (3 ml) 13 ml plastic tubes or for large volumes (100 ml) 
Erlenmeyer flasks were used, respectively. For long-term storage, 800 μl of an E.coli overnight culture 
was vigorously mixed with 200 μl 100% glycerol and stored at -80°C. 
 
2.2.2 Biomolecular methods 
2.2.2.1 Purification of nucleic acids 
2.2.2.1.1 Extraction of nucleic acids from agarose gels 
DNA fragments were extracted and purified from agarose gels or directly from PCR reactions using 
the Zymoclean™ Gel DNA Recovery Kit or the Promega Wizard® SV Gel and PCR Clean-Up System 
according to manufacturer’s instructions. DNA was eluted from the column with 10-50 µl nuclease-
free dH2O. 
 
2.2.2.1.2 Alcohol precipitation of nucleic acids 
Nucleic acids were precipitated from aqueous solution by adding 1/10 volume of 3 M sodium acetate 
(pH 4.8) and one volume isopropanol or 2.5 volumes 100% ethanol (-20°C), respectively. To avoid co-
precipitation of short oligonucleotides 1/3 volume of 7.5 M ammonium acetate was alternatively 
used instead of sodium acetate. Samples were centrifuged at 15,000 rpm at 4°C for 30 min. The 
supernatant was discarded, the resulting DNA pellet washed with 70% ethanol and then air-dried 
before being dissolved in an appropriate volume dH2O and stored at -20°C. 
 
2.2.2.1.3 Phenol-chloroform extraction of nucleic acids 
Protein contaminations were removed from nucleic acid samples by adding an equal volume of 
phenol-chloroform-isoamyl alcohol (25:24:1) and thoroughly mixed. For phase separation, the 
mixture was centrifuged and the DNA-containing aqueous phase was transferred into a new reaction 
tube. This procedure was repeated once with chloroform only. Subsequently, nucleic acids were 
precipitated using the alcohol precipitation method (see 2.2.2.1.2). 
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2.2.2.2 Isolation of nucleic acids 
2.2.2.2.1 Plasmid DNA preparation 
LB medium containing an appropriate antibiotic was inoculated with a single bacterial colony from a 
LB agar plate or some bacterial suspension of a frozen glycerol stock and incubated at 37°C and 200 
rpm overnight (see 2.2.1.2). Plasmid DNA was isolated either from 1.5 ml overnight culture for 
plasmid mini preparation or from 100 ml for plasmid midi or maxi preparation, respectively, 
according to manufacturer’s instructions using kits listed in Table 2.15. For isolation of non-
preparative plasmid DNA (e.g., for test restriction endonuclease digestion), E. coli were treated with 
buffers for alkaline lysis according to standard protocol (Birnboim & Doly, 1979). Subsequently, DNA 
was precipitated by addition of 80% isopropanol to the mixture, washed with 70% ethanol and 
dissolved in dH2O (see 2.2.2.1.2). 
 
2.2.2.2.2 Genomic DNA preparation 
One million to 5 x 106 cells were harvested, washed with PBS and resuspended in 500 µl lysis buffer. 
The suspension was incubated in a thermomixer at 50°C and 500 rpm overnight. To remove proteins 
and other contaminants and for subsequent precipitation of the genomic DNA, the cell lysis was 
followed by a phenol-chloroform extraction (see 2.2.2.1.3) and an alcohol precipitation (2.2.2.1.2) 
using 2 volumes 100% ethanol and 1/10 volume 5 M lithium chloride (LiCl). Genomic DNA was 
dissolved in dH2O or 8 mM NaOH and stored at 4°C.  
 
Lysis buffer: 100 mM NaCl 
50 mM EDTA, pH 8.0 
10 mM Tris-HCl, pH 8.0 
0.5%  Sodium dodecyl sulfate (SDS) 
0.1 mg/ml Proteinase K 
20 µg/ml RNase A 
dissolved in  dH2O 
 
2.2.2.2.3 RNA preparation 
The TRIzol® reagent was used to isolate RNA from 106 to 5 x 106 cells or 100 mg tissue according to 
the manufacturer’s protocol. In brief, after tissue homogenization and cell harvest, 1 ml TRIzol® 
reagent was added to lyse the cells. For phase separation, 200 µl chloroform were used. 
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Subsequently, the colorless upper aqueous phase, containing the RNA, was transferred into a new 
reaction tube and 500 µl 100% ethanol were added to precipitate RNA. Followed by a washing step 
with 1 ml 75% ethanol, the resulting RNA pellet was air-dried, resuspended in 50 µl RNase-free dH2O 
and stored at -80°C. Quality of RNA was assured by visualization of the integrity of 18S and 28S RNA 
loaded on a 1% agarose gel (see 2.2.2.5). All RNA samples were quantified with a spectrophotometer 
at a wavelength of 260 nm (see 2.2.2.6). 
 
2.2.2.3 Amplification of nucleic acids 
2.2.2.3.1 Polymerase chain reaction (PCR) 
The PCR is a technique used for DNA analysis and molecular cloning and is based on the in vitro 
amplification of a specific DNA segment (Mullis et al., 1986). The basic reaction includes three 
repetitive temperature steps allowing denaturation of double-stranded DNA (dsDNA), primer 
annealing to the single-stranded DNA (ssDNA) template and elongation by a DNA polymerase. 
For analytical proposes, Taq DNA polymerase was used and the reaction was set up as follows: 
2.5 μl  10 x Taq PCR buffer 
0.5 μl  dNTP mix (10 mM of each dNTP: dATP, dCTP, dGTP, dTTP) 
5 pmol/µl sense primer 
5 pmol/µl  anti-sense primer 
100 ng  template DNA 
5 Units (U)  Taq DNA polymerase 
add to 25 μl dH2O 
 
For preparative proposes such as molecular cloning and site-directed mutagenesis, PCR reactions 
were performed using Phusion High-Fidelity DNA polymerase, since this enzyme possess 3' → 5' 
proofreading activity. To introduce point mutations in DNA constructs, the respective construct was 
subjected to PCR using two oligonucleotide primers containing the desired mutation in the middle. 
The PCR reaction was then incubated with 1 µl Diplococcus pneumonia I (DpnI) endonuclease at 37°C 
for 1 h to digest the parental, methylated DNA template plasmid. The following PCR setup was used: 
10 μl  5 x Phusion PCR buffer 
1 μl  dNTP mix (10 mM each) 
10 pmol/µl sense primer 
10 pmol/µl anti-sense primer 
100 ng  template DNA 
2 U Phusion DNA polymerase 
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add to 50 μl dH2O 
 
The PCR cycler program was adapted with respect to temperature and time for denaturation, 
annealing and elongation steps. Denaturation as well as elongation temperatures and times were 
associated with the DNA polymerase specifications and were set according to manufacturer’s 
instructions. Annealing temperatures were set according to the specific melting temperature of the 
primers which were used. An exemplary PCR program for the amplification of the MICA gene 
sequence (1152 bp) using the pCMV6-AC-MICA-129Met/Val construct as template and the Phusion 
DNA polymerase is indicated in the Table 2.16.  
Table 2.16:    Exemplary PCR program 
Step Temperature Time 
Initial denaturation 98°C 3 min 
Denaturation* 98°C 30 sec 
Primer annealing* 65°C 25 sec 
Elongation* 72°C 30 sec 
Final elongation 72°C 5 min 
* in 30 cycles   
 
2.2.2.3.2 cDNA synthesis 
For qRT-PCR, it is necessary to transcribe RNA into cDNA. For this purpose, random hexamers, which 
are short oligodeoxyribonucleotides of random sequence [d(N)6] that anneal to random 
complementary sites on the target RNA, and M-MLV reverse transcriptase were used. 
Two μg RNA were mixed with 2 μl random hexamer primers and filled up with dH2O to a final volume 
of 15 μl. This mixture was incubated at 70°C for 10 min to break up secondary structures of the RNA. 
The sample was chilled down on ice to prevent reforming of these structures. Subsequently, the 
following master mix was added to the sample: 
 
5 μl 5× reverse transcriptase buffer 
2 μl  dNTP mix (10 mM) 
1 μl  DTT (0.1 M) 
1 μl  RNasin plus RNase inhibitor (40 U/μl) 
1 μl  M-MLV reverse transcriptase (200 U/μl) 
 
The reverse transcription reaction was incubated at 37°C for 1 h for transcription of RNA into cDNA 
and afterwards stored at -20°C. 
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2.2.2.3.3 Quantitative real-time PCR (qRT-PCR) 
Quantitative PCR in real-time was performed to determine the relative amount of specific mRNA 
transcripts of a gene of interest using the ABI 7500 Real-Time PCR system and the ABsolute™ Blue 
QPCR SYBR® green mix, which comprises polymerase buffer, dNTPs, a hot start polymerase and SYBR 
green dye to amplify and detect DNA. The cDNA was diluted 1:40 with dH2O and the reaction was set 







The following qRT-PCR cycler program was used: 
Table 2.17:    qRT-PCR program 
Step Temperature Time 
Enzyme activation 50°C 2 min 
Initial denaturation 95°C 10 min 
Denaturation* 95°C 15 sec 
Annealing/elongation* 60°C 1 min 
Dissociation stage 95°C 15 sec 
 60°C 20 sec 
Recording of the stepwise rising of the 20 sec 
dissociation curve temperature to 95°C  
* in 40 cycles   
 
The stepwise increase in temperature during the dissociation stage was used to verify product 
specificity. Since SYBR green dye intercalates non-specifically into DNA, unintended products, such as 
primer dimers, contaminations and mispriming artifacts, could cause a false positive fluorescence 
signals. Since the melting temperatures of intended products were known, their 
specificity was assured by comparison with the temperature peak of the according dissociation 
curve. For cycle threshold (Ct) values above 30, no qRT-PCR data were calculated, since this late 
amplification was considered to be unspecific. All genes of interest were analyzed in triplicates to 
reduce expression variation. cDNAs obtained from human and mouse tumor cell lines were analyzed 
with specific MICA primers and primers for the housekeeping gene Hprt or Gapdh, respectively (see 
Table 2.9). After each PCR cycle, the amount of dsDNA was measured and calculated by the AB 7500 
10 μl  ABsolute™ Blue QPCR SYBR® green mix 
5 pmol/µl sense primer 
5 pmol/µl anti-sense primer 
1 μl template cDNA 
add to 20 μl dH2O 
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System SDS Software. Ct values of the target genes were subtracted by the Ct values of the 
housekeeping gene (ΔCt). The quantity was calculated as 2-ΔΔCt relative to the control (Livak and 
Schmittgen, 2001). 
 
2.2.2.3.4 TaqMan MICA-129 genotyping assay 
Genomic DNA of all patient and donor (P/D) pairs of the allogeneic hematopoietic stem cell 
transplantation (HSCT) cohort transplanted in the Department of Hematology and Medical Oncology 
at the University Medical Center Göttingen was isolated from EDTA-treated peripheral blood 
samples. For discrimination of MICA-129 genotypes of each studied pair of alleles, a SNP genotyping 
TaqMan assay on demand from Applied Biosystems was used. The 40x SNP genotyping assay 
contains unlabeled sequence-specific PCR primers to amplify the polymorphic MICA sequence of 
interest in the exon 3 and two MICA-129 allele-specific TaqMan minor groove binder (MGB) probes: 
One probe is labeled with VIC® dye detecting the MICA-129Met allele sequence and the other probe 
is labeled with FAM™ dye detecting the MICA-129Val allele. The sequences of the forward and 
reverse primer are shown above (see Table 2.12: MICA-129_Ex3_F and MICA-129_Ex3_R) and of the 
two probes were as follows: MICA-129_Ex3_Met, VIC-5´-AATGGACAATGCCCC; MICA-129_Ex3_Val, 
FAM-5´-AATGGACAGTGCCCC. The assay enables scoring of both alleles in a single well. It was 
performed in 384-well plates and is optimized to work with genomic DNA. The pipetting scheme of 






The assay utilizes the thermal cycling parameters described in Table 2.18: 
Table 2.18.:    Thermal cycler conditions for TaqMan genotyping assay 
Step Temperature Time 
Initial steps 95°C 10 min 
Denaturation* 92°C 15 sec 
Annealing/elongation* 60°C 1 min 
* in 40 cycles   
 
2.5 μl  2x TaqMan Universal PCR Master Mix 
0.125 µl 40x PCR primer and TaqMan MGB probe mix 
2.375 µl genomic DNA (10 ng) diluted in dH2O 
add to 5 μl dH2O 
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The two dye-labeled MGB probes, specific for either the MICA-129Met or MICA-129Val allele, 
provide a fluorescence readout of the amplification of each allele. For analysis, the AB 7900HT 
System SDS Software was used. 
In parallel to MICA-129 genotyping of the P/D pair genomic DNAs, also control samples were 
genotyped by the TaqMan assay. These were determined to be heterozygous or homozygous for the 
MICA-129 alleles as checked before by nucleotide sequencing. 
 
2.2.2.4 Molecular cloning 
2.2.2.4.1 Restriction endonuclease digestion of nucleic acids 
For site-directed cleavage and generation of 3'-hydroxyl and 5'-phosphate termini, substrate DNA 
was incubated with type II restriction endonucleases in a thermoblock at 37°C and 300 rpm for at 
least 1 h up to 16 h (overnight digestion) depending on the applied enzyme and the DNA amount. 
Endonucleases recognize restriction sites of 4-8 nucleotides which are usually undivided and 
palindromic. Nucleic acids were digested in a reaction volume of at least 20 μl up to a maximum of 
100 µl according to the specific reaction conditions of the different restriction enzymes to assure 
complete digestion, which was subsequently probed by agarose gel electrophoresis (see 2.2.2.5). 
 
2.2.2.4.2 Dephosphorylation of vector DNA 
To prevent religation of vector DNA, especially in case of blunt ended DNA fragments, which were cut 
with only one restriction endonuclease, phosphate residues were removed using calf intestine 
phosphatase (CIP). Usually, 1 µl of CIP enzyme (10 U) was added directly to the restriction mixture 
and incubated at 37°C for 30 min.  
 
2.2.2.4.3 Ligation of DNA fragments 
The T4 DNA ligase was used for the formation of phosphodiester bonds between linearized vector 
DNA and insert DNA fragments. A 20 µl reaction with 1 μl (5 U) of the ligase in an ATP-containing T4 
DNA Ligase buffer was prepared and incubated at room temperature (RT) for 1 h or at 16°C 
overnight. The corresponding amounts of insert DNA and vector DNA were calculated according to 
the formula shown below. 10 µl of the ligation mixture were subsequently used for transformation of 
chemo-competent E. coli cells (see 2.2.1.1). 






2.2.2.4.4 TA cloning 
The Invitrogen TA cloning kit was used for direct ligation of DNA fragments amplified with Taq 
polymerase. DNA amounts and reaction volumes were set up according to manufacturer’s 
instructions. For the direct ligation of blunt ended DNA fragments which were produced, e.g., by the 
Phusion DNA polymerase or by specific restriction endonucleases, the Fermentas CloneJET PCR 
cloning kit was used according to the manufacturer’s protocol. 
 
2.2.2.5 Agarose gel electrophoresis of nucleic acids 
Agarose gel electrophoresis was performed for identification and separation of DNA fragments using 
the Perfect Blue™ gel system. The agarose concentration varied between 0.7% up to 2% (w/v) 
according to the size of DNA fragments. TAE buffer was used as running buffer and for preparation of 
agarose solutions, which were dissolved in the microwave at 300 W for 5 min. Ethidium bromide, 
which intercalates into the DNA double helix, was added to a final concentration of 0.1% (v/v) to 
identify DNA fragments when exposed to UV light. DNA samples were mixed with 6x DNA loading dye 
to facilitate the loading procedure. An electric field of 90-120 V and 220 mA was applied for 30-60 
min according to the DNA fragment size. In addition, the DNA molecular weight standard GeneRuler 
1 kb DNA ladder was loaded on the gel for determination of DNA size. The running time for RNA 
samples should not exceed 15 min to avoid RNA degradation. 
 
6x DNA loading dye: 34% (w/v) Sucrose       or 10 mM  Tris-HCl, pH 7.6  
  0.02% (w/v) Cresol red dye 0.03% Bromophenol blue 
  dissolved in  dH2O  60% Glycerol 
 
1x TAE buffer: 40 mM Tris-acetate, pH 8.0 
  1 mM EDTA, pH 8.0 
  dissolved in  dH2O 
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2.2.2.6 Photometric determination of nucleic acid concentration 
Concentration of dsDNA and RNA was determined with an Eppendorf BioPhotometer in UVettes or 
with a NanoDrop™ ND-1000 spectrophotometer and calculated using the following equations: 
1 A260 Unit of dsDNA = 50 µg DNA/ml diluent or 1 A260 Unit of RNA = 40 µg DNA/ml diluent 
The purity of DNA or RNA can be estimated by the value for pure DNA of A260/A280 ≥ 1.8 or for pure 
RNA of A260/A280 ≥ 2.0. 
 
2.2.3 Biochemical methods 
2.2.3.1 Production and purification of recombinant Fc-fusion proteins 
For generation of Fc-fusion proteins, expressing the Fc region (CH2 and CH3 domains) of the murine 
IgG2a heavy chain and the hinge region, which is fused to the protein of interest, 10
7 HEK293 cells 
were stably transfected (see 2.2.4.7) with 50 µg PvuI-linearized and purified DNA of the MICA-
129Met-Fc, MICA-129Val-Fc or OVA-Fc expression construct, respectively. After selection with 
geneticin (0.5 mg/ml G418), MICA-129-Fc and OVA-Fc production was analyzed using a mIgG 
screening ELISA (see 2.2.5.3.3), since the fusion proteins are secreted as MICA or OVA homodimers. 
For production of Fc-fusion protein-containing supernatants, the corresponding HEK293 
transfectants were cultured in 250 ml cell culture flasks with 75 ml FCS-free DMEM at 37°C and 5% 
CO2 for 3 days. After centrifugation at 3,000 x g and 4°C for 15 min and filtration through a 0.45 µm 
membrane the supernatants were collected and dialyzed in 20 mM sodium phosphate binding buffer 
(pH 7.0) at 4°C overnight in a SERVAPOR® dialysis tubing with a molecular weight cut-off (MWCO) of 
12-14 kDa. Subsequently, the Fc-fusion proteins were purified using 1 ml HiTrap Protein G HP 
columns and 100 mM glycine-HCl elution buffer (pH 2.7) according to manufacturer’s instructions. 
After a further buffer exchange in PBS (pH 7.2), the purified protein fractions were concentrated 
using Amicon centrifugal filter units with 30 kDa MWCO according to the manufacturer’s protocol. To 
determine the concentration and purity of the concentrated MICA-129Met-Fc, MICA-129Val-Fc and 
OVA-Fc proteins, Bio-Rad protein assays (see 2.2.3.2) and reducing sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) (see 2.2.3.3) were performed. 
 
Binding puffer: 40 mM NaH2PO4 (1.95 l)   
40 mM Na2HPO4 (3.05 l)    
add to 10 l with dH2O, pH 7.0 
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2.2.3.2 Bio-Rad protein assay for determination of protein concentration         
The protein concentration of purified Fc-fusion proteins was determined by Bio-Rad protein assays 
using a Bio-Rad reagent according to the manufacturer’s protocol. The Bio-Rad protein assay is based 
on the Bradford method. It involves the addition of an acidic dye to protein solution and subsequent 
measurement at 595 nm with a spectrophotometer or a microplate reader. Comparison to a BSA 
standard curve reaching from 5 µg/ml to 100 µg/ml provides a relative measurement of protein 
concentration.  
 
2.2.3.3 SDS-polyacrylamide gel electrophoresis (PAGE)         
Discontinuous SDS-PAGE was used for electrophoretic separation of proteins according to their 
molecular weight. Electrophoresis was performed in a gel electrophoresis system. Therefore, protein 
samples were supplemented with 1/2 volume 2x protein sample buffer (reducing) and incubated at 
95°C for 4 min to complete denaturation. Subsequently, samples were loaded and concentrated in 
the stacking gel at 20 mA following separation in the separating gel at 40 mA. Proteins were 
identified by comparison with a prestained protein marker (broad rage, 7-175 kDa). For visualization 
of proteins, SDS gels were either stained with Coomassie dye (see 2.2.3.4) or subjected to western 
blot analysis (see 2.2.3.5). 
 
2x protein sample buffer: 100 mM     Tris-HCl, pH 8.0 
   2 mM EDTA 
20% (v/v)     Glycerol 
2% (w/v)      SDS 
   10% (v/v) β-Mercaptoethanol 
0.1% (w/v)   Bromphenol blue 
 dissolved in  dH2O 
 
Stacking gel buffer (pH 6.8): 0.5 M Tris-HCl 
0.4% (w/v) SDS 
dissolved in  dH2O 
 
Stacking gel (4.8%):  16% (v/v)    Acrylamide/Bisacrylamide solution (30%) 
   25% (v/v)     Stacking gel buffer 
   59% (v/v)  dH2O 
   0.01% (v/v)  TEMED 
   0.1% (v/v)    APS (10%) 
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Separating gel buffer (pH 8.8): 1.5 M Tris-HCl 
   0.4% (w/v)  SDS 
   dissolved in  dH2O 
 
Separating gel (10%):  33% (v/v)    Acrylamide/Bisacrylamide solution (30%) 
   22% (v/v)     Separating gel buffer 
   45% (v/v)      dH2O 
   0.01% (v/v)  TEMED 
   0.1% (v/v)     APS (10%) 
 
SDS running buffer:  25 mM Tris-HCl 
   192 mM       Glycine 
   0.1% (w/v)  SDS 
   dissolved in  dH2O 
 
2.2.3.4 Coomassie blue staining 
Proteins in SDS gels were non-specifically stained using Coomassie blue staining solution. The 
Coomassie Brilliant Blue R-250 dye binds to basic side chains of amino acids. After 15 min incubation 
with the staining solution at RT and 50 rpm, the stained SDS gel was washed with dH2O several times 
until the background color in the SDS gel was removed. The gels were documented by an Intas GDS 
gel manager. 
 
Coomassie blue staining solution: 
 
 
2.2.3.5 Western blot analysis 
After SDS-PAGE (see 2.2.3.3), proteins in the SDS gel were transferred onto a nitrocellulose 
membrane using a semi-dry blotting technique for subsequent immunostaining. Therefore, a sheet of 
Whatman paper soaked with blotting buffer was put on the anode of a blotting chamber followed by 
the nitrocellulose membrane, the SDS gel, a second soaked Whatman paper and the cathode. The 
protein transfer was performed applying an electric current of 1 mA/cm2 for 1 h. For staining of 
specific proteins, unspecific binding of epitopes was inhibited by incubating the membrane in 
blocking solution at RT for 1 h on a shaker. Subsequently, the specific primary antibody (see 2.1.5.2) 
0.2% (w/v)   Coomassie Brilliant Blue R-250  
30% (v/v)       Methanol 
10% (v/v)         Acetic acid 
dissolved in dH2O 
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diluted in dilution buffer was added to the membrane and incubated at 4°C overnight at a respective 
concentration according to manufacturer’s instructions. Following three washing steps with TBS-T at 
RT for 10 min, a HRP-conjugated secondary antibody diluted in TBS-T at a concentration of 1:10,000 
was supplied and incubated at RT for 1 h. After washing of the membrane with TBS-T, the 
immunostaining of the proteins was visualized using the ECL solution and the digital Intas Chemilux 
imaging system. 
 
Blotting buffer: 48 mM  Tris 
  39 mM  Glycine 
  0.0375% (v/v) SDS 
  0.01% (w/v)  NaN3 
  20% (v/v)  Methanol 
  dissolved in  dH2O 
    
Blocking solution: 5% (w/v) BSA in TBS-T 
 
Solution A:  250 mg/l   Luminol 
  100 mM  Tris-HCl, pH 8.6 
  dissolved in  dH2O 
 
Solution B:  55 mg para-coumaric acid/50 ml DMSO 
 
ECL solution: 4 ml of solution A was freshly mixed with 400 µl solution B and 1.2 µl H2O2 
 
After probing of the blot with a specific Ab and before further testing of proteins, containing a similar 
size as previously investigated proteins, the blot was incubated in a β-mercaptoethanol-containing 
buffer for 30 min at 50°C in a water bath to detach bound Abs from the proteins on the nitrocellulose 
membrane. Subsequently, the blot was washed under running tap water until the β-
mercaptoethanol smell disappeared.  
 
Stripping buffer: 68.5 mM Tris-HCl, pH 6.8 
  2% (w/v) SDS 
  100 mM β-mercaptoethanol 
  dissolved in dH2O 
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2.2.3.6 Surface plasmon resonance (SPR) 
SPR enables detection of unlabeled interactants in real-time and can be used for determination of 
protein-protein interaction and binding avidity. SPR analysis was performed with a Reichert SPR 
Biosensor SR7500DC instrument in PBS running buffer (pH 7.2) at 20°C. The recombinant NKG2D-Fc 
fusion protein was covalently immobilized on the EDC/NHS-activated left channel (sample channel) 
of a 2-dimensional (2D) HC 1000m SPR sensorchip – at a concentration of 200 nM, a flow rate of 30 
µl/min and to a response level of 2500 response units (RUs). The right channel of the chip served as a 
reference. For the kinetic measurements increasing concentrations (2 nM, 4 nM, 8 nM, 16 nM, 32 
nM, 64 nM, 125 nM, 250 nM and 500 nM) of the analytes MICA-129Met-mIgG2a-Fc or MICA-129Val-
mIgG2a-Fc fusion proteins, respectively, were injected into the PBS running buffer for 270 seconds 
over both channels at a flow rate of 40 µl/min with following dissociation for 15 min. Kinetic analysis 
was performed using the BioLogic software Scrubber 2.0. The recorded responses were double 
referenced (right channel, buffer blank) and normalized using the molecular weight in kDa of the 
analytes. 
 
2.2.4 Cell culture methods 
2.2.4.1 Isolation of PBMCs 
Human peripheral blood mononuclear cells (PBMCs) were obtained from heparin-treated peripheral 
blood of healthy volunteers by density gradient centrifugation on Biocoll separating solution using 
Leucose® tubes with porous barrier according to manufacturer’s instructions.  
In brief, after preparation of the Leucosep® tubes the anticoagulated blood, diluted 1:1 with DMEM, 
was poured directly into the separating tubes and centrifuged at 1,000 x g and RT for 10 min. The 
enriched cell fraction was harvested and transferred into a new 50 ml centrifuge tube. Subsequently, 
PBMCs were washed two times with 10 ml PBS at 250 x g and then cultured (see 2.2.4.4.2) or 
subjected to NK cell isolation (see 2.2.4.2). 
 
2.2.4.2 NK cell isolation using MACS technology 
The magnetic-activated cell sorting (MACS) method allows the separation of various cell populations 
depending on their surface antigens by magnetic particles (magnetic MicroBeads) and a magnetic 
field. NK cells were isolated from human PBMCs (see 2.2.4.1) by the MACS technology using the 
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Human NK Cell Isolation Kit from Miltenyi Biotec according to the manufacturer’s protocol, in which 
NK cells are isolated by depletion of non-NK cells (negative selection).  
For this purpose, PBMCs were incubated with a specific NK Cell Biotin-Antibody Cocktail at 4°C for 10 
min. This antibody cocktail comprises various biotin-conjugated monoclonal anti-human antibodies 
against surface antigens of different PBMC subpopulations not expressed by human NK cells. 
Subsequently, a NK Cell MicroBead Cocktail containing magnetic MicroBeads conjugated to 
monoclonal antibodies, which attach to the antibody-labeled cells, was added and incubated at 4°C 
for 15 min. After one washing step, the cell solution was transferred on a MACS LS column placed in 
a strong magnetic field of a MACS separator. Magnetically labeled non-NK cells were retained on the 
column, while the unlabeled NK cells pass through and were collected. Purity of NK cells was 
determined by flow cytometry (see 2.2.5.1) and the percentage of CD3-CD56+ lymphocytes was 
determined. 
 
2.2.4.3 NK cell stimulation and production of NK cell lysates 
Primary human NK cells purified by MACS technology (see 2.2.4.2) were stimulated with 100 U/ml 
recombinant human interleukin-2 (rhIL-2) for 4 days (see 2.2.4.4.2). NK cells were additionally 
stimulated with recombinant human MICA-129Met/Val-mIgG2a-Fc fusion proteins to investigate 
functional effects mediated by these proteins.  For cross-linking of the NKG2D receptor on NK cells to 
MICA-129-Fc homodimers, 96-well Nunc MaxiSorpTM microtiter plates were pre-coated with 10 
µg/ml of a goat anti-mouse F(ab’)2 fragment (Jackson ImmunoResearch, Dianova GmbH) in 100 µl 
sodium carbonate coating buffer (pH 8.5) at 4°C overnight. After washing the plates with PBS (pH 
7.2), MICA-129Met-Fc, MICA-129Val-Fc or OVA-Fc, respectively, were added to the wells in a total 
volume of 100 µl PBS at various concentrations, ranging from 0.1 µg/ml to 100 µg/ml, followed by an 
incubation at RT for 1 h and a further washing step. Subsequently, 2.5 x 105 IL-2-activated NK cells in 
100 µl DMEM were transferred in each well, centrifuged at 1200 rpm for 1 min and incubated at 37°C 
and 5% CO2 for 3 min, 10 min or 30 min. Afterwards plates were put on ice and 100 µl PBS/EDTA 
were added to all wells to detach NK cells from the plates. The cell suspension was centrifuged at 
1200 rpm and 4°C for 10 min and the supernatant thoroughly removed. 20 µl Noidet P-40 (NP-40) 
lysis buffer were added to 106 NK cells and thoroughly mixed. This mixture was incubated on ice for 
20 min followed by a 20 min centrifugation at 2500 rpm at 4°C. The supernatant was then harvested 
and directly used for SDS-PAGE (see 2.2.3.3) or aliquots were frozen at -20°C.   
For performance of CD107a expression assays (see 2.2.5.1.1), stimulation with Fc-fusion proteins was 
performed as described above in microtiter plates but the NK cell-containing medium was 
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additionally supplemented with an anti-CD107a antibody (4 µl/100 µl DMEM) during the 1 h 
incubation period at 37°C and 5% CO2. 
 
Sodium carbonate coating buffer: 0.2 M Na2CO3 (85 ml) 
0.2 M NaHCO3 (40 ml) 
add to 500 ml dH2O, pH 8.5 
 
PBS/EDTA solution:   1 mM EDTA in PBS, pH 7.2 
 
NP-40 lysis buffer:  140 mM NaCl 
   10 mM Tris-HCl, pH 8.0 
   1.5 mM MgCl2  
   0.5% (w/v) NP-40 
   dissolved in dH2O 
 
2.2.4.4 Culture of eukaryotic cells 
All target and effector cell lines were cultured in a 5% CO2 humidified atmosphere at 37°C. FCS was 
heated to 56°C for 30 min for inactivation of complement factors. All cell culturing was done under 
sterile conditions in laminar flow cabinets and with sterile equipment. The sterility of medium 
additives was assured by manufacturers or achieved by autoclaving or sterile filtration through a 0.2 
µM filter unit, if necessary. Centrifugation of eukaryotic cells was performed at 1200 rpm and RT for 
5 min.  
 
2.2.4.4.1 Tumor cell culture 
Human and murine tumor cell lines were cultured in DMEM+GlutaMax™ supplemented with various 
medium additives as indicated below. Cells were maintained in the exponential growth phase by 
regular cell passages twice a week. After aspiration of the culture medium, adherent and confluent 
cells were washed with PBS and subsequently incubated with 0.5-1 ml trypsin/EDTA for 
approximately 2 min until cells started to detach from the culture dish. For trypsin inactivation, 5-10 
ml FCS-containing medium were added. Single cell suspensions were obtained by pipetting the 
suspension gently up and down. After centrifugation and resuspension in 10 ml fresh medium, 
approximately 1/10 volume of the cell suspension was passaged into a new cell culture vessel for 
further cell culture, while the rest of the cells were used for analysis or discarded. 
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Target cell medium: DMEM+GlutaMax™ 
  + 10% (v/v)  FCS 
  + 50 µM  2-β-Mercaptoethanol 
  + 50 U/ml  Penicillin 
  + 50 µg/ml  Streptomycin 
 
Trypsin/EDTA: 0.25% (w/v)  Trypsin 
  0.02% (w/v)  EDTA 
  dissolved in   PBS, pH 7.2 
 
2.2.4.4.2 Effector immune cell culture 
Primary human PBMCs were obtained by density gradient centrifugation (see 2.2.4.1). NK cells were 
isolated by MACS separation (see 2.2.4.2). To obtain lymphokine-activated killer (LAK) cells or 
activated NK cells, PBMCs or isolated NK cells were cultured for 4 days in 5 ml or 10 ml suspension 
culture dishes in DMEM supplemented with 100 U/ml rhIL-2. The cell density ranged from 106 to 107 
cells/ml. 
 
Effector cell medium: DMEM+GlutaMax™ 
  + 10% (v/v)  FCS 
  + 50 U/ml  Penicillin 
  + 50 µg/ml  Streptomycin 
  + 100 U/ml  rhIL-2 
 
The human non-Hodgkin's lymphoma NK cell line NK-92 was cultured in X-VIVO™ 10 medium 
optimized for the culture of LAK cells. 
 
NK-92 medium: X-VIVO™ 10 medium 
  + 12.5% (v/v) FCS 
  + 12.5% (v/v) Horse serum, heat-inactivated 
  + 50 U/ml  Penicillin 
  + 50 µg/ml  Streptomycin 
  + 100 U/ml  rhIL-2 
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2.2.4.5 Freezing and thawing of cells 
Cells were harvested from cell culture dishes depending on their specific growth conditions. 
Subsequently, cells were centrifuged at 1200 rpm for 5 min and resuspended in an adequate volume 
of cell specific medium. 500 μl of the cell suspension was transferred into a cryo conservation tube 
and 500 μl 2x freezing medium was added. The cell density was about 106 cells/ml. Cryo tubes were 
slowly frozen in a closed styrofoam box at -80°C. After 24 h cryo tubes were transferred to -140°C for 
long-term storage.  
 
 2x freezing medium: 
    
Frozen cells were thawed by incubating the cryo tubes briefly in a water bath at 37°C, diluted in 10 
ml DMEM medium and centrifuged for 5 min at 1200 rpm. Subsequently, cells were resuspended in 
their specific growth medium and plated in an appropriate cell culture dish. 
 
2.2.4.6 Counting of cells 
For cell counting a Neubauer counting chamber and a Zeiss inverted microscope were used. After 
thorough resuspension of cells in an appropriate volume, 10 µl of the suspension were loaded on the 
loading groove (0.1 mm depth) between the chamber and the cover slip. The counting was 
performed according to manufacturer’s instructions of the Neubauer chamber. Before the number of 
lymphocytes was determined, a 1/10 dilution was prepared by mixing 10 µl cell suspension with 90 µl 
0.4% trypan blue counting solution. Trypan blue selectively colors dead cells blue. Since living cells 
are excluded from staining, this staining method is also called trypan blue exclusion method. 
 
Trypan blue counting solution: 0.4% (w/v) trypan blue in PBS, pH 7.2 
 
2.2.4.7 Transfection of cells 
Linearized plasmid DNA was stably introduced into eukaryotic cells using electroporation. Endotoxin-
free and highly purified plasmid DNA was used to increase the transfection efficiency. At first, 107 
cells were harvested and resuspended in 800 μl sterile PBS. Subsequently, 50 μg DNA were added, 
the suspension was gently mixed and then transferred into an electroporation cuvette. 
Electroporation was performed at 250 mV and 960 μF. After incubation at RT for 5 min, the cells 
20% (v/v)       DMSO 
80% (v/v)       FCS 
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were diluted in 10 ml pre-warmed growth medium and seeded in a 10 cm cell culture dish. Selection 
procedure of transfected cells started at the earliest 24 h after electroporation by adding geneticin 
(G418), which is an aminoglycoside and commonly used as a selective agent for eukaryotic cells. The 
required G418 concentration, at which untransfected cells of the respective parental cell line died, 
was tested before (0.5 mg/ml or 1 mg/ml G418 for HEK293 or Ltk- cells, respectively). Approximately 
7 days after addition of G418, single cell colonies were picked and plated in 96-well tissue culture 
plates with 200 µl selection medium. Seven to 14 days later stable transfectants were visible and 
grown for further analysis. Transfection efficiency and selection of stable clones were examined by 
flow cytometry after staining with respective antibodies (see 2.2.5.1). 
 
Selection medium: DMEM+GlutaMax™ 
  + 10% (v/v)  FCS 
  + 50 µM  2-β-Mercaptoethanol 
  + 50 U/ml  Penicillin 
  + 50 µg/ml  Streptomycin 
  + 0.5-1 mg/ml  G418 
 
2.2.4.8 Cell culture for analysis of secreted proteins 
2.2.4.8.1 Cell culture conditions for the IFN-γ ELISA 
IFN-γ ELISAs (see 2.2.5.3.1) were performed to determine the level of this secreted cytokine in the 
supernatants of primary human NK cells co-cultured with L-con cells, L-MICA-129Met or L-MICA-
129Val-expressing target cells, respectively, for 24 h.  
Therefore, 5 x 104 target cells in 100 µl medium (see 2.2.4.4.1) were transferred into each well of a 
96-well culture plate. Afterwards 2.5 x 105 NK cells in 100 µl medium, stimulated with 100 U/ml rhIL-
2 for 4 days (see 2.2.4.4.2), were added in an E:T ratio of 5:1 to each well and centrifuged at 1200 
rpm for 2 min to ensure contact between target and effector cells. The plates were then incubated at 
37°C and 5% CO2 in a humidified atmosphere for 24 h. Afterwards the plates were centrifuged at 
1200 rpm for 5 min and the supernatants were harvested by transferring them to a new 96-well 
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2.2.4.8.2 Cell culture conditions for the sMICA ELISA 
Levels of soluble MICA (sMICA) in the supernatants of mouse Ltk- and human tumor cell lines, 
transfected either with the empty vector as negative control or the MICA-129Met or MICA-129Val 
constructs, were analyzed using the sMICA ELISA (see 2.2.5.3.2).  
For this purpose, 106 cells of several clones of each MICA-129 variant were cultured in a 10 cm tissue 
culture dish (ad 70% to 90% confluence) with 10 ml medium (see 2.2.4.4.1) for 24 h. The next day the 
medium was aspirated and 10 ml fresh medium were added. After 24 h the supernatant was 
harvested by centrifugation at 500 x g and 4°C for 5 min. Subsequently, the supernatant was 
transferred in a new plastic tube, vortexed and 3 aliquots of 1 ml supernatant per cell line were 
frozen at -80°C. After harvesting of the supernatants, the cells were detached from the dishes using 
trypsin/EDTA to determine the cell number and for analysis of the MICA cell surface expression by 
flow cytometry (see 2.2.5.1).  
 
2.2.5 Immunological methods 
2.2.5.1 Flow cytometry 
Flow cytometry is a laser-based, biophysical technology which facilitates cell counting and detection 
of different characteristics of a single cell suspension. Fluorescent dyes can be detected as well as cell 
size and granularity. Flow cytometry was performed with a BD Biosciences FACScanTM flow cytometer 
and CellQuestTM software.  
Cell surface expression of MICA on propidium iodide (PI; 1 µg/ml) negative cells was examined using 
1 µl of the anti-MICA mAb AMO1 per 106 cells resuspended in 100 µl PBS. The binding of this 
unlabeled mouse IgG mAb was revealed using a polyclonal FITC-conjugated goat anti-mouse IgG 
antibody as secondary reagent (1 µl per 106 cells in 100 µl PBS). Determination of the MICA cell 
surface expression on the target cells was performed in parallel to each 51Cr release assay, IFN-γ and 
sMICA ELISA, CD107a expression and NKG2D down-regulation assay. Furthermore, this FITC-
conjugated anti-mouse antibody was used to detect binding of the recombinant MICA-129Met/Val-
mIgG2a-Fc or OVA-mIgG2a-Fc fusion proteins to the NKG2D receptor of primary human NK cells. For 
the recombinant human NKG2D-Fc chimeric fusion protein (2 µl per 106 cells in 100 µl PBS), which 
was used to determine the binding avidity of this NKG2D protein to its ligand MICA on target cells, a 
polyclonal FITC-conjugated goat anti-human IgG antibody served as secondary reagent (1 µl per 106 
cells in 100 µl PBS).  
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Characterization of primary human PBMCs, LAK and NK cells enriched and depleted fractions was 
performed using antibodies reactive against different cell surface epitopes (see 2.1.5.1, Table 2.4).   
 
2.2.5.1.1 CD107a degranulation assay 
Granule exocytosis of NK cells leads to the expression of the degranulation marker CD107a (also 
known as LAMP-1) at the NK cell surface, therefore being a sensitive marker for cytotoxic NK cell 
activity (Alter et al., 2004; Aktas et al., 2009). Thus, CD107a expression of human IL-2-stimulated NK 
cells co-cultured with L-con, L-MICA-129Met, L-MICA-129Val cells or stimulated with recombinant 
MICA-129Met/Val-mIgG2a-Fc or OVA-mIgG2a-Fc fusion proteins, respectively, was measured using an 
anti-CD107a mAb.  
For the co-culture, 106 human LAK cells were incubated at an E:T ratio of 25:1 with 4 x 104 harvested 
target cells for 1 h. The effector and target cells were transferred into a FACS tube and centrifuged at 
1200 rpm and RT for 5 min. Subsequently, the cells were resuspended in 100 µl FCS-containing 
DMEM and 4 µl of the anti-CD107a antibody or the respective mIgG1 isotype control were added. To 
ensure contact between effector and target cells the tubes were centrifuged again for 5 min and 
then incubated at 37°C and 5% CO2 for 1 h. After this time the cells were washed once with PBS, 
resuspended in 100 µl PBS supplemented with anti-CD16 and anti-CD56 antibodies at a 
concentration according to manufacturer’s instructions and incubated in the dark at 4°C for 30 min. 
The staining with these two NK cell markers enabled the gating during flow cytometric analysis on 
CD56-positive NK cells. Afterwards the cells were washed and resuspended in 300 µl PBS for analysis. 
CD107a expression assays of human NK cells stimulated with MICA-129Met-Fc, MICA-129Val-Fc or 
OVA-Fc were performed in Nunc MaxiSorpTM microtiter plates as described above (see 2.2.4.3). NK 
cell-containing medium was supplemented with the anti-CD107a antibody (4 µl/100 µl DMEM) 
during an incubation period of 1 h at 37°C and 5% CO2. 
 
2.2.5.1.2 NKG2D down-regulation assay 
An anti-NKG2D antibody was used to examine the regulation of this immunoreceptor on human IL-2-
stimulated NK cells exposed to L-con cells, L-MICA-129Met or L-MICA-129Val-expressing target cells, 
respectively. In brief, 2.5 x 105 NK cells in 100 µl FCS-containing DMEM were transferred into each 
well of a 96-well culture plate. Subsequently, 5 x 104 target cells in 100 µl medium were added 
resulting in E:T ratio of 5:1 and the plate was centrifuged at 1200 rpm for 5 min followed by an 
incubation at 37°C and 5% CO2 for 4 h and 24 h, respectively. Afterwards the cell suspensions were 
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transferred into FACS tubes and washed with PBS before 5 µl of the PE-labeled anti-NKG2D antibody 
as well as 5 µl of a FITC-labeled anti-CD94 antibody per 100 µl PBS were added and incubated in the 
dark at 4°C for 1 h. The CD94 staining served as a control to include a parameter, which was not 
expected to be down- or up-regulated after co-culture of NK cells with the respective target cells. 
Afterwards cells were washed and subjected to flow cytometric analysis. For the time point t=0, NK 
cells were directly stained with the anti-NKG2D and anti-CD94 antibody and the receptor expression 
was then determined. 
 
2.2.5.2 Chromium-51 (51Cr) release assay 
The 51Cr release assay is an in vitro method for quantification of cellular cytotoxicity. 51Cr release 
assays were performed as previously described (Dressel et al., 2000; Elsner et al., 2007; Elsner et al., 
2010) to assess the susceptibility of different target cells to cytotoxic effector cells. The principle of 
this assay is that target cells labeled with 51Cr release this isotope when lysed by cytotoxic effector 
cells.  
As target cells several clones of the mouse L-MICA-129Met and L-MICA-129Val transfectants were 
used expressing the MICA cell surface protein of the respective MICA-129 variant. As negative control 
empty vector-transfected MICA-negative L control (L-con) cells were used, while human 
erythroleukemia K562 cells, which are known to be highly susceptible to killing by human NK cells, 
served as positive control. One million harvested target cells were incubated in 100 μl FCS and 50 μCi 
Na2
51CrO4 at 37°C for 1 h. In between, a serial 1:1 dilution of human LAK cells or NK cells, stimulated 
with 100 U/ml rhIL-2 for 4 days, in FCS-containing DMEM (100 µl) was prepared in a 96-well plate to 
achieve different effector to target (E:T) ratios ranging from 200:1 to 3.125:1 for LAK cells or from 
20:1 to 0.3125:1 for NK cells, respectively. After 1 h the target cells were washed three times with 10 
ml Hepes-buffered DMEM at 1200 rpm for 10 min to remove free 51Cr, which was not taken up by 
the cells. Subsequently, 104 labeled target cells in 100 µl medium were added to each well of the 
prepared effector cell dilutions followed by an incubation at 37°C and 5% CO2 for 4 h in a final volume 
of 200 μl. At the end of the 4 h incubation, the plates were centrifuged at 600 rpm for 3 min. Then 50 
μl supernatant were removed and transferred into a 96-well Wallac plate. For cell lysis and release of 
all 51Cr isotopes, 5 μl 10% Triton-X were added to each well containing the cell pellets and the 
remaining 150 µl supernatant. After thorough resuspension, 50 μl of the sediment part were 
transferred into another 96-well Wallac plate. All probes were mixed with 200 μl scintillator and 
sealed with an adhesive film before measurement in the MicroBeta2 plate counter was performed. 
The lysis was calculated according to the following formula: 






The assay was performed in triplicates for each target cell line and E:T ratio. The specific lysis of the 
target cells was calculated by subtracting the values of the spontaneous release (51Cr release in the 
absence of effector cells) from the determined lysis values. The relative lysis compared to K562 cells 
was calculated to normalize individual experiments. Therefore, the percentage of the specific lysis of 
K562 cells at the highest E:T ratio (200:1 or 20:1) was adjusted to 100% in each test and the relative 
lysis of the other target cells by LAK or NK cells at different E:T ratios was calculated. 
 
2.2.5.3 ELISA 
The ELISA method uses enzyme-linked antibodies and changes in color of a substrate to identify a 
substance of interest. Within this study, the so-called sandwich ELISA technique was applied using a 
specific capture antibody and a detection antibody. All ELISAs were performed in 96-well Nunc 
MaxiSorpTM microtiter plates and a BioTek PowerWave 340 microplate spectrophotometer was used 
to measure absorbance at the appropriate wavelength. For coating of the microtiter plates a sodium 
carbonate coating buffer (pH 8.5) was used (see 2.2.4.3). The chemical compound ABTS, which is a 
redox indicator, served as substrate for the HRP. 
 
Substrate buffer: 0.1 M C2H3NaO2 
  0.05 M  NaH2PO4 
  dissolved in  dH2O, pH 4.0 
 
ABTS solution: 40 mM ABTS in dH2O 
 
Substrate solution: 10 ml  Substrate buffer 
   500µl   ABTS solution 
10µl  H2O2 (30%) 
 
2.2.5.3.1 IFN-γ ELISA 
To determine IFN-γ levels in the supernatants after 24 h co-culture of primary human NK cells with L-
con cells, L-MICA-129Met or L-MICA-129Val-expressing target cells (see 2.2.4.8.1), ELISAs were 
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performed using the human IFN-γ ELISA set from ImmunoTools according to the manufacturer’s 
protocol.  
Briefly, a Nunc microtiter plate was coated with the coating antibody against IFN-γ in a total volume 
of 100 µl coating buffer. The plate was sealed and incubated at 4°C overnight. After washing the 
plate five times with PBS, 200 µl blocking buffer (1% BSA in PBS) were added per well before the 
plate was covered and incubated at RT for 1 h. Followed by five times washing of the plate with 
washing buffer (0.005% Tween-20 in PBS), 100 µl of the respective supernatants or the diluted IFN-γ 
standard were added to the wells. After an incubation period, the plate was washed and the 
biotinylated anti-human IFN-γ antibody was added to the wells. After further incubation for 1 h and 
washing, a streptavidin-HRP conjugate was added. This time the plate was incubated at RT for 30 
min. After a last washing step, 100 µl ABTS substrate solution (see 2.2.5.3) were added to each well 
and the plate was incubated at RT in the dark. Experiments were performed in duplicates for all 
samples. Measurement of absorbance was performed at 405 nm and 490 nm for calculation of Δ 
optical density (OD) BLANK values within the next 10 min in a microplate spectrophotometer. The 
amount of IFN-γ in each well was determined by extrapolating absorbance values to IFN-γ 
concentrations using a standard curve of recombinant human IFN-γ. 
 
2.2.5.3.2 sMICA ELISA 
Levels of sMICA proteins in the supernatants of MICA-129-transfected or empty vector-transfected 
mouse Ltk- and human tumor cell lines, produced as described above (see 2.2.4.8.2), were analyzed 
using the human MICA DuoSet ELISA from R&D Systems. The ELISA was conducted according to 
manufacturer’s instructions. All samples were investigated in duplicates and the amount of sMICA in 
each well was determined by extrapolating absorbance values to sMICA concentrations by means of 
a standard curve using a recombinant human MICA protein. 
 
2.2.5.3.3 mIgG screening ELISA 
The mIgG screening ELISA was used to select HEK293-MICA-129-mIgG2a-Fc and OVA-mIgG2a-Fc-
secreting clones. Therefore, Nunc microtiter plates were coated with 10 µg/ml of a goat anti-mouse 
IgG antibody diluted in 50 µl coating buffer per well, incubated at 4°C overnight and then blocked 
with 150 µl 1% gelatin in PBS. After washing 50 µl of the corresponding cell culture supernatants or 2 
µl of mouse IgG serum (10 µg/ml) diluted in 48 µl medium, which served as positive control, were 
added to each well and incubated at 37°C for 1 h. For detection, a goat anti-mouse HRP-conjugated 
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antibody diluted 1:4000 in PBS with 0.05% Tween-20 was added and the plates were incubated again 
at 37°C for 1 h. After a further washing step, 50 µl ABTS substrate solution (see 2.2.5.3) were added 
to each well and the OD values were determined after 5 min using a microplate spectrophotometer 
set to 405 nm. 
 
2.2.6 Histology 
2.2.6.1 Hematoxylin and eosin (H&E) staining 
For histopathological examination, paraffin sections of tumor tissue (2.5 µm) were stained using the 
H&E staining method. After incubation of the paraffin sections at 37°C overnight or at 60°C for 30 
min, tissue sections were deparaffinized using xylol (2 x 7 min), rehydrated in a descending alcohol 
series (ethanol 98%, 75% and 60% for 5 min each step) and put into dH2O for 5 min. For H&E staining, 
the samples were incubated in Mayer’s hemalum solution for 5 min, rinsed with dH2O for 5-10 min 
and incubated in eosin for additional 5 min. Subsequently, sections were briefly incubated in dH2O 
followed by an ascending alcohol series (60%, 75% and 98% ethanol). After a 5 min incubation in 98% 
ethanol, sections were transferred into isopropanol for 5 min and then incubated two times in xylol 
for 5 min before they were embedded using the Roti®-Histokitt. Hemalum, the complex formed from 
aluminium ions and hematein, which is an oxidation product of hematoxylin, colors nuclei of cells 
blue, while eosin colors eosinophilic structures such as the cytoplasm of cells as well as extracellular 
proteins in various shades of red, pink and orange. If staining of specific proteins was of interest, 
additional immunohistochemistry was performed (see 2.2.6.2). 
 
Eosin solution: 1%  Eosin  
  200 µl   Acetic acid 
add to 100 ml dH2O 
 
2.2.6.2 Immunohistochemistry 
For immunohistochemistry, paraffin sections were stained with specific antibodies to detect proteins 
of interest. After deparaffinization and rehydration in a descending alcohol series (see 2.2.6.1), tissue 
sections were cooked three times in citrate buffer for 5 min for antigen retrieval. Subsequently, the 
sections were blocked with 4% BSA in PBS for 1 h before incubation with a biotinylated goat anti-
human MICA antibody, diluted 1:5 in PBS with 1% BSA, at 4°C overnight. Tissue sections were 
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incubated in 3% H2O2 (30%) in PBS at RT for 10 min to block endogenous peroxidases. Afterwards 
streptavidin-HRP diluted 1:200 in PBS was added and sections were incubated at RT for 1 h. The 
sections were stained with a DAB substrate solution and then embedded using the Roti®-Histokitt 
according to manufacturer’s instructions. If preferable, before embedding an additional staining with 
Mayer’s hemalum solution followed by an ascending alcohol series was performed (see 2.2.6.1). 
 
Citrate buffer: 0.1 M Citric acid (C6H8O7 ; 9 ml) 
0.1 M Sodium citrate (NaC6H5O7 ; 41 ml) 
add to 500 ml dH2O 
 
DAB substrate solution: 0.05% DAB 
  0.015% H2O2  
  dissolved in  PBS 
 
2.2.7 Animal experiments 
2.2.7.1 Inoculation of tumor cells 
L-MICA-129Met, L-MICA-129Val or L-con cells, respectively, cultured in vitro (see 2.2.4.4.1) were 
harvested, washed two times with PBS and adjusted to 106 or 5 x 106 cells/100 µl PBS. Subsequently, 
100 µl of the cell suspension were subcutaneously (s.c.) injected into the flank of manually 
immobilized mice (see 2.1.9, Table 2.8) using a 1 ml syringe with a 26 G needle. Tumor growth was 
monitored by palpation and tumor size was recorded using a linear caliper. Tumor volume was 
calculated by the formula V = πabc/2, where a, b, c are the orthogonal diameters. 
 
2.2.7.2 Adoptive NK cell transfer 
For the adoptive NK cell transfer, human NK cells were isolated via MACS technology (see 2.2.4.2) 
from peripheral blood and stimulated in vitro for 4 days with 100 U/ml rhIL-2 (2.2.4.4.2). After 
washing the cells twice with PBS, 106 to 5 x 106 NK cells/100 µl PBS were intravenously (i.v.) injected 
into the tail vein of immunodeficient C.B.-17-SCID or C57BL/6-Rag2-/-/cγc-/- mice (see 2.1.9, Table 
2.8), which were inoculated with tumor cells into the flank (see 2.2.7.1) 4 days before, using a 1 ml 
syringe and a 26 G needle. 
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2.2.7.3 Sacrification and tissue preparation 
The mice were sacrificed in a CO2 atmosphere when a tumor volume of 1 cm
3 was reached or when 
weight loss (>20% for more than 48 h) or any signs of pain were recorded. Blood was directly gained 
by heart puncture using a 1 ml syringe and one part of the fresh blood was transferred in an EDTA-
containing 1 ml plastic tube. For flow cytometric analysis, the blood was stained with antibodies of 
interest and erythrocytes were lysed with FACS™ lysis solution according to manufacturer’s 
instructions. The other part of the blood was added into a 1.5 ml reaction tube, incubated for 1 h at 
RT followed by 1 h at 4°C. Subsequently, the blood was centrifuged at 10,000 rpm at RT for 5 min. 
The serum was carefully transferred into a fresh tube and the centrifugation step repeated. 
Afterwards the serum was stored at -20°C. After blood taking, the primary tumor was prepared and 
cut into three parts. One part was placed in phosphate-buffered 4% formalin for 16 h and then 
embedded in paraffin. Tissue sections were stained with H&E (see 2.2.6.1). The second part was 
immediately frozen in liquid nitrogen for gene expression analyses and the third part was stored in 
medium on ice for subsequent flow cytometry. Then autopsies were continued and the abdomen 
and thoracic cavity were examined systematically for the presence of metastases. The spleen, liver 
and lung were prepared to look for transferred NK cells by flow cytometry. The tumor sample for 
flow cytometry was cut into small pieces and incubated in medium supplemented with collagenase 
(1 mg/ml) and DNase I (20 U/ml) in a thermoblock at 500 rpm and 37°C for 1 h. The other tissues 
were passed through a 40 µm nylon mesh with ice-cold PBS or DMEM using a syringe plug. The cell 
suspensions of the different tissues were centrifuged at 1200 rpm for 10 min and the pellet 
resuspended in PBS followed by a further centrifugation step. Before antibody staining for 
investigation by flow cytometry, the homogenized spleen was additionally treated with erythrocyte 
lysis buffer. 
 
Erythrocyte lysis buffer:  155 mM NH4Cl 
   10 mM KHCO3 
   0.1 mM EDTA 
   dissolved in  dH2O, pH 7.2 
 
2.2.8 Clinical study population 
In this study, 320 consecutive patients (Ps), who underwent allogeneic HSCT in the Department of 
Hematology and Medical Oncology in the University Medical Center Göttingen between October 
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2002 and March 2011, and their donors (Ds) were included. Approval for the analysis was obtained 
from the Institutional Review Board of the Göttingen University Medical Center and was conducted 
according to the Declaration of Helsinki. The SNP rs1051792 (A/G), which is responsible for the MICA-
129Met/Val dimorphism, was genotyped by a TaqMan MICA-129 genotyping assay (see 2.2.2.3.4).  
 
2.2.9 Statistical analysis 
Statistical analysis was performed using WinStat software. If not otherwise indicated, student’s 
unpaired t test and analysis of variance (ANOVA) were used. Data are depicted as mean ± standard 
deviation (SD) or standard error of the mean (SEM). A P value of less than 0.05 (*), less than 0.01 (**) 
or less than 0.001 (***) was considered statistically significant, whereas n.s. means not significant. 
More complex statistical models for the analysis of the 51Cr release assays, CD107a expression assays, 
NKG2D down-regulation experiments, IFN-γ ELISAs and of the clinical study cohort undergoing HSCT 
were performed by statisticians from the Department of Genetic Epidemiology of the UMG.  
The experimental data were evaluated with the WinStat software employing t tests or two-way 
ANOVAs with interactions. The SAS software was used to estimate linear mixed models with 
adjustment for the interaction with MICA expression level. Dependent on the experimental design, 
random effects were included into the models to account for the longitudinal correlation (relative 
cell lysis; cell surface expression of NKG2D and CD94) or for a random trial effect (IFN-γ release).  
Statistical analyses of clinical and genotyping data were performed with R software (http://www.R-
project.org). The analysis comprised patient/donor (P/D) pairs matched on the MICA-129 genotype 
(274 pairs) and the whole dataset (320 pairs). The influence of the MICA-129 dimorphism on the 
outcome in HSCT patients was evaluated. The outcome parameters were occurrence of aGVHD, 
occurrence of cGVHD, occurrence of relapse, treatment-related mortality (TRM), death due to 
aGVHD (probability of event analysis with logistic regression) and overall survival (time to event 
analysis with Cox proportional hazard models). Important clinical covariates (donor gender, T cell 
depletion, reduced intensity conditioning and HLA-matched unrelated donor) were identified and 
adjusted for in all analyses. The co-dominant model was employed to determine the most 
appropriate risk model (additive, dominant or recessive). Reported are the results of the most 





3.1 MICA-129Met/Val gene expression in L-MICA-129 transfectants 
To study the functional effects of the MICA-129Met/Val polymorphism, we generated cells 
expressing MICA variants differing only at position 129. For this purpose, a pCMV6-AC expression 
vector containing the MICA gene (Origene) was purchased and subsequently sequenced. Two 
positions in this construct, encoding the amino acid positions 24 and 360 of the MICA protein, had to 
be altered by site-directed mutagenesis to obtain the human MICA*00701 allele, which contains a 
Met at amino acid position 129. The MICA-129Val variant (pCMV6-AC-MICA-129Val) of the 
MICA*00701 allele was generated by site-directed mutagenesis of the pCMV6-AC-MICA-129Met 
construct. NK cell-resistant mouse fibroblast tumor L cells were stably transfected with these 
constructs, since the MICA gene and its homolog MICB are not present in the mouse genome. During 
the screening for stable L-MICA-129Met and L-MICA-129Val clones, we observed that clones of the 
MICA-129Met variant with high MICA cell surface expression were rare. After prolonged selection 
with G418, we finally got stable L-MICA-129Met clones with similar expression levels as L-MICA-
129Val clones. Altogether, a broad range of MICA expression intensities was reached on different 
clones for both variants as shown in Figure 3.3 D and E (section 3.2.1).  
To determine whether the MICA mRNA expression level differs between the two MICA-129 variants, 
mRNA was isolated from several clones of each MICA-129 variant and after cDNA synthesis qRT-PCRs 
were performed. For normalization of mRNA amounts of the MICA target gene (tg), Hprt 
(hypoxanthine-guanine phosphoribosyltransferase) was used as housekeeping gene (hkg). In parallel, 
the MICA protein expression was determined by flow cytometry. The statistical analysis revealed no 
significant difference in the MICA protein expression intensity between the two MICA-129 variants in 
these experiments (P = 0.2132, t test) but a significant difference in the MICA mRNA expression level 
(P = 0.0212, t test) as depicted in Figure 3.1 A. These data suggest that for the MICA-129Met variant 
higher amounts of MICA mRNA are required than for the MICA-129Val variant to obtain a similar 
MICA protein expression level at the cell surface. Additionally, the MICA cell surface expression 
appears to be more directly dependent on the MICA gene expression level for the MICA-129Val than 

























































































































P = 0.2132 P = 0.0212
 
 
Figure 3.1: MICA mRNA expression significantly differs between the MICA-129Met and MICA-129Val 
variants. 
(A) Diagrams represent the MICA protein expression (MFI = mean fluorescence intensity, left panel) and MICA 
gene expression (Δ Ct tg-hkg , right panel) of L-MICA-129Met (n = 14) and L-MICA-129Val (n = 12) clones cultured 
under normal conditions. MICA gene expression and MICA protein expression were determined by qRT-PCR 
and flow cytometry, respectively. Expression values of the target gene (tg) MICA were calculated from mean of 
technical triplicates after normalization to the housekeeping gene (hkg) Hprt. The data were compared by an 
unpaired t test and are shown in box-and-whisker plots. It should be noted that lower Δ Ct tg-hkg values indicate 
higher mRNA expression levels. (B) The linear regression of MICA gene expression and MICA protein expression 
is shown for L-MICA-129Met (left panel) and L-MICA-129Val cells (right panel). The regression line and the 
coefficient of determination (R
2






3.2 Influence of the MICA-129Met/Val polymorphism on binding avidity 
Two experimental systems were used to analyze the interaction of NKG2D and MICA-129Met/Val. 
Firstly, we stably transfected MICA-negative mouse L cells with MICA-129Met or Val expression 
constructs as described above (section 3.1) and determined the binding of a recombinant NKG2D-Fc 
fusion protein. Secondly, we produced the MICA-129Met/Val variants as recombinant mouse IgG2a-Fc 
fusion proteins in HEK293 cells and analyzed their binding to primary human NK cells. 
 
3.2.1 Binding of NKG2D-Fc fusion protein to L-MICA-129 cells 
In order to investigate the influence of the MICA-129Met/Val polymorphism on NKG2D binding 
avidity, we analyzed the binding of NKG2D to the MICA-129Met/Val-transfected L cells. Both the L-
MICA-129Met and L-MICA-129Val cells, in contrast to empty vector-transfected L control (L-con) 
cells, expressed the MICA ligand at the cell surface and bound a soluble NKG2D protein (Figure 3.2) 
as shown by flow cytometry using an anti-MICA mAb and a recombinant human NKG2D-Fc fusion 
protein.  
 
Figure 3.2: L-MICA-129Met and L-MICA-129Val cells, in contrast to vector-only transfected L-con cells, bind a 
recombinant human NKG2D-Fc fusion protein.  
The expression of MICA was analyzed by flow cytometry on L-con, L-MICA-129Met and L-MICA-129Val cells 
using a primary mouse anti-human MICA mAb in combination with a FITC-conjugated goat anti-mouse IgG Ab 
as secondary reagent. In parallel, the binding of a recombinant human NKG2D-Fc fusion protein was measured 
using a FITC-conjugated goat anti-human IgG as secondary Ab. Staining with the respective primary reagent 
plus secondary Ab (blue or red line) and FITC-labeled secondary Ab only (black line) is shown. The MFIs of MICA 























A broad range of MICA expression intensities was reached on different clones but these were on 
average similar (P = 0.3690, t test) for both variants (Figure 3.3 A). However, the binding of NKG2D to 
both MICA-129 variants appeared to be different (Figure 3.3 B), although only at borderline level (P = 
0.0808, t test). Analysis of the ratios of MICA expression and NKG2D binding (Figure 3.3 C) clearly 
revealed a higher avidity of the MICA-129Met than MICA-129Val variant for NKG2D (P = 0.0016, t 
test). Moreover, the binding of NKG2D to the MICA-129Met isoform was more dependent on the 
intensity of MICA expression (coefficient of determination R2 = 0.62) than binding to the MICA-129Val 
isoform (R2 = 0.39). The slope of NKG2D binding with increasing MICA expression intensity was 
steeper for the MICA-129Met (Figure 3.3 D) than for the MICA-129Val variant (Figure 3.3 E). Thus, 























































































































































Figure 3.3: The MICA-129Met variant binds NKG2D with higher avidity than the MICA-129Val variant.  
(A) The MICA expression intensity on L-MICA-129Met (n = 79) and L-MICA-129Val cells (n = 81) was determined 
as MFI by flow cytometry and is shown in box-and-whisker plots. The data were compared by an unpaired t 




129Val cells was measured by flow cytometry and the MFIs are shown in box-and-whisker plots. A difference 
between the cell lines was assessed by an unpaired t test. (C) The ratios of the NKG2D binding and MICA 
expression for the L-MICA-129Met and L-MICA-129Val cells are summarized in box-and-whisker plots revealing 
a difference between the MICA-129 variants in NKG2D binding (unpaired t test). (D) The linear regression of 
MICA expression and NKG2D binding both determined as MFI is shown for the L-MICA-129Met and (E) L-MICA-
129Val cells. The slope of the regression line and the coefficient of determination (R
2
) are indicated for both 
MICA variants.  
 
3.2.2 Binding of MICA-129-Fc fusion proteins to NKG2D of human NK cells 
In addition to the L-MICA-129 cell lines, recombinant mouse IgG2a-Fc fusion proteins of both MICA-
129 variants were produced to analyze binding of these proteins to NKG2D of primary human NK 
cells. Therefore, pcDNA3.1-MICA-129-mIgG2a-Fc expression constructs of both variants were used for 
stable transfection of HEK293 cells which then secret the fusion proteins as MICA homodimers into 
the cell supernatant. We chose the mIgG2a-Fc part to minimize cross-reactions with human NK cells. 
Protein purification was performed by affinity chromatography using Protein G sepharose columns 
binding the Fc part of the fusion proteins. The purified MICA-129Met-mIgG2a-Fc and MICA-129Val-
mIgG2a-Fc proteins were separated by SDS-PAGE and stained with Coomassie blue or probed with an 
anti-MICA mAb and an anti-mouse IgG polyclonal Ab on immunoblots. Both assays revealed the 
proteins at a size of approximately 90 kDa (Figure 3.4 A). The expected size of the fusion proteins 
calculated based on the nucleotide sequence using a peptide molecular weight calculator offered by 
genscript (https://www.genscript.com/ssl-bin/peptide_mw) was 61 kDa. Since MICA proteins are 
glycosylated, deglycosylation was performed with a recombinant fusion protein of endoglycosidase H 
(Endo Hf, apparent molecular weight of 70 kDa), which cleaves within the chitobiose core of high 
mannose and some hybrid oligosaccharides from N-linked glycoproteins. SDS-PAGE after Endo Hf 
digestion showed now a protein size of approximately 80 kDa (Figure 3.4 C). Herein, it is to consider 
that Endo Hf is a glycosidase, which only partly deglycosylates proteins. An OVA-mIgG2a-Fc fusion 
protein was generated as a control protein and showed a size of about 70 kDa after SDS-PAGE and 
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Figure 3.4: Identification of MICA-129Met-Fc, MICA-129Val-Fc and OVA-Fc fusion proteins. 
(A) MICA-129Met-mIgG2a-Fc and L-MICA-129Val- mIgG2a-Fc proteins (~90 kDa) were separated together with a 




Coomassie blue (left panel) to demonstrate the integrity of the recombinant fusion proteins. Both fusions 
proteins (5 µg) were separated and blotted. The blot was probed with a biotinylated anti-MICA Ab and 
subsequently with an anti-mouse IgG Ab (right panel). (B) The OVA- mIgG2a-Fc control (~70 kDa) was separated 
with a marker (M) on a SDS-PAGE and stained with Coomassie blue (left panel). The OVA-Fc fusion protein (1 
µg) was separated together with OVA (2 µg) and blotted. The blot was probed with an anti-OVA Ab. (C) Both 
MICA-129-Fc proteins (which were stored with 0.1% of the carrier protein BSA before analysis) were partly 
deglycosylated using a recombinant fusion protein of the endoglycosidase H (Endo Hf, 70 kDa). SDS-PAGE after 
Endo Hf digestion is indicated showing partial deglycosylation of the MICA-129-Fc proteins by this glycosidase 
(80 kDa). 
 
We used the MICA-129Met-mIgG2a-Fc and MICA-129Val-mIgG2a-Fc fusion proteins to analyze their 
binding to the NKG2D receptor of human NK cells. For these experiments, primary human PBMCs 
were separated by density gradient centrifugation from peripheral blood of voluntary donors and NK 
cells were isolated by MACS and stimulated with recombinant human IL-2 for 4 days. In parallel to 
the analysis of the binding of the recombinant MICA-129-Fc proteins to NKG2D of the activated NK 
cells, NK cells were always characterized and their purity was evaluated by using Abs against the two 
NK cell markers CD16 and CD56 and the three NK cell receptors CD94, NKp44 (CD336) and NKG2D 
(CD314) (Figure 3.5). The purity of NK cells, used for all performed experiments, always varied within 




























Flow cytometric analysis of the binding avidity of the two MICA-129-mIgG2a-Fc proteins and the OVA-
mIgG2a-Fc negative control to NKG2D of IL-2-stimulated human NK cells revealed that both MICA 
proteins, in contrast to the OVA protein, bound specifically and concentration-dependent (P = 4.28 x 
10-9, ANOVA) to NK cells (Figure 3.6 A, B). The maximal binding occurred at concentrations of MICA-
129-Fc fusion proteins between 5 µg/ml and 20 µg/ml. In these binding assays, the MICA-129Met 
protein appeared to bind stronger at lower concentrations, whereas the MICA-129Val protein 
Figure 3.5: Characterization of purified 
IL-2-stimulated human NK cells. 
For NK cell characterization the NK cell 
markers and receptors CD16, CD56, 
CD94, NKp44 and NKG2D as well as the 
T cell marker CD3 were always 
determined by flow cytometry on the 
surface of MACS-isolated human NK 
cells, stimulated for 4 days with IL-2 
(100 U/ml), before the cells were used 
in experiments. The means plus SD of 
the percentage of cells positive for the 




seemed to gain advantages at higher concentrations. Overall there was no statistical significant 
difference between the MICA-129Met-Fc and MICA-129Val-Fc fusion proteins when the MFI (P = 
0.2833) or the percentage of MICA-binding NK cells (P = 0.2050) were evaluated (ANOVA adjusted for 




















































































































Figure 3.6: MICA-129Met-Fc and MICA-129Val-Fc fusion proteins, but not OVA-Fc protein, bind to NKG2D of 
human NK cells.  
(A) The binding of MICA-129Met-Fc, MICA-129Val-Fc and as negative control OVA-Fc fusion proteins to IL-2- 
stimulated (100 U/ml for 4 days) purified NK cells was determined by flow cytometry. The histograms show the 
staining with the fusion proteins (10 µg/ml) plus secondary FITC-labeled Ab in bold and with the secondary Ab 
only in light. The percentage of cells binding to the proteins and the MFI is indicated. The percentage of cells 
stained with the secondary Ab only was 1.1% in the range of the marker and the MFI was 5.9. (B) The binding 
of MICA-129Met-Fc, MICA-129-Val-Fc and OVA-Fc fusion proteins to NK cells was determined by flow 
cytometry at various concentrations and is shown as mean (n ≥ 3) and SD of the MFI (left panel) and the 
percentage of positive cells (right panel). 
 
Moreover, the binding avidity of the two recombinant MICA-129-Fc fusion proteins to the 
recombinant human NKG2D-Fc fusion protein was determined in four experiments by SPR analysis. 
Therefore, the NKG2D-Fc protein was covalently immobilized on an activated 2D SPR sensorchip and 
the SPR response was recorded after injection of nine different MICA-129Met-Fc and MICA-129Val-Fc 




showed that the two MICA-129-Fc proteins did not significantly differ in their binding to NKG2D (P = 
0.1449, t test) (Figure 3.7 D). Conceivably a tendency towards a higher NKG2D binding avidity of the 
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Figure 3.7: MICA-129Met-Fc and MICA-129Val-Fc proteins bind with similar avidity to NKG2D-Fc in SPR 
analysis. 
NKG2D-Fc was covalently immobilized on an activated HC 1000m SPR sensorchip and the SPR response was 
recorded after injecting 2, 4, 8, 16, 32, 64, 125, 250 and 500 nM of MICA-129Met-Fc and MICA-129Val-Fc fusion 
proteins. (A) Equilibrium binding analysis of NKG2D-Fc binding to MICA-129Met-Fc and (B) MICA-129Val-Fc 
fusion proteins at 20°C is shown. The equilibrium binding constants (KD) of the MICA-129Met-Fc and MICA-
129Val-Fc proteins were obtained using a non-linear curve fit. (C) A typical sensogram of MICA-129Val-Fc 
binding obtained via SPR analysis is depicted showing the observed binding as black lines. Solid red lines show 
the global fit of SPR data using kinetic parameters ka and kd. (D) The results of NKG2D binding for the MICA-
129Met-Fc and L-MICA-129Val-Fc isoforms of four experiments (n = 4) are summarized (means ± SD) and 





3.3 Functional effects of the MICA-129 dimorphism on human NK cells 
Next, we addressed the question whether the MICA-129Met/Val polymorphism has an impact on 
NKG2D-mediated signaling as well as on functional effects of human NK cells including cytotoxicity 
and cytokine production. 
 
3.3.1 Impact of the MICA-129 dimorphism on NKG2D-mediated signaling 
To determine differences in NKG2D-mediated signaling events, the recombinant MICA-129-mIgG2a-Fc 
fusion proteins and as negative control also the OVA-mIgG2a-Fc fusion protein were immobilized at a 
concentration of 10 µg/ml in microtiter plates and purified IL-2-stimulated human NK cells were 
added. Binding of both MICA-129 proteins to NK cells was similar at this concentration (see section 
3.2.2, Figure 3.6 A, B). The NK cells were harvested after 3 min, 10 min and 30 min and protein 
lysates were obtained. Probing of western blots with an anti-phospho-tyrosine mAb and an anti-
phospho-Src family kinases (Tyr419 or Tyr416 when following the original nomenclature from 
chicken) Ab indicated stronger (Figure 3.8 A) and earlier phosphorylation of Src kinases in NK cells 
triggered by the MICA-129Met compared to the MICA-129Val isoform (Figure 3.8 B and see 
Appendix, Figure A.1). However, no clear differences in the phosphorylation of further downstream 
signaling molecules such as the guanine nucleotide exchange factor VAV1 (Tyr174) and the Src 
homology 2 (SH2) domain-containing leukocyte protein of 76 kDa (SLP-76) (Tyr128) were 
recognizable (Figure 3.8 B, right panel and see Appendix, Figure A.1). Probing of several blots with 
further phospho-specific antibodies for the phospholipase C-γ2 (PLC-γ2) (Tyr759), the p85 
(Tyr458)/p55 (Tyr199) subunits of phosphatidylinositol 3-kinase (PI3K), the protein kinase Akt 
(Ser473) and the spleen tyrosine kinase Syk (Tyr352), along with ζ-chain-associated protein of 70 kDa 
(ZAP-70) tyrosine kinase (Tyr319), showed no or only weak signals (data not shown). Taken all 
together, we found that the MICA-129Met variant triggers a faster and stronger phosphorylation of 
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Figure 3.8: NKG2D-mediated phosphorylation of Src family kinases in response to the MICA-129Met-Fc 
protein is stronger and faster than in response to the MICA-129Val-Fc protein.  
(A) Purified IL-2-stimulated (100 U/ml for 4 days) human NK cells (10
6
) were stimulated with immobilized MICA-
129Met/Val-mIgG2a-Fc or OVA-mIgG2a-Fc fusion proteins (10 µg/ml) for 3, 10 or 30 min in microtiter plates. The 
protein lysates of these cells were separated by SDS-PAGE and the blot was probed with an anti-phospho-Tyr 
mAb (upper panel), an anti phospho-Src family kinases (Tyr419) Ab and an anti-β-Actin mAb as loading control. 
(B) NK cells were stimulated as described above with the two MICA-129-Fc isoforms and the resulting blot was 
probed with an anti-phospho-Tyr mAb (left panel). After stripping of the blot membrane with β-
mercaptoethanol-containing buffer, the blot was probed with different anti-phospho-specific Abs (anti-
phospho-VAV1 (Tyr174), anti-phospho-SLP-76 (Tyr128) and anti-phospho-Src family kinases (Tyr419) Ab) and 




To test whether the phosphorylation of Src family kinases is a relevant step in NKG2D signaling of NK 
cells when triggered by MICA, the Src family kinases inhibitor PP2 was used. In these experiments, 
106 IL-2-stimulated NK cells were incubated with the PP2 inhibitor (25 µM), the vehicle dimethyl 
sulfoxide (DMSO) or medium only for 30 min before being added to immobilized MICA-129Met-
mIgG2a-Fc, MICA-129Val-mIgG2a-Fc or OVA-mIgG2a-Fc fusion proteins (10 µg/ml) for 10 min. After PP2 
treatment of NK cells, indeed no phosphorylation of Src family kinases in NK cells stimulated with the 
OVA-Fc, MICA-129Met-Fc and MICA-129Val-Fc proteins was apparent as shown by western blot 
analysis using an anti-phospho-tyrosine mAb and an anti-phospho-Src family kinases (Tyr419) Ab 
(Figure 3.9 A). 
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Figure 3.9: The specific inhibitor PP2 inhibits phosphorylation of Src family kinases in response to the MICA-
129Met-Fc and MICA-129Val-Fc proteins.  
(A) Purified human NK cells (10
6
), stimulated for 4 days with 100 U/ml IL-2, were incubated with the Src family 
kinases inhibitor PP2 (25 µM), the vehicle dimethyl sulfoxide (DMSO) or medium only (Ø) for 30 min before 
being added to immobilized MICA-129Met/Val-mIgG2a-Fc or OVA-mIgG2a-Fc fusion proteins (10 µg/ml) for 10 
min. The protein lysates of these cells were separated by SDS-PAGE and the blot was probed with an anti-
phospho-Tyr mAb (upper panel), an anti phospho-Src family kinases (Tyr419) Ab and an anti-β-Actin mAb as 
loading control. The blot is representative for two independent experiments. (B) The NK cells were incubated 
with the Src family kinases inhibitor PP2 (25 µM) or the vehicle DMSO for 30 min before being added to 
immobilized MICA-129Met/Val-mIgG2a-Fc or OVA-mIgG2a-Fc fusion proteins (10 µg/ml) or medium only (Ø) for 
1 h. Degranulation of the NK cells was measured by anti-CD107a staining in flow cytometry. Bold lines 
represent NK cells treated with PP2 and thin lines those treated with DMSO. The difference between DMSO 
and PP2-treated cells with respect to CD107a-positive cells and the MFI of CD107a is indicated in the 




In parallel, degranulation of NK cells after treatment with the Src family kinases inhibitor PP2 was 
measured by anti-CD107a staining in flow cytometry. Therefore, human IL-2-stimulated NK cells were 
incubated with PP2 (25 µM) for 30 min before being added to immobilized MICA-129Met-Fc, MICA-
129Val-Fc or OVA-Fc fusion proteins (10 µg/ml) or for comparison to medium only for 1 h. CD107a 
cell surface expression assays revealed that the NKG2D-triggered degranulation of NK cells after PP2 
inhibition was completely abolished (Figure 3.9 B) indicating a functional relevance of the observed 
differences in the strength and kinetics of phosphorylation of Src family kinases triggered by the two 
MICA-129 variants. Notably, the MICA-129Met variant induced more CD107a expression compared 
to the MICA-129Val variant in these experiments. 
 
3.3.2 Influence of the MICA-129 dimorphism on NK cell cytotoxicity 
3.3.2.1 Degranulation of NK cells after stimulation with MICA-129-Fc proteins 
To analyze the degranulation of human IL-2-activated NK cells stimulated with either MICA-129Met-
Fc or MICA-129Val-Fc fusion proteins in detail, more CD107a expression assays were performed. 
Granule exocytosis of NK cells leads to expression of the degranulation marker CD107a at the NK cell 
surface. In contrast to unstimulated NK cells, NK cells exposed to immobilized MICA-129Met-Fc or 
MICA-129Val-Fc proteins showed CD107a expression (Figure 3.10 A) confirming the functional 
activity of these proteins. The NK cell degranulation elicited by both MICA-129-Fc proteins (and the 
OVA-Fc protein as negative control) was compared over a broad range of protein concentrations as 
depicted in Figure 3.10 B. The statistical analysis revealed that the MICA-129-Met variant indeed 
triggered more degranulation than the MICA-129Val variant when the MFI of CD107a expression (P = 
0.0011, ANOVA adjusted for protein concentration) or the percentage of CD107a-positive NK cells (P 
= 0.0003, ANOVA adjusted for protein concentration) was evaluated (Figure 3.10 B). 
In summary, the MICA-129Met variant seems to be a stronger trigger of NK cell-mediated granule 
exocytosis than the MICA-129Val variant. This finding furthermore argued for a functional relevance 
of the observed differences in the strength and kinetics of phosphorylation of Src family kinases 






















































































































Figure 3.10: Degranulation of NK cells differs after stimulation with MICA-129Met-Fc and MICA-129Val-Fc 
proteins.  
(A) The degranulation of purified IL-2-stimulated (100 U/ml for 4 days) human NK cells in response to 
immobilized MICA-129Met-Fc and MICA-129-Val-Fc fusion proteins (5 µg/ml) was determined by flow 
cytometry performing CD107a expression assays. Representative figures of an experiment are depicted. (B) 
Granule exocytosis is shown as mean (n ≥ 3) and standard deviation (SD) of the MFI (left panel) and the 
percentage of positive cells (right panel). MICA-129Met-Fc, MICA-129-Val-Fc and as negative control OVA-Fc 
fusion proteins were immobilized at various concentrations in microtiter plates before the NK cells were added 
for 1 h. 
 
3.3.2.2 Degranulation of NK cells after co-culture with L-MICA-129 targets 
To investigate the effects of the MICA-129 dimorphism on degranulation of IL-2-activated human NK 
cells in a more physiological context, CD107a expression on NK cells exposed to MICA-129Met or 
MICA-129Val-expressing L target cells was determined. For the experiments human PBMCs were 
stimulated for 4 days with IL-2 (100 U/ml) and then characterized by flow cytometry for the 
expression of the NK cell surface markers CD16 and CD56 and the NK cell receptors CD94, NKp30 
(CD337), NKp44 (CD336), NKp46 (CD335) and NKG2D (CD314). In addition, also the percentage of 
cells positive for the T cell marker CD3 and the γδ T cell receptor (TCR), the B cell marker CD19 and 
the monocyte/macrophage marker CD14 was measured (Figure 3.11 A). For flow cytometric analysis 




CD56-positive NK cells were gated as shown in Figure 3.11 B and degranulation of these NK cells 
exposed to L-con, L-MICA-129Met and L-MICA-129Val cells for 1 h was analyzed after additional 
staining of CD107a. While NK cells exposed to L-con cells exhibited only slight CD107a expression, NK 
cells attacking MICA-Met or MICA-Val-expressing cells showed increased granule exocytosis (Figure 
3.11 C). In parallel to each degranulation assay, the MICA expression intensity of the target cells was 
determined. Statistical analysis revealed that degranulation of NK cells in response to L-MICA-
129Met and L-MICA-129Val cells was depended on the MICA expression intensity and significantly 
different between targets expressing the two MICA-129 variants. With adjustment for MICA 
expression intensity, less NK cells exposed to MICA-129Val-expressing target cells were CD107a-
positive (-10.08%, P = 0.0456, ANOVA) compared to NK cells attacking MICA-129Met-expressing 
targets (Figure 3.11 E). Also the MFI of CD107a was lower on NK cells exposed to L-MICA-129Val 
targets (-38.45%, P = 0.0174) (Figure 3.11 D). Notably, for NK cells recognizing the MICA-129Val 
variant, granule exocytosis significantly increased with MICA expression intensity (MFI of CD107a, 
slope 0.286, P = 0.0279), in contrast to NK cells exposed to the MICA129-Met variant (P = 0.4964). 
Thus, the MICA-129Met variant is overall a stronger trigger of NK cell cytotoxicity than the MICA-



















































































































































































Figure 3.11: Granule exocytosis of NK cells exposed to MICA-129Met and MICA-129Val-expressing L cells is 
significantly different and depends on the MICA expression level.  
(A) Human PBMCs were stimulated in vitro for 4 days with IL-2 (100 U/ml) and then characterized by flow 
cytometry for expression of the indicated cell surface markers. The percentage of cells positive for various 
markers (mean + SD, n > 3) is shown. (B) NK cells among PBMCs were identified by staining of CD16 and CD56. 
The CD56
+
 NK cells were gated as shown in this dot plot for subsequent analysis of CD107a expression. (C) The 
degranulation of CD56
+
 NK cells exposed to L-con, L-MICA-129Met or L-MICA-129Val cells for 1 h was 
determined by flow cytometry after staining of CD107a. Black lines indicate CD107a staining, while gray-lined 
histograms show the isotype control. The percentages of CD107a
+
 cells and the MFI of CD107a of these 
measurements are indicated in the histograms. (D) CD107a cell surface expression of NK cells exposed to L-
MICA-129Met (n = 27) or L-MICA-129Val cells (n = 27) was analyzed. In parallel, the MICA expression on target 
cells was determined. The linear regression of CD107a on NK cells and MICA expression on targets, both 
determined as MFI, is shown for the L-MICA-129Met (left panel) and L-MICA-129Val cells (right panel). The 
coefficient of determination (R
2
) and the slope of the regression line are indicated for both MICA variants. (E) 
The CD107a expression on NK cells was also analyzed with respect to the percentage of CD107a
+
 cells. The 
linear regression of CD107a
+
 NK cells and MICA expression on targets (MFI) is shown for the L-MICA-129Met 
(left panel) and L-MICA-129Val cells (right panel). 
 
3.3.2.3 Susceptibility of MICA-129-expressing targets to NK cell-mediated killing 
To further establish the functional relevance of the MICA-129 dimorphism for killing of target cells, 
the susceptibility of the two L-MICA-129 variants to killing by IL-2-stimulated human LAK and MACS-
isolated NK cells was analyzed using Chromium-51 (51Cr) release assays. A representative experiment 
is depicted in Figure 3.12. A showing the specific cell lysis of MICA-negative L-con cells and one clone 
of MICA-129Met and MICA-129Val-expressing L cells by LAK cells at different effector to target (E:T) 
ratios. K562 cells, which are known to be highly susceptible to killing by human NK cells, were 
included as positive control. The results demonstrate that MICA-expressing cells were effectively 
killed by human LAK cells in contrast to the vector-only transfected L-con cells, which were largely 
resistant to killing indicating that the lysis of the MICA-positive L transfectants was MICA-dependent. 
The MICA expression intensity on the target cells as well as the binding of a recombinant NKG2D-Fc 
protein was always determined in parallel to the cytotoxicity assays (Figure 3.12 A, box). In this 
experiment, the L-MICA-Met clone exhibited besides an increased NKG2D binding also an increased 
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Figure 3.12: Cytotoxicity of NK cells in response to the MICA-129Met and MICA-129Val isoforms significantly 
varies and depends on the MICA expression intensity.  
(A) A representative experiment is shown demonstrating the specific cytotoxic activity of human LAK cells 
stimulated for 4 days with IL-2 (100 U/ml) against L-MICA-129Met, L-MICA-129Val and L-con cells as negative 
control. K562 cells were included as positive control. The means of specific lysis of triplicates ± standard 
deviation (SD) at different effector:target (E:T) ratios (200:1 to 3:1) are shown as measured in a 
51
Cr release 
assay. The MICA expression intensity and binding of a recombinant NKG2D-Fc fusion protein to the target cells 
was always determined in parallel by flow cytometry and the MFIs for the experiment shown here are 
indicated in the box. This individual experiment is included in the summary shown in panel B and D. (B) The 
mean of relative lysis ± SD of the before mentioned target cells by IL-2-stimulated LAK cells was determined in 




relative lysis ± SD of target cells by MACS-isolated IL-2-activated NK cells was determined in 3 independent 
experiments using 6 different clones of each MICA-129 variant (n ≥ 11). The percentage of specific lysis of K562 
cells at the highest E:T ratio (200:1 for LAK cells or 20:1 for NK cells) was adjusted to 100% in each test and the 
relative lysis of the target cells by various effector cells at different E:T ratios was calculated. (D) Based on a 
linear statistical model, the MICA expression intensity was integrated in the calculation of the expected relative 
lysis of the target cells expressing the MICA-129Met or Val variant by LAK cells at different E:T ratios for the 
lower and upper MICA expression quartile (MFI: 43.92 or 40.45 and 94.23 or 102.12 for the MICA-129Met or 
MICA-129Val variant, respectively). 
 
For determination of the relative cell lysis, killing of K562 cells at an E:T ratio of 200:1 was set to 
100% in every experiment and used to calculate the relative lysis of the other targets as depicted in 
Figure 3.12 B. This graphical representation, which does not include the MICA expression of the 
target cells, showed no difference in lysis between the two MICA variants for all performed 
experiments using LAK cells as effectors. However, with adjustment to the MICA expression intensity, 
the statistical analysis revealed that the relative lysis of the MICA-129Val variant expressing L cells 
was significantly reduced compared to cells expressing the Met variant (n = 84, P = 0.0044, ANOVA,   
-13.0 % at an E:T ratio of 200:1). Importantly, the MICA expression intensity had even a negative 
influence on killing for targets expressing the MICA-129Met variant, (P = 0.0083, ANOVA, regression 
coefficient slope -0.0834,). In contrast, killing increased with expression intensity of the MICA-129Val 
variant on target cells (slope 0.1257, P < 0.0001). Based on a linear statistical model adjusted for the 
MICA expression intensity, Figure 3.12 D depicts the expected relative cell lysis of MICA-129Met/Val-
expressing target cells with low or high expression levels (lower MICA expression quartile with a MFI 
of 43.92 or 40.45 and upper MICA expression quartile with a MFI of 94.23 or 102.12 for the MICA-
129Met or MICA-129Val variant, respectively). These data show that high MICA expression intensities 
are associated with lower killing of cells expressing the MICA-129Met than MICA-129Val variant.  
Instead of using human LAK cells, containing between 10% to 15% NK cells, we also used purified IL-
2-stimulated NK cells comprising 95% to 98% of NK cells (Figure 3.12 C). Similar results were obtained 
with isolated NK cells but with reduced values for the relative cell lysis of MICA-expressing L targets 
and L-con cells suggesting a better activation of NK cells by IL-2 in a co-culture with other PBMCs or 
an involvement of a further cell population. Since γδ T cells also express NKG2D on their cell surface 
and do not necessarily need additional stimulation of other activating receptors to be activated 
(Girardi et al., 2001; Whang et al., 2009), this type of T cells might be also involved in killing of the 
target cells.  
In summary, the MICA-129Met variant elicited stronger NK cell cytotoxicity at lower MICA expression 
intensities compared to the MICA-129Val variant. Notably, cytotoxic effector function increased with 




129Met variant even decreased cytotoxic activity of NK cells. Thus, the Met variant is overall a 
stronger trigger of NK cell cytotoxicity but the Val variant gains advantages at high MICA expression 
intensities on target cells. 
 
3.3.3 Effect of the MICA-129 dimorphism on IFN-γ release 
Besides target cell killing we also analyzed IFN-γ release, which is a further effector function of NK 
cells triggered by NKG2D stimulation. The IFN-γ release in the supernatant of purified human IL-2-
stimulated NK cells co-cultured with L-con or MICA-129Met or Val-expressing L target cells for 24 h 
was determined by an ELISA detecting IFN-γ and the MICA expression of the target cells was 
measured in parallel by flow cytometry. Statistical analysis of the data adjusted to MICA expression 
intensity revealed that IFN-γ production was significantly higher for NK cells exposed to L-MICA-
129Met compared to L-MICA-129Val cells (176.53 pg/ml, P < 0.0001, ANOVA) (Figure 3.13). For NK 
cells exposed to the MICA-129Val variant, the MICA expression intensity had a strong effect on IFN-γ 
release (1.103 pg/ml per MFI unit for MICA, P < 0.0001), in contrast to NK cells exposed to cells 
expressing the MICA-129Met variant (0.142 pg/ml per MFI unit, P = 0.0001). IFN-γ secretion of NK 
cells cultured in the absence of target cells or of NK cells exposed to L-con cells was not detectable or 
less than 25 pg/ml (data not shown).  
 
Figure 3.13: IFN-γ release of NK cells in response to the MICA-129Met and MICA-129Val variants is 
significantly different.  
The IFN-γ release of 2.5 x 10
5
 purified IL-2-stimulated human NK cells (100 U/ml for 4 days) co-cultured with 5 x 
10
4
 L-MICA-129Met (n = 34) or L-MICA-129Val target cells (n = 32) for 24 h was measured in the supernatant by 
ELISA. In parallel, the MICA expression on target cells was determined by flow cytometry. The linear regression 
of IFN-γ release (pg/ml) by NK cells and MICA expression on targets (MFI) is shown for L-MICA-129Met (left 
panel) and L-MICA-129Val cells (right panel). The slope of the regression line and the coefficient of 
determination (R
2
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In summary, the MICA-129Met variant is a stronger trigger not only of cytotoxic effects but also of 
IFN-γ release by NK cells than the MICA-129Val variant. However, for the MICA-129Val variant again 
a significant main effect of the MICA expression intensity was apparent, in contrast to the Met 
variant. 
 
3.4 Impact of the MICA-129 dimorphism on MICA shedding and NKG2D 
counter-regulation 
Because of the different functional effects of the two MICA-129 variants on NK cell activity, including 
cytotoxicity and cytokine production, the question came up why an increasing expression of the high 
avidity MICA-129Met isoform did not trigger continuously stronger functional responses of NK cells 
as the low avidity MICA-129Val isoform did. It is known that ADAM proteases are able to cleave MICA 
from the cell surface (Groh et al., 2002; Salih et al., 2002; Kaiser et al., 2007; Waldhauer et al., 2008; 
Chitadze et al., 2013). This phenomenon, called MICA shedding, is thought to constitute a major 
counter-regulating mechanism of tumor cells to subvert NKG2D-mediated immunosurveillance 
(Waldhauer et al., 2008). Therefore, one possibility was that higher expression of MICA leads to 
higher concentration of soluble MICA (sMICA), which can inhibit NKG2D signaling by blocking or 
down-regulation of the receptor (Groh et al., 2002). This sMICA could block NKG2D signaling and 
blocking would presumably be more efficient for the MICA-129Met variant.  
 
3.4.1 Influence of the MICA-129 dimorphism on MICA shedding 
3.4.1.1 MICA shedding of mouse L-MICA-129-expressing cells 
First, we analyzed whether the mouse L-MICA-129Met and Val transfectants, which we used for the 
previous functional experiments, show MICA shedding. The concentration of sMICA in the 
supernatant of L-MICA-129Met and L-MICA-129Val-expressing cells cultured for 24 h was determined 
using a sMICA ELISA. The MICA cell surface expression of these cells was measured in parallel by flow 
cytometry. It turned out that the MICA-129-transfected L cells did not release MICA into the 
supernatant in contrast to human melanoma cell lines which served as positive control and released 
detectable amounts of sMICA into the medium, especially after induction of the MICA expression 




shedding in MICA-129Met/Val-expressing L cells is likely a feature of mouse L cells, or perhaps of 
mouse cells in general which do not possess MICA/B, since both variants were shed when they were 
expressed in a human tumor cell lines (see 3.4.1.2). 
 
Table 3.1: Analysis of MICA shedding from L-MICA-129Met and L-MICA-129Val cells. 








mean ± SEM 
Ltk
-
 3 0.8 ± 0.0 0.0 ± 0.0 
L-con 3 0.5 ± 0.2 0.0 ± 0.0 
L-MICA-129Met 12 83.6 ± 16.9 0.0 ± 0.0 
L-MICA-129Val 12 136.1 ± 17.1 0.0 ± 0.0 
Melanomas 4 13.0 ± 4.6 14.2 ± 8.3 
Melanomas + SAHA
2
 4 48.4 ± 18.4 79.2 ± 12.7 
 
1
 For the control cells (Ltk
-
 and L-con) 3 replicates cultured at different time points were analyzed, for L-MICA-
129Met and L-MICA-129Met 12 independent clones were used and for melanomas, which served as positive 
controls, 4 different melanoma cell lines (Juso, Mel Ho, Parl and Sk Mel-29) were tested. 
2
 The melanoma cell lines were treated with 10 µM of the histone deacetylase (HDAC) inhibitor suberoylanilide 
hydroxyamic acid (SAHA, Qbiogene-Alexis, Grünberg, Germany) for 20 h before analysis to increase MICA 
expression as described previously (Elsner et al., 2010). 
 
3.4.1.2 MICA shedding of human tumor cell lines 
To clarify whether the absence of the MICA shedding phenomenon in the L-MICA-129Met/Val cells is 
a feature of mouse L cells, the three human tumor cell lines Malme (melanoma), T47D (breast 
carcinoma) and EPLC-272 (non-small cell lung carcinoma) were stably transfected with the pCMV6-
AC-MICA-129Met/Val expression constructs which were also used for transfection of the mouse L 
cells. We chose these three human tumor cell lines because the parental cell lines exhibited hardly 
any MICA cell surface expression and also treatment with the HDAC inhibitor SAHA did not 
considerably increase MICA expression compared to other human melanoma cell lines such as 































Malme, T47D and EPLC-272 cells were transfected with either the MICA-129Met or MICA-129Val 
expression construct. The non-clonal pools of stably transfected cells revealed an increased MICA cell 
surface expression and higher amounts of sMICA in the cell supernatant compared to the 
corresponding wild type cell lines (Figure 3.15 A) as determined by flow cytometry and sMICA ELISA, 
respectively. These results indicate that the MICA-129Met/Val proteins are shed by different human 
tumor cells in contrast to MICA on mouse L tumor cells transfected with MICA-129Met/Val 
expression constructs. 
Furthermore, we were interested whether the MICA-129 genotype affects the MICA shedding. In 
contrast to T47D and EPLC-272 cells, which normally grow only in cell aggregates and died when 
single cells were seeded, MICA-129Met/Val-transfected Malme cells could be used for clonal 
selection. We compared the amount of sMICA of several MICA-129Met and MICA-129Val-expressing 
Malme clones. The statistical analysis indicated that the MICA expression intensities on different 
clones of both MICA-129 variants were similar (P = 0.3749, t test) but the variants significantly 
differed in the amount of sMICA in the cell supernatant (P = 0.0280, t test) as depicted in Figure 3.15 
B. In addition, both variants showed a dependency of the MICA shedding on the MICA expression 
intensity which was stronger for the high avidity MICA-129Met variant (Figure 3.15 C). This result 
suggests that the MICA-129Met/Val dimorphism influences MICA shedding likely by a conformational 
change affecting the accessibility for ADAM proteases. 
 
Figure 3.14: MICA cell surface 
expression of human tumor cell lines. 
Malme, HT144, Juso, Mel Ei, Mel Ho 
and Sk Mel-29 are melanoma cell 
lines, T47D is a breast carcinoma and 
EPLC-272 a lung carcinoma cell line. 
For induction of MICA expression cell 
lines were also treated with the HDAC 
inhibitor SAHA (10 µM) for 20 h 
before analysis. The MICA membrane 
expression was determined by flow 
cytometry using an anti-MICA mAb. 
The means plus SD of the MFIs of the 
MICA cell surface expression are 



























































































































































P = 0.3749 P = 0.0280
R2= 0.7838 R2= 0.6874
 
 
Figure 3.15: MICA shedding significantly differs between the MICA-129Met and MICA-129Val variants and is 
dependent on the MICA expression intensity. 
(A) The MICA membrane expression intensity (left panel) and the amount of sMICA in the supernatant after 24 
h (right panel) of the parental Malme, T47D and EPLC-272 cell lines (wild types) and of the pools of each of 
these three cell lines transfected with the MICA-129Met or MICA-129Val expression construct, respectively, 
before clonal selection are shown. In parallel to measurement of sMICA (pg/10
6
 cells) by ELISA, MICA 
expression (MFI) was determined by flow cytometry. (B) The left panel illustrates the MICA expression intensity 
and the right panel the amount of sMICA in the supernatant of Malme-MICA-129Met (n = 9) and Malme-MICA-
129Val cells (n = 10). The data were compared by an unpaired t test and are shown in box-and-whisker plots. 




129Met (left panel) and Malme-MICA-129Val cells (right panel). The regression line and the coefficient of 
determination (R
2
) are indicated in the figure for both MICA variants.       
 
3.4.2 NKG2D down-regulation on NK cells after co-culture with L-MICA-129 cells 
Besides soluble NKG2D ligands such as sMICA also sustained exposure of NK cells to NKG2D ligand-
expressing cells can down-regulate the NKG2D receptor (Coudert et al., 2005; Oppenheim et al., 
2005; Wiemann et al., 2005). For instance, it has been shown that the prolonged encounter with 
tumor cell-bound, but not soluble, ligand can completely uncouple NKG2D from the intracellular 
mobilization of calcium and the exertion of cell-mediated cytolysis (Coudert et al., 2005). Since the 
MICA-129-transfected mouse L cells did not show MICA shedding, we investigated whether the 
MICA-129 dimorphism has an impact on the NKG2D down-regulation of NK cells exposed to the L-
MICA-129 cells. Therefore, the NKG2D expression on IL-2-stimulated human NK cells exposed for 4 h 
and 24 h to L-con, L-MICA-129Met and L-MICA-129Val cells was analyzed by flow cytometry using an 
anti-NKG2D mAb (Figure 3.16 A). In parallel, CD94 expression was tested as a control which was 
expected not to be down- or up-regulated in response to MICA encounter (Figure 3.16 B). Analysis of 
the data revealed that NKG2D was indeed down-regulated on NK cells co-cultured with MICA-
expressing cells compared to L-con cells (Figure 3.16 C). The percentage of NKG2D-positive NK cells  
(-9.5%, P = 0.0309 for the Val variant and -19.4%, P < 0.0001 for the Met variant, ANOVA) and the 
MFI of NKG2D (-11.8%, P = 0.0006 for the Val variant and -13.7%, P < 0.0001 for the Met variant, 
ANOVA) decreased. Notably, the percentage of NKG2D-positive cells decreased more among NK cells 
recognizing L-MICA-129Met than L-MICA-129Val targets (-9.3%, P = 0.0008, ANOVA). In addition, the 
MFI of NKG2D was significantly different between NK cells exposed to L-MICA-129Met and L-MICA-
129Val targets (P = 0.0225, ANOVA; accounting for differences in the 24-hour time course). 
Moreover, the percentage of NKG2D-positive NK cells decreased with the time of co-culture (P < 
0.0001). NK cells co-cultured with MICA-negative or MICA-expressing L cells did not show any 
differences in CD94 expression indicating the specificity of the effect (Figure 3.16 D). Hence, the 
MICA-129Met variant induces a stronger NKG2D counter-regulation on NK cells than the MICA-
129Val variant. This counter-regulation appears to limit the initially stronger functional effects of the 























































































































































Figure 3.16: Less NKG2D down-regulation on NK cells co-cultured with L-MICA-129Val cells compared to L-
MICA-129Met cells.  
(A) NKG2D expression on purified IL-2-stimulated human NK cells (100 U/ml for 4 days) co-cultured with L-con, 






were co-cultured with target cells (5 x 10
4
) in 200 µl medium, stained with 10 µl anti-NKG2D mAb and analyzed 




 cells. Black-lined histograms represent the NKG2D staining, while gray-lined 
histograms show the isotype control. The percentages of NKG2D
+
 cells and the MFI of NKG2D of these 
measurements are indicated in the histograms. (B) In parallel, the CD94 expression on the NK cells was 
determined. Black-lined histograms represent CD94 staining, while gray lines show the isotype control. The 
percentages of CD94
+
 cells and the MFI of CD94 of these measurements are indicated in the histograms. (C) 
NKG2D expression on NK cells exposed to L-MICA-129Met (n = 25) and L-MICA-129Val target cells (n = 25) for 0, 
4 and 24 h. The means and SD means of the percentage of NKG2D
+
 NK cells (left panel) and of the MFI of 
NKG2D (right panel) are shown. Differences between the groups were analyzed by ANOVA. (D) CD94 
expression was determined in parallel. The means and SD means of the percentage of CD94
+
 NK cells (left 
panel) and of the MFI of CD94 (right panel) are shown. Differences between the groups were analyzed by 
ANOVA. The significance levels are given in the figure (* P < 0.05, ** P < 0.01 and *** P < 0.001). 
 
3.5 Establishment of a mouse model for studying the impact of the MICA-
129 dimorphism on an experimental adoptive immunotherapy of cancer 
Our data, showing that the MICA-129Met/Val polymorphism is functionally relevant, encouraged us 
to investigate whether the SNP may also affect the therapeutic efficacy of an experimental adoptive 
immunotherapy of MICA-expressing tumors with activated human NK cells using immunodeficient 
mice. In parallel, we tried to optimize the in vitro stimulation of human NK cells for targeting MICA-
expressing tumors in vivo as well as the NK cell transfer protocol. 
 
3.5.1 Tumor growth after inoculation of L-MICA-129 cells 
Initially, 106 or 5 x 106 mouse L tumor cells were subcutaneously (s.c.) injected into the flank of C.B-
17/Ztm-scid mice, which lack B and T lymphocytes but still possess functional NK cells, to examine 
whether tumor growth is caused. The experiment indicated that injection of L cells leads to tumor 
growth within approximately 2 or 4 weeks for both injected tumor cell doses (Table 3.2). At the time 
point of autopsy, the tumor frequency was 100%. Dissection of the animals revealed a non-invasive 














Number and cell type of 











Day of autopsy 












 3 0% (day 10) 28.0 ± 0.0 3.35 ± 1.72 

























 L-MICA-129Val 3 100% (day 28) 18.0 ± 0.0 1.60 ± 0.26 
 
1




 are deficient in B, T 




 or 5 x 10
6
 cells in 100 µl sterile PBS were subcutaneously (s.c.) inoculated into the left flank of the animals. 
3
 Percentage of animals in which primary tumors were palpable at different time points. 
4
 After scarification tumors were prepared and tumor size was measured using a linear caliper. Tumor volume 
was calculated by the formula V = πabc/2, where a, b, c are the orthogonal diameters. 
 
In a second experiment, 106 MICA-129Met and Val-expressing L cells as well as MICA-negative L-con 
cells were s.c. inoculated into the flank of C57BL/6-Rag2-/-/cγc-/- immunodeficient mice lacking 
besides B and T cells also NK cells. Tumor formation was observed in all animals at autopsy and 
dissections also revealed non-invasive tumor growth without development of metastases (Table 3.2). 
Injection of 106 L-con cells showed similar tumor formation as inoculation of the same amount of 
parental L cells in SCID mice. The three mice injected with MICA-129Val-expressing cells had to be 
scarificed early at day 18. However, this must not indicate an effect of the MICA-129Val variant but 
could also be due to clonal variation. This finding indicated the necessity to use several clones of 
each MICA-129 variant with similar MICA cell surface expression and similar proliferation rates for in 
vivo experiments. Immunohistochemistry of tumor sections using an anti-MICA mAb exemplified that 
inoculation of L-MICA-129 tumor cells (L-MICA-129Met clone 1 and L-MICA-129Val clone 1) resulted 
in growth of MICA-expressing tumors in contrast to injection of L-con cells (Figure 3.17). 
Next, we analyzed the proliferation of several clones of each MICA-129 variant and L control cells by 
3H-thymidine incorporation assays. However, we did not find a major difference in the in vitro 
proliferation rate between cell clones expressing the MICA-129Met or MICA-129Val variant in vitro 





Figure 3.17: Immunohistochemistry of non-invasive tumors after injection of L-MICA-129 and L-con cells. 
For immunohistochemistry, paraffin sections were incubated with an anti-MICA mAb followed by an additional 
staining of the cell nuclei with hemalum (blue). DAB staining (brown) indicates MICA membrane expression in a 
non-invasive primary tumor after s.c. injection of 10
6
 L-MICA-129Met cells (upper panel) or L-MICA-129Val cells 




 immunodeficient mouse. As control 10
6
 L-con cells were 
inoculated resulting in growth of a primary MICA-negative tumor (lower panel).  
L-MICA-129Met (10 x) L-MICA-129Met (40 x)
L-MICA-129Val (10 x) L-MICA-129Val (40 x)




3.5.2 Adoptive NK cell therapy of L-MICA-129-bearing mice 
In a pilot experiment, we treated immunodeficient mice with L-MICA-129Met/Val-expressing tumors 
by adoptive transfer of human NK cells. In total, 36 C57BL/6-Rag2-/-/cγc-/- mice divided in six different 
groups, each comprising of six mice, were treated (Table 3.3). First, 106 L-con cells, MICA-
129Met/Val-expressing L cells (L-MICA-129Met clone 2 and L-MICA-129Val clone 2) were s.c. 
inoculated into the flank of 12 animals. At day 4 after tumor cell inoculation, 6 animals in each group 
were treated with 3 x 106 human NK cells, stimulated for 4 days with 100 U/ml IL-2, and the other 6 
mice received as control only 100 µl PBS injected intravenously (i.v.) into the tail vein. The mice were 
sacrificed between day 18 and 39 depending on the tumor growth (Table 3.3). They showed non-
invasive growth of primary tumors without the development of metastases. No difference in the 
lifespan or in the tumor size was observed between mice treated with NK cells or the PBS control 
(Table 3.3). At the time of autopsy, the transferred NK cells were not detectable anymore by flow 
cytometry in blood, spleen or tumor (data not shown) indicating a limited lifespan of the human NK 
cells in the recipient mice.   
 
Table 3.3: Tumor growth of different L cell lines in immunodeficient C57BL/6-Rag2-/-/cγc-/- mice. 
Number and cell type of 













Day of  
autopsy 










 L-con 3 x 10
6
 NK cells 6 83% 25.3 ± 4.8 1.93 ± 0.75 
10
6
 L-con PBS 6 100% 24.0 ± 3.6 1.89 ± 0.84 
10
6
 L-MICA-129Met 3 x 10
6
 NK cells 6 100% 21.7 ± 2.1 1.86 ± 0.59 
10
6
 L-MICA-129Met PBS 6 83% 23.7 ± 4.6 1.13 ± 0.37 
10
6
 L-MICA-129Val 3 x 10
6
 NK cells 6 67% 32.7 ± 4.4 1.22 ± 0.53 
10
6





 cells in 100 µl sterile PBS were subcutaneously (s.c.) inoculated into the left flank of the animals. 
2
 3 x 10
6
 human NK cells, stimulated for 4 d with 100 U/ml IL-2, in 100 µl sterile PBS or as control 100 µl PBS 
only were intravenously (i.v.) injected into the tail vein at day 4 after tumor cell inoculation. 
3
 Percentage of animals in which primary tumors were palpable at day 28. 
4
 After scarification tumors were prepared and tumor size was measured using a linear caliper. Tumor volume 






3.5.3 Optimization of NK cell stimulation for adoptive transfer 
It has been reported that in addition to IL-2 stimulation pre-activation of NK cells with the three 
cytokines IL-12, IL-15 and IL-18 improved antitumor NK cell activity (Ni et al., 2012). Therefore, we 
added IL-12, IL-15 and IL-18 to MACS-isolated human NK cells for the last 16 h of an overall 4 day 
stimulation with IL-2. The expression of the two NK cell markers CD16 and CD56, the activation 
marker CD69, the NK cell receptors CD94, NKG2D, DNAM-1, and 2B4 as well as the three natural 
cytotoxicity receptors (NCRs) NKp30, NKp44 and NKp46 was determined by flow cytometry. The NK 
cells of four different donors at three different time points – directly after MACS isolation, after 4 d 
IL-2 stimulation (100 U/ml) only and after IL-2 stimulation plus additional activation with IL-12, IL-15 
and IL-18 – were analyzed. The expression of the activation marker CD69 increased after stimulation 
with the additional cytokines in comparison to NK cells stimulated only with IL-2 (Figure 3.18 A). The 
expression of the NK cell receptors and NCRs was similar but CD16 expression decreased. The 
amount of CD56dim compared to CD56bright NK cells increased after additional stimulation suggesting 
an increase of NK cells with cytotoxic activity. In parallel, we also investigated whether the additional 
cytokine activation indeed resulted in changes of the cytotoxic activity of NK cells towards MICA-129-
expressing target cells using the CD107a expression assay. However, the NK cells showed no major 
difference regarding degranulation when attacking MICA-129Met or MICA-129Val-expressing L target 
cells after the two different pre-stimulation protocols (Figure 3.18 B).  
Moreover, we co-cultured isolated human NK cells together with irradiated allogeneic PBMCs, so-
called ´feeder cells´, and 250 U/ml IL-2 for 2 weeks to expand and pre-activate the NK cells. The initial 
number of NK cells increased 3-fold within 7 days, however, prolonged co-culture did not lead to a 
further increase of NK cells in our hands. The MFI of CD56 expression strongly increased during 
culture, while the percentage of CD56-positive cells remained similar from day 0 to day 14 indicating 
that the portion of CD56bright NK cells increased (see Appendix, Figure A.3). In addition, the MFI of 
CD16 expression decreased, whereas the percentage of CD94-positive cells as well as the MFI of 
CD94 increased. Thus, the expansion of NK cells was associated with a decrease of the portion of 
CD56dim NK cells which are known to exert the cytotoxic activity.  
In summary, the preliminary in vivo experiments for the treatment of MICA-expressing tumors with 
an adoptive transfer of activated human NK cells revealed the necessity to further optimize the in 
vitro stimulation of NK cells as well as the NK cell transfer protocol to obtain long NK cell survival and 








































































































IL-2 (d4) IL-2 + IL12/15/18 (d4)
 
 
Figure 3.18: Expression of NK cell receptors and degranulation of NK cells after IL-12/15/18 pre-activation. 
(A) The expression of the two NK cell markers CD16 and CD56, the activation marker CD69 and different NK cell 




Nkp44 and Nkp46 was determined by flow cytometry using mAbs against these receptors. Human NK cells of 
different donors (n = 4) directly after MACS isolation, after 4 d IL-2 stimulation (100 U/ml) only and after IL-2 
stimulation plus additional pre-activation with IL-12 (10 ng/ml), IL-15 (10 ng/ml) and IL-18 (50 ng/ml) was 
analyzed. The three additional cytokines were added for the last 16 h of the 4-day IL-2 stimulation. The upper 
panel shows the means of the NK cell receptor expression as MFIs plus SEM and the lower panel shows the 
percentage of positive cells plus SEM. (B) NK cells, stimulated with IL-2 only or with IL-2 plus IL-12/15/18, were 
exposed to no target cells, L-con, two clones of L-MICA-129Met and L-MICA-129Val cells and K562 cells. 
CD107a expression was determined by flow cytometry using an anti-CD107a mAb and is given as mean (n = 3) 
and SEM of MFIs (left panel) or percentage of CD107
+
 cells plus SEM (right panel). 
 
3.6 Association of the MICA-129 dimorphism with survival and GVHD after 
HSCT 
To investigate further whether the MICA-129 dimorphism is clinically relevant, 320 patient and donor 
(P/D) pairs undergoing allogeneic HSCT in the Department of Hematology and Medical Oncology at 
the University Medical Center Göttingen were typed for the SNP rs1051792 (A/G), which is 
responsible for the MICA-129Met/Val polymorphism. For typing an allele-specific TaqMan MICA-129 
genotyping assay was used. An example for an allelic discrimination plot of several control DNAs 




Figure 3.19: Genotyping for the MICA-129 dimorphism by an allele-specific TaqMan assay. 
Genomic DNA (10 ng) from heterozygous and homozygous human tumor cell lines and mouse L-MICA-
129Met/Val transfectants (n = 12) were genotyped for the MICA-129 dimorphism using an allele-specific 
TaqMan genotyping assay. These cell lines, which were already typed before for the SNP 454 (rs1051792, A 
(Met) or G (Val)) by PCR using sequence-specific oligonucleotides, served as controls for the genotyping of 
genomic DNAs of the 320 patients and donors from the Göttingen HSCT cohort. The allelic discrimination plot 
indicates which cell lines are homozygous for MICA-129Val (Allele X detected via a FAM-labeled MGB probe), 






The analysis of the data obtained from the MICA-129 genotyping of the 320 P/D pairs revealed that 
the Met (A) or Val (G) alleles occurred with a frequency of 31.5% or 68.5% in patients and 32.4% or 
67.6% in donors, respectively (Table 3.4). The majorities of patients and donors were homozygous for 
Val (G/G) (48.1% or 47.2%), more than one third were heterozygous (A/G) (36.9% or 36.6%) and the 
minority was homozygous for Met (A/A) (12.2% or 13.1%), which approximately reflects the reported 
genotype frequencies for this polymorphism in the Caucasian population (Zou and Stastny, 2011). 
Most of the P/D pairs (274, 85.6%) had the same MICA-129 genotype. 175 of the patients undergoing 
HSCT experienced aGVHD (54.7%, any grade), 104 cGVHD (32.5%, any grade) and in 69 (21.6%) a 
relapse of disease occurred. The overall survival rate was 48.1% and the treatment-related mortality 
22.8%. 
 
Table 3.4: HSCT pairs, diseases, transplantation characteristics and outcome. 
Characteristics Values 
Recipients (n = 320)  
   Median age, y 51 
   Younger than 20 y, n (%) 6 (1.9) 
   20 to 40 y, n (%) 53 (16.9) 
   Older than 40 y, n (%) 261 (81.6) 
   Male, n (%) 191 (59.7) 
   MICA-129 polymorphism  
      Genotype frequencies  
         Met/Met, n (%) 39 (12.2) 
         Met/Val, n (%) 118 (36.9) 
         Val/Val, n (%) 154 (48.1) 
         ND, n (%) 9 (2.8) 
      Allele frequencies  
         Met, n (%) 196 (31.5) 
         Val, n (%) 426 (68.5) 
Underlying diagnosis  
   Hodgkin lymphoma, non-Hodgkin lymphoma, n (%) 133 (41.6) 
   Acute leukemia, n (%) 118 (36.9) 
   Multiple myeloma, n (%) 32 (10.0) 
   Myelodysplastic syndrome, n (%) 18 (5.6) 
   Myeloproliferative diseases, chronic myeloid leukemia, n (%) 12 (3.8) 
   Other diagnoses, n (%) 7 (2.2) 
Disease status for malignant disorders  
   Early, n (%) 97 (30.3) 
   Intermediate, n (%) 99 (30.9) 
   Advanced, n (%) 124 (38.8) 




   Median age, y 41 
   Younger than 20 y, n (%) 1 (0.3) 
   20 to 40 y, n (%) 134 (41.9) 
   Older than 40 y, n (%) 137 (42.8) 
   ND, n (%) 48 (15.0) 
   Male, n (%) 180 (56.3) 
   Female donor to male recipient, n (%) 57 (17.8) 
   HLA-matched unrelated donor, n (%) 211 (65.9) 
   HLA-mismatched donor, n (%) 51 (15.9) 
   Related donor, n (%) 111 (34.7) 
   MICA-129 polymorphism  
      Genotype frequencies  
         Met/Met, n (%) 42 (13.1) 
         Met/Val, n (%) 117 (36.6) 
         Val/Val, n (%) 151 (47.2) 
         ND, n (%) 10 (3.1) 
      Allele frequencies  
         Met, n (%) 201 (32.4) 
         Val, n (%) 419 (67.6) 
Transplantation  
   Source of stem cells  
      Peripheral blood, n (%) 311 (97.2) 
      Bone marrow, n (%) 9 (2.8) 
   Conditioning  
      Busulfan-based, n (%) 284 (88.8) 
      Total-body irradiation-based, n (%) 36 (11.3) 
      Reduced intensity conditions, n (%) 67 (20.9) 
      T cell depletion, n (%) 149 (46.6) 
Outcome  
   Occurrence of acute GVHD, n (%) 175 (54.7) 
      Grade I to II, n (%) 108 (33.8) 
      Grade III to IV, n (%) 67 (20.9) 
   Occurrence of chronic GVHD, n (%) 104 (32.5) 
   Relapse, n (%) 69 (21.6) 
   Mortality, n (%) 166 (51.9) 
      Treatment-related mortality, n (%) 73 (22.8) 
      Mortality due to acute GVHD, n (%) 54 (16.9) 
 
ND indicates not determined or missing data. 
 
The association of the MICA-129 dimorphism with the outcome of HSCT for P/D pairs matched on the 
MICA-129 genotype was analyzed after adjustment for relevant clinical covariates. Carriers of the Val 




1.31 (95%-confidence interval (CI) 1.013-1.689; P = 0.0395, additive risk model) and homozygous 
carriers had a two times higher risk estimate on the logarithmic scale. A similar trend was observed in 
the whole cohort (HR = 1.23 for heterozygous patients; 95%-CI 0.968-1.571; P = 0.0897). Particularly, 
homozygous carriers of the Val variant had a lower probability of survival compared to homozygous 
carriers of the Met variant (Figure 3.20 A-B). The Met/Met genotype was associated with an 
increased risk of aGVHD (odds ratio (OR) = 2.27; 95%-CI 1.09-5.09; P = 0.0361, recessive risk model) 
in the whole cohort but presence of Met alleles was also associated with a lower risk of death due to 
aGVHD (OR = 0.42; 95%-CI, 0.25-0.90; P = 0.0012). Inversely, the Val/Val genotype was associated 
with an increased risk of death due to aGVHD (OR = 2.40; 95%-CI, 1.11-4.04; P = 0.0012). These 
outcomes were statistically significant also for P/D pairs matched on the MICA-129 genotype. The 
Met variant appeared to be associated with a higher risk of cGVHD without reaching the 5%-
significance-level in the whole cohort (OR = 1.40 for heterozygous and 1.96 for homozygous patients; 
95%-CI, 0.961-2.042; P = 0.0795, additive risk model). The MICA-129 SNP was not significantly 
associated with the risk of relapse.  
In summary, the MICA-129Met variant appeared to confer a higher risk of aGVHD but overall 
beneficial effects on survival after HSCT. Since we have shown that the MICA-129 dimorphism is 
functionally relevant, it is conceivable that this polymorphism is not only associated with but is 
directly causative for the observed differences in the outcome of HSCT.  
 
































































Figure 3.20: Cumulative survival according to the MICA-129 genotype.  
(A) Kaplan-Meier survival curves of patients receiving a graft matched for the MICA-129 genotype (n = 274) are 
shown grouped according to their MICA-129 genotype. (B) Kaplan-Meier survival curves of all patients in the 





4.1 Different functional effects of the high and low avidity MICA-
129Met/Val variant on NK cell activity 
We showed that the MICA-129Met/Val polymorphism, causing a single amino acid substitution of 
Met by Val at position 129, affects the binding avidity of the activating NK cell receptor NKG2D 
confirming the previous report of Steinle and colleagues (Steinle et al., 2001). The amino acid 129 is 
located in the β4 strand of the β-pleated sheet in the α2 domain of the MICA protein (Li et al., 1999; 
Li et al., 2001). It has been suggested that the replacement of Met by Val affects NKG2D binding 
indirectly by a conformational change instead of a direct participation in the MICA-NKG2D interface. 
The side chain of Met 129 is partially buried and forms hydrophobic interactions with the 
neighboring amino acids Glu 136, Ala 139 and Met 140 in the first α2 helical stretch, which may thus 
become differently positioned by the Val 129 substitution (Steinle et al., 2001).  
Within our study, we used two experimental systems to analyze the MICA-129Met/Val and NKG2D 
interaction. Firstly, MICA-negative mouse fibroblast L tumor cells were stably transfected with 
pCMV6-AC-MICA-129Met/Val expression constructs encoding MICA variants, which differ only at 
position 129. Using these cells, we found a higher avidity of the MICA-129Met than MICA-129Val 
variant for NKG2D similarly as Steinle et al. (2001) did, who used stably MICA-transfected human C1R 
B cell lines. Furthermore, we observed that the binding of NKG2D to the MICA-129Met isoform was 
more dependent on the intensity of MICA expression than binding to the MICA-129Val isoform.  
Secondly, we produced the MICA-129Met/Val variants as recombinant mouse IgG2a-Fc fusion 
proteins in HEK293 cells and analyzed their binding to the NKG2D receptor on primary human NK 
cells, stimulated for 4 days with 100 U/ml human IL-2. Surprisingly, we did not find a significantly 
different binding of these two MICA-129 isoforms to NKG2D. Also in SPR analysis both MICA-129-Fc 
variants bound NKG2D with similar avidity. However, a tendency towards a higher NKG2D binding 
avidity of the MICA-129Met isoform was apparent. 
Since the MICA-129-Fc fusion proteins were produced in human HEK293 cells, they were glycosylated 
as shown by digestion with the endoglycosidase Endo H, which partly cleaves high mannose and 
some hybrid oligosaccharides from N-linked glycoproteins. Three N-linked glycosylation sites are 
present in the MICA α1α2 domain (Asn 8, Asn 56 and Asn 102) (Steinle et al., 2001). Steinle and 
colleagues had compared MICA proteins produced in bacteria and in insect cells and found more 




glycosylation enhanced the interaction with NKG2D (Steinle et al., 2001). They also compared the 
variants MICA*01 (with a Met at position 129) and MICA*04 (with a Val at position 129) produced in 
bacteria and found that only the MICA*01 was able to form a stable complex with NKG2D (Steinle et 
al., 2001). Thus, the glycosylation and/or conformation of the MICA molecules expressed on mouse L 
cells or produced as IgG2a-Fc fusion proteins in human HEK293 cells might be slightly different leading 
to masking of the effect of the amino acid position 129 on NKG2D binding when the MICA-Fc 
proteins were analyzed.  
 
4.1.1 NKG2D-mediated signaling 
Notably, the recombinant MICA-129Met/Val-mIgG2a-Fc fusion proteins varied in their efficacy to elicit 
downstream biological effects – similarly as MICA-129Met/Val molecules expressed on L cells – 
despite having a comparable binding avidity to the NKG2D receptor of human primary NK cells. This 
strongly suggests that the functional difference of the MICA-129Met/Val dimorphism is not 
explainable alone by variations of NKG2D binding avidity. In addition, the MICA isoforms appear to 
vary also in their efficacy to transduce signals after binding to NKG2D. The structural basis of this 
difference remains to be elucidated. 
The first alteration that we observed downstream of NKG2D binding was a faster and stronger 
phosphorylation of Src family kinases in NK cells stimulated by the immobilized MICA-129Met 
compared to the MICA-129Val isoform. This included the tyrosine residue Tyr419 (or Tyr416 when 
following the original nomenclature from chicken), which is auto-phosphorylated during activation 
(Irtegun et al., 2013). Activated Src family kinases are known to phosphorylate ITAMs which are 
present also in many natural killer receptor or adaptor molecules (Koch et al., 2013). Src family 
kinases are essential for NKG2D-trigged cytotoxicity in human NK cells although the signals are not 
transduced via an ITAM (Billadeau et al., 2003). NKG2D has no signaling motif within its short 
intracellular domain. In human NK cells, the NKG2D receptor associates with the DAP10 adaptor 
protein (or hematopoietic cell signal transducer, HCST) which carries a tyrosine-based YxxM motif in 
its cytoplasmic part (Wu et al., 1999). The adaptor DAP12, which can alternatively associate with 
mouse NKG2D, contains ITAMs. Their phosphorylation induces recruitment and activation of the 
spleen tyrosine kinase Syk or the ζ-chain-associated protein of 70 kDa (ZAP-70) tyrosine kinase 
leading to phosphorylation of downstream effectors which finally trigger effector cell activation. We 




findings that the NKG2D-DAP10 receptor complex, unlike ITAM-containing NK cell receptors, does 
not require Syk family or ZAP-70 tyrosine kinases for initiation of a downstream signaling cascade 
(Billadeau et al., 2003; Zompi et al., 2003; Chiesa et al., 2006). 
Phosphorylated DAP10 recruits either the p85 subunit of PI3K and subsequently the small adaptor 
CrkL (Segovis et al., 2009) or Grb2 in association with the guanine nucleotide exchange factor VAV1 
and SOS1 (Billadeau et al., 2003; Upshaw et al., 2006; Lanier, 2008). The latter event induces 
phosphorylation of the effector molecule SLP-76 and the phospholipase PLC-γ2 (Upshaw et al., 2006). 
Through these signaling proteins, Ca2+-flux and cytoskeletal reorganization are induced resulting 
finally in cytotoxicity and cytokine secretion (Lanier, 2008; Long et al., 2013). However, probing of 
various blots with further phospho-specific Abs detecting molecules of underlying signaling 
pathways, including Abs for the p85 (Tyr458)/p55 (Tyr199) subunits of PI3K and the protein kinase 
Akt (Ser473) or VAV1 (Tyr174), SLP-76 (Tyr128) and PLC-γ2 (Tyr759), showed no detectable or only 
weak signals.  
Interestingly, cytokine secretion, in contrast to cytotoxicity, was observed only after NKG2D cross-
linking by NKG2D ligands, including MICA (Andre et al., 2004), but not by anti-NKG2D Abs (Billadeau 
et al., 2003; Andre et al., 2004) although this difference has been questioned recently (Lanier, 2008). 
In our experiments using MICA for cross-linking, the upstream event of NKG2D signaling – i.e. 
phosphorylation of Src family kinases – was clearly affected by the MICA-129Met/Val dimorphism. To 
demonstrate the relevance of this signaling step when using MICA to cross-link NKG2D instead of 
anti-NKG2D Abs, we utilized the specific Src family kinases inhibitor PP2 and showed that granule 
exocytosis was indeed completely abolished. The latter experiment suggested moreover that the 
different efficacies of the MICA-129Met and MICA-129Val variants to elicit NKG2D signaling resulted 
in different degrees of NK cell degranulation. 
Taken together, the MICA-129Met/Val polymorphism does not only affect the binding avidity of 
NKG2D, both MICA isoforms appeared to differ also in their efficacy to trigger NKG2D-mediated 
signaling after binding to the immunoreceptor. 
 
4.1.2 NK cell cytotoxicity 
We tested the degranulation of human NK cells triggered by both recombinant MICA-129-Fc fusion 
proteins over a broad range of protein concentrations and found that the MICA-129Met variant was 




For both variants the extend of NK cell degranulation increased up to protein concentrations of 10 or 
20 µg/ml. Afterwards it remained stable or even decreased. Similarly, also MICA-129Met ligands 
expressed on L transfectants triggered significantly more granule exocytosis of human NK cells than 
MICA-129Val ligands in terms of CD107a cell surface expression intensity and proportion of CD107a-
positive NK cells. These experiments showed that the amount of degranulation was highly dependent 
on the MICA expression intensity on target cells only for the MICA-129Val variant. The expression 
intensity of MICA-129Met ligands, in contrast, had hardly any effect on the magnitude of NK cell 
degranulation.  
The triggering of NKG2D signals by MICA ligands on target cells requires conjugate formation with NK 
cells and building of an immunological synapse. Thus, this situation represents the physiological 
conditions better than receptor stimulation by immobilized recombinant MICA ligands. To clarify 
further the effect of the MICA-129Met/Val dimorphism on the downstream point – i.e. killing of 
MICA-expressing target cells – we performed 51Cr release assays. The MICA-129Met variant on L cells 
was also a significantly stronger trigger of NK cell cytotoxicity than the MICA-129Val variant. Notably, 
the expression intensity of the MICA-129Met variant had overall even a negative influence on the 
killing of target cells, whereas killing increased steadily with expression intensity of the MICA-129Val 
variant.  
51Cr release assays were not only performed with human LAK cells, which contain between 10% to 
15% NK cells, but also with isolated human NK cells. Analysis revealed similar results but with 
reduced values for the relative cell lysis of MICA-expressing L targets by isolated NK cells suggesting a 
better activation of NK cells by IL-2 in a co-culture with other PBMCs or an involvement of a further 
cell population. Besides expressing a γδ TCR, human γδ T cells also express the NKG2D receptor on 
their cell surface and do not necessarily need additional stimulation of other activating receptors, 
such as CD8+ αβ T cells do, to be activated (Girardi et al., 2001; Whang et al., 2009). In addition to 
TCR-dependent recognition, activation of NKG2D-positive γδ T cells by tumor cell-expressed NKG2D 
ligands can also trigger cytotoxic effector function (Wrobel et al., 2007). Since human γδ T cells have 
been shown to lyse a broad range of epithelial tumor cells with the involvement of NKG2D ligands 
including MICA (Wrobel et al., 2007), this type of T cells might be involved in killing of the target cells 
in our experiments. For elucidation, further experiments have to be performed including cytotoxicity 
assays of isolated γδ T cells and flow cytometric analyses of the degranulation of these effector cells 
after exposure to our MICA-129-expressing L cells. Although we have not investigated this T cell 
subset so far, we assume that the MICA-129Met/Val dimorphism may also have an influence on the 




4.1.3 NKG2D-triggered cytokine release 
The functional effects of the MICA-129Met/Val polymorphism on NKG2D signaling were not 
restricted to NK cell cytotoxicity. Besides NK cell degranulation and target cell killing we also analyzed 
IFN-γ secretion of purified IL-2-stimulated human NK cells co-cultured with MICA-129Met/Val-
expressing L target cells. Our experimental data revealed that the MICA-129Met variant was also a 
significantly stronger trigger of IFN-γ release by NK cells than the MICA-129Val variant. Similarly to 
NK cell-mediated cytotoxicity, the amount of secreted IFN-γ was also highly dependent on the MICA 
expression intensity on target cells only for the MICA-129Val but not for MICA-129Met variant. 
This result is in agreement with a report by Yoshida et al. (2011) who used recombinant MICA-
glutathione S-transferase (GST)-fusion proteins to analyze IFN-γ production from the human NK92MI 
cell line. They combined in their fusion proteins the MICA-129Met variant with the A9 variant of the 
transmembrane region and the MICA-129Val variant with the A5 variant. The transmembrane region 
of MICA, encoded in exon 5, contains a triplet repeat microsatellite polymorphism (GCT)n in the 
transmembrane region, which varies in the number of alanine-encoding GCT repeats (Mizuki et al., 
1997). The MICA 129Met;A9-GST protein induced more IFN-γ release from the NK92MI cell line than 
the MICA 129Val;A5-GST protein (Yoshida et al., 2011). Thus, our results indicate that the MICA-
129Met/Val polymorphism is responsible for the varying IFN-γ release of primary human NK cells.  
 
4.2 Influence of the MICA-129 dimorphism on MICA shedding and NKG2D 
counter-regulation 
Based on our findings regarding the influence of the MICA-129Met/Val polymorphism on functional 
effects of NK cells the following question came up: Why do the functional NK cell responses elicited 
by the MICA-129Met in contrast to the MICA-129Val variant not continuously increase with MICA 
expression intensity on target cells? 
The MICA shedding phenomenon is thought to constitute a major counter-regulation mechanism of 
tumor cells to subvert NKG2D-mediated immunosurveillance (Waldhauer et al., 2008). Therefore, 
one possibility was that higher MICA expression leads to higher concentration of sMICA, which can 
inhibit NKG2D signaling by blocking or down-regulation of the receptor (Groh et al., 2002). However, 
our data showed that MICA-129Met/Val-transfected mouse L cells did not shed MICA thus excluding 




these experiments. Since several human tumor cell lines transfected with the MICA-129Met/Val 
expression constructs secreted higher amounts of sMICA compared to the corresponding wild type 
cell lines, the absence of MICA shedding in the L-MICA-129Met/Val transfectants is a feature of 
mouse L cells and not a feature of the MICA-129Met/Val constructs. Moreover, first experiments 
using MICA-129Met/Val-expressing human Malme cells showed that the two MICA-129 variants 
varied in the amount of released sMICA, whereat the MICA-129Met variant exhibited increased MICA 
shedding compared to the MICA-129Val variant. This may indicate an influence of the MICA-129 
dimorphism on the shedding of this NKG2D ligand, possibly mediated by a conformational change.  
Besides soluble NKG2D ligands, such as sMICA, also sustained exposure of NK cells to NKG2D ligand-
expressing cells can down-regulate the immunoreceptor NKG2D (Coudert et al., 2005; Oppenheim et 
al., 2005; Wiemann et al., 2005). Therefore, we also investigated whether the MICA-129 dimorphism 
has an impact on NKG2D expression of IL-2-stimulated human NK cells exposed to L-MICA-
129Met/Val target cells, since this might potentially result in enhanced down-modulation of NKG2D 
on NK cells after exposure to the MICA-129Met variant. Indeed, we found a stronger down-
regulation of NKG2D on NK cells exposed to L-MICA-129Met than L-MICA-129Val target cells. This is 
in accordance with the finding of Yoshida et al. showing that the MICA 129Met;A9-GST fusion protein 
reduced the NKG2D expression on human NK92MI cells more than the MICA 129Val;A5-GST protein 
(Yoshida et al., 2011). Hence, the explanation for the fact that an enhanced expression of the MICA-
129Met in contrast to the Val variant of the MICA-129-transfected L cells did not result in 
continuously stronger functional NK cell responses seems to be an increased NKG2D down-regulation 
on NK cells exposed to this variant. 
Taken together all experimental data, our findings showed that the MICA-129 dimorphism is 
functionally relevant and fine-tunes NK cell activity (Figure 4.1). The MICA-129Met isoform was 
functionally characterized by higher NKG2D binding avidity, stronger and faster NKG2D signaling, 
triggering of more NK cell cytotoxicity, including granule exocytosis and target cell lysis, and IFN-γ 
release but also increased NKG2D down-regulation on NK cells. Notably, the degree of NK cell-
mediated cytotoxicity and cytokine production increased steadily with the MICA expression intensity, 
if the MICA-129Val variant was present on target cells. Augmented expression of the MICA-129Met 
isoform, in contrast, had no or even a negative effect on NK cell function. These data demonstrate a 
strong interdependency of the MICA expression intensity and the MICA-129 genotype. Furthermore, 
the stronger capacity of the high avidity MICA-129Met variant to signal via NKG2D itself seems to 
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Figure 4.1: Functional effects of the MICA-129Met/Val dimorphism on NK cell activity and tumor-associated 
counter-regulation mechanisms. 
The MICA-129Met/Val dimorphism is functionally relevant and fine-tunes NK cell activity. Especially at low 
MICA expression intensity (upper panel), the high avidity MICA-129Met variant has stronger functional effects, 
including triggering of more NK cell cytotoxicity and IFN-γ release, than the MICA-129Val variant. However, at 
high expression levels (lower panel), the low avidity MICA-129Val variant gains advantages. For this variant, the 
degree of NK cell-mediated cytotoxicity and cytokine production increase steadily with the MICA expression 
intensity. In contrast, augmented expression of the MICA-129Met variant has no or even a negative effect on 
NK cell function. This demonstrates a strong interdependency of the MICA expression intensity and the MICA-
129 genotype. Moreover, the MICA-129Met variant is associated also with increased NKG2D down-regulation 
on NK cells (*
1
) and MICA shedding from tumor cells (*
2
). Thus, the stronger capacity of the MICA-129Met 
variant to signal via NKG2D itself seems to limit the biological effects of an increased MICA expression intensity 




4.3 Association of the MICA-129 dimorphism with the outcome of HSCT 
Allogeneic HSCT offers an option to cure several hematological diseases. Depending on the disease 
entity, 5-year-survival rates vary, with limitations imposed by severe post-transplant complications 
such as GVHD, relapse of malignancy and infection (Dickinson, 2008). HLA matching is mandatory to 
reduce the risk of graft rejection and GVHD, however minor histocompatibility antigens (mHags) also 
can affect transplant outcome playing a role in both GVHD and GVL mechanisms (Warren et al., 
2012). Moreover, an increasing number of studies in the last 15 years have demonstrated the impact 
of SNPs on the outcome of HSCT (Dickinson, 2008). For instance, SNPs in the TNF-α gene have been 
associated with an increased risk of GVHD and some of them lead to increased expression of this pro-
inflammatory cytokine, which might explain the observed association with GVHD (Dickinson, 2008). 
Furthermore, polymorphisms of NK cell receptors, such as KIRs (Cooley et al., 2009; Venstrom et al., 
2010), have been shown to play a role in HSCT, thereby suggesting a link between NK responses and 
GVHD (Moretta et al., 2009). Those SNPs, which alter the regulation of genes or the function of 
proteins, might not only be useful to predict risks; they might also identify pathophysiological 
pathways, which could be targeted by new therapeutics.  
In this study, we focused on the MICA-129Met/Val dimorphism, which has been associated 
previously with the risk of cGVHD and relapse after HSCT (Boukouaci et al., 2009). The polymorphism 
could potentially be causative for the observed disease association due to a higher avidity of MICA-
129Met than MICA-129Val variants to NKG2D. Additionally, we found that the degree of NK cell 
cytotoxicity and cytokine production increased steadily with the MICA expression intensity, if the 
MICA-129Val variant was present on target cells. Augmented expression of the MICA-129Met 
isoform, in contrast, had no or even a negative effect on NK cell function. This interaction between 
MICA-129 genotype and MICA expression intensity has to our knowledge not been noticed before 
but is likely highly important when interpreting MICA-129 disease associations. 
Analysis of the cohort undergoing allogeneic HSCT in the University Medical Center in Göttingen 
revealed an increased probability of survival after HSCT for carriers of MICA-129Met variants. The 
homozygous MICA-129Met/Met carriers had an increased risk to experience aGVHD, however MICA-
129Met variants conferred also a lower probability to die due to this complication. Since this 
association was observed not only in the whole cohort but also in the subgroup of patients receiving 
a graft matched for the MICA-129 genotype, the MICA-129 dimorphism is apparently not important 




Taken together, the presence of MICA-129Met variants appeared to augment GVL and GVH 
reactions. MICA-129Met variants, especially in homozygous carriers, seemed to support initiation of 
aGVHD but also to limit the severity of this complication. It has been reported previously that the risk 
of developing cGVHD was increased for recipients with the MICA-129Val/Val genotype and the risk of 
relapse was increased for the MICA-129Met/Met genotype (Boukouaci et al., 2009). Thus, the SNP 
MICA-129 was significantly associated with the outcome of HSCT in two independent cohorts, 
however it was predictive for different outcome parameters. This could be due to differences in the 
clinical cohorts, such as different clinical and treatment characteristics, but it could also point 
towards confounding factors such as expression intensity, which modulate the biological effect of 
this SNP and need to be taken into account. 
In view of the expression pattern of MICA and NKG2D, the MICA-129 dimorphism could affect several 
cell types and pathophysiological pathways after transplantation. MICA is constitutively expressed in 
gastrointestinal epithelium (Groh et al., 1996), i.e. a target organ of GVHD. This stress-inducible 
NKG2D ligand can be up-regulated in many other tissues under conditions of inflammation (Raulet et 
al., 2013), which occur regularly after pre-conditioning. MICA/B was indeed found in skin and liver 
during aGVHD (Gannage et al., 2008). MICA is also expressed on many malignancies (Champsaur and 
Lanier, 2010; Choy and Phipps, 2010; Raulet et al., 2013), including leukemias (Salih et al., 2003; 
Sconocchia et al., 2005; Boissel et al., 2006; Kato et al., 2007; Diermayr et al., 2008; Nückel et al., 
2010; Sanchez-Correa et al., 2011; Hilpert et al., 2012) and lymphomas (Dulphy et al., 2009; Reiners 
et al., 2013), however the expression intensities and the amounts of sMICA in patient sera were 
variable (Salih et al., 2002; Sconocchia et al., 2005; Boissel et al., 2006; Nückel et al., 2010; Hilpert et 
al., 2012). In a recent study including 205 patients, the majority of leukemias were positive for MICA 
(AML 53%, ALL 65%, CML 33% and CLL 61%) and MICA was the most frequently detected NKG2D 
ligand especially among acute leukemias but with quite variable expression intensities (Hilpert et al., 
2012). Hence, it is conceivable that the variable MICA expression level on malignant cells modifies 
the effect of the MICA-129 SNP. Notably, also sMICA was detected most frequently and in high 
amounts in acute leukemias (Hilpert et al., 2012).  
In cancer, the interaction of NKG2D with MICA should activate antitumor NK cell responses but the 
immunoreceptor is down-regulated when associated with circulating tumor-derived sMICA (Groh et 
al., 2002; Kaiser et al., 2007). Several clinical studies have shown an association between tumor-
associated or soluble NKG2D ligands and disease progression and poor prognosis in different 
malignancies, including pancreatic and prostate cancer (MICA and MICB) (Wu et al., 2004; Duan et 




2009) and multiple myeloma (MICA) (Rebmann et al., 2007). For instance, elevated sMICA plasma 
levels in high-risk neuroblastoma patients treated with allogeneic IL-2-stimulated NK cells after 
haplo-identical SCT correlated with impaired NK cell cytotoxicity and showed the influence of shed 
ligand on tumor immune evasion (Kloess et al., 2010). Moreover, MICA polymorphisms are 
associated with several diseases related to NK cell activity, such as infection, malignancy, 
autoimmune disease, graft rejection and GVHD. Underlying mechanisms include NK cell-mediated 
cytotoxicity as well as MICA shedding producing immunosuppressive sMICA (Choy and Phipps, 2010). 
It has been reported, e.g., that the MICA-129Val/Val genotype was more frequent in ulcerative colitis 
patients and that these patients had also higher sMICA levels compared to those with the Met/Val or 
Met/Met genotype (Zhao et al., 2011). In the HSCT cohort described by Boukouaci and colleagues, 
the MICA-129Val/Val genotype and increased serum levels of sMICA after HSCT were independently 
associated with the incidence of cGVHD, i.e. MICA-129 genotypes and sMICA serum levels exerted an 
independent but additive effect on the cGVHD incidence (Boukouaci et al., 2009). Patients carrying 
the Val/Val genotype and having sMICA level greater than 80 pg/ml were at high risk of developing 
cGVHD, whereas the lowest risk was observed for patients with the Met/Met or Met/Val genotype in 
combination with sMICA level below 80 pg/ml (Boukouaci et al., 2009). Our analysis of the shedding 
of MICA-129Met/Val-expressing human Malme cells showed that the MICA-129Met variant exhibited 
increased MICA shedding compared to the MICA-129Val variant. Furthermore, we found that the 
MICA shedding was dependent on the MICA expression intensity indicating again the importance of 
the MICA expression level for data interpretation. Altogether, sMICA appears to be a further factor, 
which modulates the biological effect of this SNP. Moreover, the presence of anti-MICA Abs before 
transplantation in the cohort described by Boukouaci et al. (2009) was associated with protection 
against cGVHD. This inverse relationship between anti-MICA Abs and sMICA suggests an antibody-
based neutralization of deleterious effects of sMICA (Boukouaci et al., 2009). 
After HSCT, NK cells contribute to GVL effects, provide protection against certain pathogens such as 
cytomegalovirus and appear to reduce GVHD (Ruggeri et al., 2002; Leung, 2011; Babor et al., 2013; 
Palmer et al., 2013). Alloreactive donor NK cells contribute to preventing the occurrence of GVHD 
and graft rejection by killing also recipient APCs and CTLs alongside malignant cells (Locatelli et al., 
2013). Parts of these effects could be mediated by recognizing of NKG2D ligands including MICA. 
However, the overall effect of NKG2D signaling on aGVHD is not clear. Hence, MICA variants eliciting 
more NK cell cytotoxicity and cytokine release might confer advantages especially with respect to the 
eradication of malignant cells and the limitation of virus infections. MICA-129Met variants triggering 




observed in our homozygous carriers of MICA-129 variants. The severity of aGVHD, however, might 
be limited due to a faster and stronger NKG2D counter-regulation resulting in a lower risk to die from 
this complication. In our HSCT cohort, the MICA-129Val/Val genotype was associated with an 
increased risk of death due to aGVHD. Inversely, in the cohort described by Boukouaci et al. (2009) 
the Val/Val genotype was associated with an increased incidence of cGVHD. This might be linked to 
lesser NKG2D down-regulation elicited by the Val/Val genotype which in turn might lead to sustained 
NK cell activity in contrast to the stronger down-modulated NK cell responses triggered by MICA-
129Met variants. In parallel, carriers of MICA-129Met variants might profit initially from stronger GVL 
effects but of limited duration resulting in a higher risk of relapse in homozygous carriers as observed 
in the before mentioned HSCT cohort (Boukouaci et al., 2009).  
Our data showed that the MICA-129Met variant triggers more NK cell activity at low expression 
intensities, whereas the MICA-129Val variant gains advantages at high expression, at which the 
MICA-129Met variant already down-regulates NKG2D leading to impaired NK cell function. Both 
variants may confer advantages and disadvantages in certain situations, such as virus infections, 
suggesting balancing evolution of MICA alleles. Differences in MICA expression levels in GVHD-
affected tissues (Gannage et al., 2008) and on malignant cells (Sconocchia et al., 2005; Boissel et al., 
2006; Nückel et al., 2010; Hilpert et al., 2012) could further explain why the SNP was associated with 
different outcomes in our cohort and the previously investigated cohort (Boukouaci et al., 2009). The 
situation becomes even more complicated by sMICA (Boukouaci et al., 2009), which can block 
NKG2D-mediated cytotoxicity and down-regulate NKG2D on NK cells. Although the MICA-129Val/Val 
genotype and elevated sMICA serum levels after HSCT were independently associated with the 
incidence of cGVHD, sMICA seems to be a modifying factor (Boukouaci et al., 2009). A further level of 
complexity is added by anti-MICA Abs (Boukouaci et al., 2009), which can neutralize sMICA but also 
sensitize MICA expressing cells to complement-dependent cellular cytotoxicity and therefore appear 
to modulate the effects of the SNP MICA-129 (Zou et al., 2002; Jinushi et al., 2006; Zou and Stastny, 
2010).  
Besides cytotoxicity, NKG2D-mediated signaling in NK cells triggers also release of cytokines, which 
modulate further immune reactions. IFN-γ, e.g., can up-regulate HLA class I molecules and thereby 
aggravate T cell-mediated GVHD. Moreover, not only NK cells but also several T cell subtypes, 
including CD8+ αβ T cells and γδ T cells, express NKG2D. In addition to TCR-dependent recognition, 
activation of γδ T cells by NKG2D ligands can also elicit cytotoxic effector functions. It has been 




squamous cell carcinomas and lung carcinoma, by human γδ T cells involves the NKG2D pathway 
(Wrobel et al., 2007). Their ability to display potent anti-tumor activity against leukemias among 
other malignancies and the fact that these cells do not cause GVHD make γδ T cells to be considered 
as a promising tool for tumor immunotherapy in the context of allogeneic HSCT (Locatelli et al., 
2013). Thus, NKG2D-mediated co-stimulation of CD8+ αβ T cells and stimulation of γδ T cells could 
contribute to GVH or GVL reactions, respectively. Although we have not investigated T cells in our 
study, we assume that the MICA-129Met/Val dimorphism affects the strength and kinetics of NKG2D 
signaling also in these cell types. 
In conclusion, we have shown that the MICA-129Met/Val polymorphism has a significant impact on 
the outcome of HSCT. We have demonstrated that it affects the strength and kinetics of NKG2D 
signaling resulting in differences of NK cell cytotoxicity and cytokine secretion but also NKG2D 
counter-regulation suggesting that the MICA-129 dimorphism directly affects the outcome of HSCT. 
Important factors, which modulate the effects of this SNP, are the MICA expression intensity as 
shown here but also sMICA and anti-MICA Abs as shown previously (Boukouaci et al., 2009). The SNP 
MICA-129 could be highly informative for the prediction of the outcome of HSCT but likely the 
confounding factors have to be considered carefully. The SNP could also be predictive for the success 
of other immunotherapies, e.g., adoptive NK cell transfer, using NK cells to treat MICA-positive 
malignancies (Leung, 2011; Vivier et al., 2012). Moreover, this might be highly relevant when NKG2D 
signaling is targeted by new therapies aiming at up-regulation of MICA by histone deacetylase 
(HDAC) inhibitors (Kato et al., 2007; Diermayr et al., 2008) or blocking of signaling by soluble NKG2D 
(Hilpert et al., 2012).  
 
4.4 Open questions – MICA-129 gene expression and adoptive NK cell 
transfer 
During our experiments, the question came up whether the MICA-129Met/Val polymorphism also 
has an influence on the MICA gene expression level. Regarding this our first experiments showed a 
difference in the MICA mRNA expression level but no significant difference in the MICA cell surface 
expression between MICA-transfected mouse L cells of both MICA-129 variants. The data suggest 
that for the MICA-129Met variant higher amounts of MICA mRNA are required for a high MICA 




appears to be more directly dependent on the MICA gene expression level for the MICA-129Val than 
the Met variant.  
Because of these observations we furthermore genotyped 12 human melanoma and 3 breast 
carcinoma cell lines for the MICA-129 dimorphism and determined the MICA mRNA levels (see 
Appendix, Table A.1). For the qRT-PCRs, Gapdh (glyceraldehyde 3-phosphate dehydrogenase) was 
chosen as housekeeping gene for normalization of mRNA amounts. Human erythroleukemia K562 
cells, which express MICA, were used as reference cell line and the mRNA expression in this cell line 
was set to 1. Amounts of MICA mRNA in the melanoma and breast carcinoma cell lines were 
quantified relative to those of the K562 cells. Treatment of the cells with the HDAC inhibitor SAHA 
resulted in an increase of the MICA mRNA amount of all cell lines compared to their untreated 
counterparts (Table A.1). However, on the basis of these 15 investigated human tumor cell lines it is 
not possible to make a statement whether an association exists between the MICA-129 genotype 
and the MICA gene expression level because of the small number of cell lines which were 
homozygous, especially for the MICA-129Met variant.  
One aim of our study was to investigate whether the MICA-129 dimorphism has an influence on the 
therapeutic efficacy of an experimental adoptive immunotherapy of cancer with activated human NK 
cells using immunodeficient mouse models.  
Preliminary in vivo experiments, in which various clones of MICA-129Met/Val-expressing L cells were 
s.c. injected into immunodeficient C57BL/6-Rag2-/-/cγc-/- mice, lacking B, T and NK cells, revealed 
different tumor growth rates. However, to answer the question it is important to use MICA-
expressing tumor cells of both MICA-129 variants with similar tumor growth rates for the 
experiments. A further important factor which has to be taken into account is the MICA cell surface 
expression of L-MICA-129-expressing cells used for future experiments, since the MICA expression 
intensity affects NK cell-mediated cytotoxicity and IFN-γ secretion as shown in our in vitro 
experiments. To avoid clonal effects the production of comparable cell populations of each MICA-129 
variant using a retroviral infection system could be conceivable. 
In a pilot study, after s.c. injection of MICA-129Met/Val-expressing L tumor cells into 
immunodeficient C57BL/6-Rag2-/-/cγc-/- mice, the animals were i.v. inoculated with IL-2-stimulated 
human NK cells. Since it was not possible to detect the transferred NK cells in different taken tissues 
after autopsy (day 19-39) and since there was no difference in the lifespan between animals treated 
with NK cells or the PBS control, it seems that the NK cells did not survive long enough in the mice to 




in vitro as shown previously for C57BL/6 mouse NK cells by Ni et al. (2012) or missing stimulation in 
vivo with cytokines such as IL-2.  
Taken together, these preliminary in vivo experiments indicate that it is necessary to further optimize 
the in vitro stimulation of NK cells and the adoptive NK cell transfer protocol to obtain prolonged NK 
cell survival and vigorous NK cell activity. For additional NK cell pre-activation, e.g., besides IL-2 the 
three cytokines IL-12, IL-15 and IL-18 could be added to the NK cells co-cultured together with other 
PBMCs. It could be also considered to transfer the stimulated human NK cells to tumor-bearing mice 
which already reveal established tumor growth. Furthermore, rhIL-2 could be administered in parallel 
to the adoptive NK cell transfer as well as at later time points to improve the survival and function of 
the transferred NK cells in vivo. 
Previous studies of our research group showed also that mouse C.B.-17/Ztm-scid NK cells can kill 
MICA/B-expressing human melanoma cells in vitro and that HSP70 and inducible NKG2D ligands, such 
as MICA, synergistically promote the activation of mouse NK cells resulting in a reduced tumor 
growth and suppression of metastatic disease (Elsner et al., 2007). Based on these findings, it could 
be investigated whether NK cells of C.B.-17/Ztm-scid or C57BL/6-Rag2-/- mice, which do not possess B 
and T cells but still have functional NK cells, can efficiently recognize and kill MICA-expressing tumors 
after injection of L-MICA-129 cells. If this would be the case, the next step would be to analyze 
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5 Summary and Conclusions 
Several studies within the last 15 years have demonstrated the impact of SNPs on the outcome of 
HSCT. Those SNPs, which alter the regulation of genes or the function of proteins, might not only be 
useful to predict risks they might also identify new targets for therapy. In this study, we focused on 
the MICA-129Met/Val polymorphism which has been associated previously with the risk of cGVHD 
and could be causative itself due to a higher avidity of MICA-129Met than MICA-129Val variants to 
NKG2D. To validate the biological relevance of the MICA-129 dimorphism, we evaluated whether this 
SNP affects NKG2D-mediated signaling and NK cell functions, including cytotoxicity and cytokine 
release, and whether it is associated with the outcome of allogeneic HSCT. 
Using transfected cell lines and recombinant proteins for both variants we showed that the MICA-
129Met isoform was characterized by higher NKG2D binding avidity, faster and stronger NKG2D 
signaling, triggering of more NK cell cytotoxicity and IFN-y release. At low MICA expression intensity, 
the Met variant had stronger functional effects than the Val variant. However, the degree of NK cell 
cytotoxicity and cytokine production increased steadily with expression intensity of the MICA-129Val 
variant, whereas an enhanced expression of the MICA-129Met isoform had no or even a negative 
effect on NK cell function. These data demonstrated a strong interdependency of the MICA 
expression intensity and the MICA-129 genotype. Since the functional NK cell responses elicited by 
the MICA-129Met in contrast to the MICA-129Val variant did not continuously increase with MICA 
expression intensity on target cells, we analyzed counter-regulation mechanisms such as tumor cell-
mediated MICA shedding and NKG2D down-regulation of NK cells. We could exclude the possibility 
that sMICA-129Met blocks NKG2D signaling more efficiently than sMICA-129Val in these 
experiments, since MICA-129Met/Val-transfected mouse L cells did not shed MICA. However, the 
MICA-129Met variant down-regulated NKG2D more efficiently than the MICA-129Val variant. 
Moreover, experiments with MICA-129Met/Val-expressing human Malme cells suggested that the 
MICA-129Met variant exhibited also increased MICA shedding. In summary, our data demonstrate 
that the MICA-129Met/Val polymorphism is functionally relevant and fine-tunes NK cell activity. The 
effect of this SNP depends on the MICA expression intensity and the generally stronger signaling 
capacity of the MICA-129Met variant is compromised or even inverted at higher MICA expression 
intensities.  
To elucidate whether the differences between the MICA variants are indeed clinically relevant, the 
MICA-129 dimorphism was determined in a cohort of patients undergoing allogeneic HSCT in the 
Department of Hematology and Medical Oncology at the University Medical Center Göttingen (320 
genotyped P/D pairs with clinical characteristics). In recipients matched on the MICA-129 genotype, 
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MICA-129Met variants increased the chance of survival and reduced the risk to die due to aGVHD, 
although homozygous carriers had an increased risk to experience this complication after HSCT. Thus, 
the presence of the high avidity variant of MICA-129 may lead to a favorable outcome of HSCT due to 
initially stronger NKG2D signaling followed, however, by a more rapid NKG2D counter-regulation. 
In conclusion, we have confirmed that the MICA-129Met/Val dimorphism has a significant impact on 
the outcome of allogeneic HSCT. We have shown that it affects the strength and kinetics of NKG2D 
signaling resulting in differences of NK cell cytotoxicity and cytokine secretion but also NKG2D 
counter-regulation suggesting that the MICA-129 dimorphism directly affects the outcome of HSCT. 
Important factors, which modulate the effects of this SNP, are the MICA expression intensity but also 
sMICA and anti-MICA Abs. Thus, the SNP MICA-129 could be highly informative for the prediction of 
the outcome of allogeneic HSCT but the MICA expression intensity has likely to be considered. 
Moreover, the data suggest that new therapy regimens aiming at an up-regulation of MICA to 
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Figure A.1: NKG2D-mediated phosphorylation of Src family kinases in response to the MICA-129Met-Fc 
protein is faster than in response to the MICA-129Val-Fc protein.  
Purified IL-2-stimulated (100 U/ml for 4 days) human NK cells (10
6
) were stimulated with immobilized MICA-
129Met/Val-mIgG2a-Fc or OVA-mIgG2a-Fc fusion proteins (10 µg/ml) for 3, 10 or 30 min in microtiter plates. The 
protein lysates of these cells were separated by SDS-PAGE and the blot was probed with an anti-phospho-Tyr 
mAb (upper panel) and an anti-β-Actin mAb as loading control. After stripping of the blot membrane with β-
mercaptoethanol-containing buffer, the blot was probed with different anti-phospho-specific Abs for the 
downstream effectors VAV1 (101 kDa) and SLP-76 (76 kDa) using an anti-phospho-VAV1 (Tyr174) and anti-



































Figure A.2: Proliferation of different mouse L tumor cell lines in vitro. 
A 
3
H-thymidine incorporation assay was performed with L-con cells and three different clones of the L-MICA-
129Met (n = 3) and L-MICA-129Val variant (n = 3) to determine cell proliferation. After 24 h incubation under 
normal cell culture conditions, 1 µCi/well 
3
H-thymidine was added to the cells and incubated for additional 24 
h. Proliferation is indicated by 
3
H-thymidine incorporation (counts per min) and is shown as means of triplicates 
+ SEM for four different cell concentrations (5 x 10
3
, 2.5 x 10
3
, 1.25 x 10
3
 and 0.625 x 10
3
 cells per 100 µl 






























































Figure A.3: Co-culture of human NK cells and irradiated human allogeneic PBMCs (´feeder cells´). 
MACS-isolated human NK cells were co-cultured together with irradiated human allogeneic PBMCs, so-called 
´feeder cells´, and 250 U/ml IL-2 for 2 weeks. (A) The MFI of the three NK cell marker CD16, CD56 and CD94 (B) 
and the percentage of NK cells positive for these cell surface markers were determined by flow cytometry at 











Table A.1: Genotyping and analysis of the MICA mRNA expression of human tumor cell lines. 
Cell line MICA-129 genotype  n
5
 
Relative MICA gene expression [%] 
mean ± SEM 
A375II (Mel
1
) Met/Val 2 10.71 ± 1.37 
+ SAHA
4
  1 113.55 
Ge (Mel) Met/Val 2 11.31 ± 0.57 
+ SAHA  1 77.56 
HT144 (Mel) Met/Val 2 360.74 ± 83.08 
+ SAHA  1 421.83 
Juso (Mel) Val/Val 2 391.12 ± 40.57 
+ SAHA  1 813.04 
Malme (Mel) Met/Met 2 5.52 ± 1.76 
+ SAHA  1 205.15 
Mel Ei (Mel) Met/Val 2 37.72 ± 13.68 
+ SAHA  1 227.63 
Mel Ho (Mel) Met/Val 2 13.42 ± 2.84 
+ SAHA  1 86.25 
Mel Im (Mel) Met/Val 2 16.36 ± 0.10 
+ SAHA  1 122.26 
Mel La (Mel) Met/Val 2 115.43 ± 22.12 
+ SAHA  1 253.15 
Mel Wei (Mel) Met/Val 2 126.01 ± 34.20 
+ SAHA  1 297.59 
Parl (Mel) Val/Val 2 43.78 ± 4.19 
+ SAHA  1 442.80 
Sk Mel-29 (Mel) Met/Val 2 10.77 ± 1.05 
+ SAHA  1 121.14 
WM266-4 (Mel) Val/Val 2 120.72 ± 0.14 
+ SAHA  1 509.82 
MCF-7 (BC
2
) Met/Val 1 67.99 
+ SAHA  1 565.69 
MDA-MB (BC) Val/Val 1 178.18 
+ SAHA  1 437.72 
T47D (BC) Met/Met 1 59.05 
+ SAHA  1 854.45 
K562 (EL
3
) Met/Val 3 100.00 
 
1-3
 The abbreviations indicate the type of cancer: Mel = melanoma, BC = breast cancer and EL = 
erythroleukemia. 
4
 The cell lines were treated with 10 µM of the HDAC inhibitor SAHA for 20 h before analysis to increase MICA 
expression as described previously (Elsner et al., 2010). 
5
 Cells were cultured and analyzed at different time points. 
 
Curriculum vitae 
XXII 
 
Curriculum vitae 
 
 
 
 
 
 
 
